Piperacillin is a broad-spectrum penicillin antibiotic, synthesized by attaching a 2-thiazolylacetyl side chain to the 6-amino group of 6-aminopenicillanic acid. It exhibits potent activity against gram-negative bacteria, including Pseudomonas aeruginosa, which is often resistant to other penicillin antibiotics. Piperacillin works by inhibiting bacterial cell wall synthesis, leading to cell death. It is commonly used to treat a wide range of infections, including pneumonia, urinary tract infections, skin infections, and septicemia. Piperacillin is often administered in combination with the beta-lactamase inhibitor tazobactam (Piperacillin/Tazobactam) to overcome resistance mechanisms in certain bacteria. Research on piperacillin focuses on understanding its mechanisms of action, optimizing its therapeutic efficacy, and exploring its potential applications in various clinical settings. Its importance lies in its ability to treat infections caused by multidrug-resistant bacteria, making it a valuable therapeutic option in combating bacterial infections.'
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
5-(2-azetidinylmethoxy)-2-chloropyridine: affects neuronal nicotinic acetylcholine receptors; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 43672 |
| CHEMBL ID | 702 |
| CHEBI ID | 8232 |
| SCHEMBL ID | 33894 |
| MeSH ID | M0016883 |
| PubMed CID | 9907432 |
| CHEMBL ID | 2104964 |
| SCHEMBL ID | 7417623 |
| MeSH ID | M0016883 |
| Synonym |
|---|
| peperacillin |
| BIDD:GT0167 |
| AB01275515-01 |
| BRD-K86873305-236-03-0 |
| piperacilline |
| piperacillina |
| piperacillin |
| (2s,5r,6r)-6-{[(2r)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| piperacilina [inn-spanish] |
| piperacilline [inn-french] |
| piperacillinum [inn-latin] |
| pipracil, piper |
| 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2r)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2s,5r,6r)- |
| (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxo-piperazine-1-carbonyl)amino]-2-phenyl-acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| piperacillin hydrate |
| PRESTWICK2_000755 |
| BPBIO1_000848 |
| BSPBIO_000770 |
| DB00319 |
| pipc |
| ccris 7362 |
| pipercillin |
| pipril |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6beta(s*)))- |
| (2s-(2alpha,5alpha,6beta(s*)))-6-(((((4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid |
| einecs 262-811-8 |
| 6-(d-(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-7-oxo-, (2s-(2-alpha,5-alpha,6-beta(s*)))- |
| 61477-96-1 |
| piperacillin anhydrous |
| PRESTWICK1_000755 |
| PRESTWICK0_000755 |
| SPBIO_002709 |
| PRESTWICK3_000755 |
| 6beta-{(2r)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid |
| CHEBI:8232 , |
| HMS2090H19 |
| bdbm50240426 |
| chembl702 , |
| (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| D08380 |
| piperacillin (inn) |
| peracin (tn) |
| WPP , |
| AKOS016007827 |
| piperacilina |
| piperacillin [inn] |
| unii-9i628532gx |
| piperacillinum |
| 9i628532gx , |
| piperacillin [mart.] |
| peracin |
| piperacillin [jan] |
| piperacillin [who-dd] |
| piperacillin [mi] |
| piperacillin, anhydrous |
| EPITOPE ID:116652 |
| SCHEMBL33894 |
| W-105153 |
| piperacillin, antibiotic for culture media use only |
| 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2r)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2s,5r,6r)- |
| DTXSID2023482 |
| (2s,5r,6r)-6-[(2r)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| (2s,5r,6r)-6-[[(2r)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| mfcd00865043 |
| Q423787 |
| (2s,5r,6r)-6-((r)-2-(4-ethyl-2,3-dioxopiperazine- |
| pipracil,(s) |
| AS-13671 |
| (2s,5r,6r)-6-((r)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| gtpl10921 |
| tazocin (piperacillin + tazobactam) |
| 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,6-[[(2r)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2s,5r,6r)- |
| A868701 |
| (2s,5r,6r)-6-((r)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid |
| HY-B1923 |
| CS-0013978 |
| (2s,5r,6r)-6-[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| EN300-6733491 |
| Z2587996977 |
| 198283-74-8 |
| abt 594 |
| 5-(2-azetidinylmethoxy)-2-chloropyridine |
| tebanicline tosylate |
| ebanicline tosylate |
| a-16659447 |
| tebanicline tosilate |
| CHEMBL2104964 |
| cp1a26546z , |
| tebanicline tosylate [usan] |
| a-166594.47 |
| pyridine, 5-((2r)-2-azetidinylmethoxy)-2-chloro-, mono(4-methylbenzenesulfonate) |
| a-165594 |
| 5-(((r)-2-azetidnyl)methoxy)-2-chloropyridine mono-p-toluenesulfonate |
| unii-cp1a26546z |
| a-166594 |
| tebanicline tosylate [mi] |
| pyridine, 5-( (2r)-2-azetidinylmethoxy)-2-chloro-, mono(4-methylbenzenesulphonate) |
| 5-(((r)-2-azetidnyl)methoxy)-2-chloropyridine mono-p-toluenesulphonate |
| pyridine, 5-( (2r)-2-azetidinylmethoxy)-2-chloro-, mono(4-methylbenzenesulfonate) |
| SCHEMBL7417623 |
| 4-methylbenzene-1-sulfonic acid--5-[(azetidin-2-yl)methoxy]-2-chloropyridine (1/1) |
| DTXSID70941658 |
| 5-[[(2r)-azetidin-2-yl]methoxy]-2-chloropyridine;4-methylbenzenesulfonic acid |
| 5-[[(2r)-azetidin-1-ium-2-yl]methoxy]-2-chloropyridine;4-methylbenzenesulfonate |
| 198283-74-8 (tosylate) |
| Q27275600 |
| AKOS040755538 |
Piperacillin-tazobactam is a broad-spectrum antimicrobial agent that is commonly used in clinical practice. Piperacillin is a β-lactam penicillin antibiotic commonly used for the empirical therapy of sepsis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Piperacillin (Pip) is a broad spectrum β-lactam against most Gram-positive and Gram-negative aerobic and anaerobic bacteria. " | ( Piperacillin Encapsulation in Nanoliposomes Using Modified Freeze-Drying of a Monophase Solution Method: Preparation, Characterization and In Vitro Antibacterial Activity. Hallaj-Nezhadi, S; Hashemzadeh, N; McMillan, NAJ; Milani, M; Panahi, V; Savadi, P; Taghavi-Fard, T, 2020) | 3.44 |
| "Piperacillin-tazobactam is a broad-spectrum antimicrobial agent that is commonly used in clinical practice. " | ( An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage. Lv, J; Su, X; Wu, G; Zhang, F, 2022) | 2.49 |
| "Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly prescribed in the intensive care unit setting. " | ( Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses. Caissy, JA; El-Haffaf, I; Marsot, A, 2021) | 3.51 |
| "Piperacillin-tazobactam is a beta-lactam/beta-lactamase combination antibiotic used in patients with moderate to severe infection. " | ( A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. Guerra Valero, YC; Lipman, J; Naicker, S; Ordenez Meija, JL; Parker, SL; Roberts, JA; Wallis, SC, 2018) | 2.17 |
| "Piperacillin is a β-lactam penicillin antibiotic commonly used for the empirical therapy of sepsis and other hospital-acquired infections. " | ( Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Sinnollareddy, MG, 2018) | 2.25 |
| "Piperacillin is a broad spectrum beta-lactam antibiotic used in combination with tazobactam for hospital-related bacterial infections. " | ( Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin/tazobactam stability study. Cabri, W; Cerisoli, L; Ferrazzano, L; Martelli, G; Ricci, A; Tolomelli, A; Viola, A, 2019) | 2.17 |
| "Piperacillin/tazobactam is a frequently prescribed antibiotic in pediatric intensive care units, but pharmacokinetic data to justify the optimal piperacillin/tazobactam dosing regimen are sparse in critically ill children." | ( Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. Cies, JJ; Kuti, JL; Schlichting, C; Shankar, V, 2014) | 2.13 |
| "Piperacillin/Tazobactam is a time-dependent antimicrobial combination (beta-lactam/beta-lactamase inhibitor) commonly used in the treatment of severe Gram-negative infections. " | ( Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation? Attivi, D; Gibaud, S, 2014) | 2.16 |
| "Piperacillin-tazobactam is a frequently used therapy in critically ill patients with pulmonary infection." | ( Pulmonary penetration of piperacillin and tazobactam in critically ill patients. Bentley, AM; Felton, TW; Goodwin, J; Hope, WW; Isalska, B; Malagon, I; McCalman, K; Whalley, S, 2014) | 1.43 |
| "Piperacillin-tazobactam is an antipseudomonal antibiotic frequently used in patients with cystic fibrosis (CF) to treat pulmonary exacerbations. " | ( Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis. Mayer, B; Meinus, C; Roehmel, JF; Schwarz, C, 2016) | 3.32 |
| "Piperacillin is an extended-spectrum penicillin antibiotic prescribed for moderate to severe infections." | ( Piperacillin-associated pulmonary infiltrates with eosinophilia: a case report. Kelsall, JT; Tseng, OL; Wilcox, PG, ) | 2.3 |
| "Piperacillin-tazobactam is a broad spectrum antimicrobial agent that can cause false-positive results in the commercial Platelia Aspergillus EIA test. " | ( Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market. Aquino, VR; Pasqualotto, AC; Severo, LC; Sukiennik, TC; Xavier, MO, 2009) | 2.09 |
| "Piperacillin-tazobactam is a frequently prescribed intravenous antibiotic for moderate to severe infections used in hospital settings because of its broad activity against many pathogenic bacteria including Pseudomonas aeruginosa. " | ( Pharmacokinetic evaluation of piperacillin-tazobactam. Hayashi, Y; Lipman, J; Paterson, DL; Roberts, JA, 2010) | 2.09 |
| "Piperacillin/ tazobactam is a parenteral drug." | ( Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin). Chalermsri, C; Sae-Jong, R; Suddhichupaiboon, S; Thamlikitkul, V; Tiengrim, S, 2011) | 1.3 |
| "Piperacillin-tazobactam is a good choice of treatment as monotherapy for surgical wound infection after clean-contaminated head and neck oncologic surgery." | ( Efficacy of piperacillin-tazobactam in the treatment of surgical wound infection after clean-contaminated head and neck oncologic surgery. Bernaldez, R; Collado, D; Rodrigo, JP; Sŭrez, C, 2004) | 2.15 |
| "Piperacillin-tazobactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity that includes Gram-positive and -negative aerobic and anaerobic bacteria. " | ( Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Dilay, L; Gin, A; Karlowsky, JA; Rubinstein, E; Walkty, A; Zhanel, GG, 2007) | 3.23 |
| "Piperacillin is a new semisynthetic, expanded-spectrum penicillin with marked activity against Pseudomonas aeruginosa. " | ( Biliary concentrations of piperacillin in patients undergoing cholecystectomy. Giron, JA; Hirschman, SZ; Meyers, BR, 1981) | 2.01 |
| "Piperacillin is a new semisynthetic penicillin with a broad spectrum of in vitro activity against common gram-negative urinary tract pathogens. " | ( Preliminary report comparing piperacillin and carbenicillin for complicated urinary tract infections. Lee, M; Ojeda, L; Swarifi, R; Tabib, M, 1982) | 2 |
| "Piperacillin was shown to be an effective single agent for the management of pelvic infections caused by mixed aerobic and anaerobic bacteria." | ( Comparative study of piperacillin versus cefoxitin in the treatment of obstetric and gynecologic infections. Hadley, WK; Ohm-Smith, M; Robbie, MO; Sweet, RL, 1983) | 1.31 |
| "Piperacillin sodium is a beta lactam antibiotic with a broad range of antibacterial activity that includes gram-negative bacilli, gram-positive cocci (except penicillinase-producing S. " | ( Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Finley, RS; Fortner, CL; Schimpff, SC, ) | 3.02 |
| "Piperacillin is a new semisynthetic penicillin which is similar in structure to carbenicillin and ticarcillin. " | ( Effects of sodium piperacillin on platelet function in normal volunteers. Gentry, LO; Jemsek, JG; Natelson, EA, 1981) | 2.04 |
| "Piperacillin is considered to be a safe and effective first line single agent treatment for early neonatal infection but because some Escherichia coli are resistant to it we recommend that a second agent be used in critically ill infants with neutropenia or meningitis." | ( Piperacillin in early neonatal infection. Darrell, J; Placzek, M; Sahathevan, M; Want, S; Whitelaw, A, 1983) | 2.43 |
| "Piperacillin/tazobactam is a new drug consisting of a highly active penicillin and a beta-lactamase inhibitor. " | ( Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections. Kinzig, M; Sörgel, F, 1994) | 1.99 |
| "Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-lactamase inhibitor. " | ( Pharmacokinetic characteristics of piperacillin/tazobactam. Kinzig, M; Sörgel, F, 1994) | 2.01 |
| "Piperacillin (PPR) is a widely prescribed ureidopenicillin of established efficacy against enterobacteria and P." | ( Perioperative pharmacokinetics of piperacillin during liver transplantation. Bourget, P; Ecoffey, C; Lesne-Hulin, A; Levaufre, B, 1996) | 1.29 |
| "Piperacillin/tazobactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity encompassing most Gram-positive and Gram-negative aerobic bacteria and anaerobic bacteria, including many pathogens producing beta-lactamases. " | ( Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Markham, A; Perry, CM, 1999) | 3.19 |
| "Piperacillin/tazobactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity against most Gram-positive and Gram-negative aerobic bacteria and anaerobic bacteria. " | ( Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. Plosker, GL; Young, M, 2001) | 3.2 |
| "Piperacillin is a ureido-penicillin characterized by the presence of a piperazine group at the position 6 of the beta-lactam ring. " | ( [Diffusion of piperacillin into bronchial secretions]. Bergogne-Bérézin, E; Berthelot, G; Kafe, H, 1986) | 2.07 |
| "Piperacillin sodium (PIPC) is a semisynthetic penicillin displaying high antibacterial activities against Gram-positive and Gram-negative bacteria including Pseudomonas sp., Proteus sp., etc. " | ( [Fundamental study of piperacillin sodium in term and premature neonates]. Hata, T; Hojyo, Y; Koyasu, H; Kozaki, T; Nakamura, I; Nonoda, T; Watanabe, T, 1987) | 2.03 |
| "Piperacillin is a semisynthetic penicillin with a broad-spectrum: in particular it is active against Gram positive, Gram negative, aerobic and anaerobic bacteria often resistant to other antibiotics of the same group. " | ( [Effectiveness of piperacillin in childhood infections]. Biella, CA; Portaleone, D; Siccardo, L; Simoni, L, ) | 1.91 |
| "Piperacillin is an extended-spectrum penicillin active against Pseudomonas. " | ( Pharmacokinetics of piperacillin in hospitalized patients. Lau, A; Lee, M; Sharifi, R, 1985) | 2.04 |
Piperacillin/tazobactam has a suitable spectrum of activity in vitro to suggest its use in monotherapy of mixed anerobic infections, mixed respiratory infections such as aspiration pneumonia. In combination with an aminoglycoside, it would provide Gram positive and Gram negative cover of febrile episodes in immunosuppressed patients.
Piperacillin has been found as effective as combination therapy (gentamicin or tobramycin plus carbenicillin or ticarcillin) in the treatment of serious infections. Piperacillin/tazobactam has been regarded as a standard treatment for cSSTIs.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Piperacillin-tazobactam has an excellent safety and tolerability profile and continues to be a reliable option for the empiric treatment of moderate-to-severe infections in hospitalized patients." | ( Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Dilay, L; Gin, A; Karlowsky, JA; Rubinstein, E; Walkty, A; Zhanel, GG, 2007) | 2.5 |
| "Piperacillin/tazobactam has a suitable spectrum of activity in vitro to suggest its use in monotherapy of mixed anerobic infections, mixed respiratory infections such as aspiration pneumonia and, in combination with an aminoglycoside, it would provide Gram positive as well as Gram negative cover of febrile episodes in immunosuppressed patients." | ( An evaluation of the in vitro activity of piperacillin/tazobactam. Daley, D; Dimech, W; Mulgrave, L; Munro, R; Neville, S; Smith, H, 1996) | 1.28 |
| "Piperacillin-tazobactam has a wide spectrum of activity that includes gram-positive organisms such as staphylococci and streptococci, as well as many gram-negative aerobic and anaerobic bacteria." | ( Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination. Daniel, KP; Krop, LC, ) | 2.3 |
| "Piperacillin-tazobactam has good activity against P." | ( Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Bulitta, JB; Drusano, GL; Duffull, SB; Holzgrabe, U; Kinzig-Schippers, M; Sörgel, F; Stephan, U, 2007) | 1.29 |
| "Piperacillin/tazobactam has been used extensively and empirically for EOS treatment without clinically validated dosing regimens, although the population pharmacokinetics (PPK) of piperacillin in neonates has been reported." | ( Clinical utiliy of a model-based piperacillin dose in neonates with early-onset sepsis. Dong, YN; Fang, ZY; Hao, GX; Hou, SS; Huang, X; Li, X; Shi, HY; Tang, BH; Van Den Anker, J; Wu, YE; Yao, BF; Yu, YH; Zhao, W; Zheng, Y, 2022) | 1.72 |
| "Piperacillin/tazobactam has been regarded as a standard treatment for cSSTIs because of its antibiotic spectrum, safety and clinical efficacy." | ( Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections. Hayashi, Y; Katayama, M; Suzuki, D; Takimoto, K; Wang, Q, 2017) | 1.5 |
| "Piperacillin has been reported as the drug responsible for this syndrome in 3 patients." | ( Piperacillin-induced DRESS: distinguishing features observed in a clinical and allergy study of 8 patients. Bellón, T; Bobolea, I; Caballero, T; Cabañas, R; Calderon, O; Fiandor, A; Herránz, P; López-Serrano, MC; Prior, N; Quirce, S; Ramirez, E, 2014) | 2.57 |
| "Piperacillin-tazobactam has recently been reformulated to include ethylenediaminetetraacetic acid and sodium citrate; this new formulation has been shown to be compatible in vitro with the two aminoglycosides, gentamicin and amikacin, allowing for simultaneous Y-site infusion, but not with tobramycin." | ( Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Dilay, L; Gin, A; Karlowsky, JA; Rubinstein, E; Walkty, A; Zhanel, GG, 2007) | 2.5 |
| "Piperacillin has been approved for patients with serious infection caused by susceptible strains of specific organisms in intra-abdominal, urinary tract, gynecologic, lower respiratory tract, skin and skin structure, bone and joint, and gonococcal infections and septicemia." | ( Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Finley, RS; Fortner, CL; Schimpff, SC, ) | 2.3 |
| "Piperacillin/tazobactam has excellent in vitro activity against the most pathogens involved in skin infections. " | ( Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections. File, TM; Tan, JS, 1994) | 2.04 |
| "Piperacillin-tazobactam has been reported to be superior to ticarcillin-clavulanate in community-acquired lower-respiratory-tract infections and superior to imipenem-cilastatin (at 1.5 g/day of imipenem) in intra-abdominal infection." | ( Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins. Jones, RN, 1995) | 1.01 |
| "Piperacillin has been used as antibiotic prophylaxis and been shown to be as efficacious as an aminoglycoside with metronidazole." | ( Infection after colorectal surgery: a randomized trial of prophylaxis with piperacillin versus sulbactam/piperacillin. West of Scotland Surgical Infection Study Group. Lindsay, G; Stewart, M; Taylor, EW, 1995) | 1.24 |
| "Piperacillin/tazobactam has a suitable spectrum of activity in vitro to suggest its use in monotherapy of mixed anerobic infections, mixed respiratory infections such as aspiration pneumonia and, in combination with an aminoglycoside, it would provide Gram positive as well as Gram negative cover of febrile episodes in immunosuppressed patients." | ( An evaluation of the in vitro activity of piperacillin/tazobactam. Daley, D; Dimech, W; Mulgrave, L; Munro, R; Neville, S; Smith, H, 1996) | 1.28 |
| "Piperacillin-tazobactam has a wide spectrum of activity that includes gram-positive organisms such as staphylococci and streptococci, as well as many gram-negative aerobic and anaerobic bacteria." | ( Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination. Daniel, KP; Krop, LC, ) | 2.3 |
| "Piperacillin (PIPC) has been used as one of the most useful beta-lactam antibiotics over the past 10 years. " | ( The formation of desethyl-piperacillin from piperacillin by human liver S9 in vitro. Allen, KL; Green, CE; Hayakawa, H; Komuro, M; Maeda, T, 1997) | 2.04 |
| "Piperacillin/tazobactam has shown clinical and economic advantages over standard antibacterial regimens in the treatment of intra-abdominal infections, LRTIs, febrile episodes in patients with neutropenia, and skin and soft tissue infections, although more complete published data are needed to confirm these results." | ( Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. Plosker, GL; Young, M, 2001) | 2.47 |
| "When piperacillin/tazobactam has been used to treat hospitalized patients with serious infections, including nosocomial pneumonia caused by Pseudomonas aeruginosa, it has usually been dosed at 3.375 g q4h to provide serum concentrations above commonly encountered organisms' MICs (T > MIC) for at least 40-50% of the dosing interval. " | ( Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Capitano, B; Kim, MK; Mattoes, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D, 2002) | 1.07 |
| "Piperacillin has been shown to be as safe and effective an agent as cephalothin and cefoxitin when used in patients undergoing elective intra-abdominal surgical procedures. " | ( A prospective double-blind comparison of piperacillin, cephalothin and cefoxitin in the prevention of postoperative infections in patients undergoing intra-abdominal operations. Baker, RJ; Donahue, PE; Finegold, SM; Johnson, WC; Middleton, JR; Monafo, WW; Wilson, SE, 1985) | 1.98 |
| "Piperacillin has also been found as effective as combination therapy (gentamicin or tobramycin plus carbenicillin or ticarcillin) in the treatment of serious infections, including pneumonia and several caused by gram-negative organisms and anaerobic organisms." | ( Respiratory infections: clinical evaluation. Grassi, C, 1985) | 0.99 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Piperacillin C(min) was lower than the breakpoint for Enterobacteriaceae in 37% of patients, and lower than the breakpoint for P." | ( Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Conil, JM; Cougot, P; Dieye, E; Georges, B; Houin, G; Mimoz, O; Ruiz, S; Saivin, S; Samii, K, 2006) | 1.3 |
Piperacillin/tazobactam treatment is associated with subsequent isolation of levofloxacin-resistant S. EI treatment with piperacillillin/ tazobactsam was a cost-effective approach to the management of HAP, being equally clinically effective to conventional II. Treatment with p Piperacillin alone was less effective than combinati.
Piperacillin/tazobactam has the advantage of covering Pseudomonas aeruginosa (bacteriologic success rate of 85%) Adverse event rate was non-significantly lower in the piperACillin/ tazobactsam group compared to the co-amoxiclav/aminoglycoside group.
The primary objectives of this analysis were to determine which pharmacokinetic model most accurately describes the elimination pathways for piperacillin in the presence of tazobactam and to characterize its pharmacodynamic profile.
ACHN-490 was tested alone and in combination with cefepime, doripenem, imipenam, or piperacillin-tazobactam against 25 Pseudomonas aeruginosa strains with different resistance phenotypes. The study aimed to investigate the mechanism of action of the cinnamon bark essential oil (CB) against beta-lactamase TEM-1.
The objectives of this study were to characterize the pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with CF. Monte Carlo simulations were performed to determine the probability of target attainment (PTA) for regimens.
| Role | Description |
|---|---|
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| penicillin | Any member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6. |
| penicillin allergen | Any penicillin which causes the onset of an allergic reaction. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-lactamase | Citrobacter freundii | Ki | 0.2000 | 0.0600 | 0.6000 | 2.0000 | AID405083 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 (µMol) | 1,226.0000 | 0.0003 | 2.6311 | 9.0000 | AID1207762 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 197.4000 | 0.1100 | 7.1903 | 10.0000 | AID1449628 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | Ki | 30,000.0000 | 0.1800 | 3.3933 | 9.8000 | AID238858 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 (µMol) | 1,226.0000 | 0.0003 | 2.5955 | 9.0000 | AID1207762 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 (µMol) | 1,226.0000 | 0.0003 | 2.6311 | 9.0000 | AID1207762 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 (µMol) | 1,226.0000 | 0.0003 | 2.2545 | 9.6000 | AID1207762 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-lactamase | Citrobacter gillenii | Km | 90.0000 | 10.0000 | 10.0000 | 10.0000 | AID285442 |
| Beta-lactamase | Escherichia coli | Km | 1.1000 | 1.1000 | 4.7667 | 9.4000 | AID394487 |
| Beta-lactamase | Aeromonas caviae | Km | 148.0000 | 7.0000 | 7.0000 | 7.0000 | AID374363 |
| Beta-lactamase | Shouchella clausii | Km | 21.0000 | 0.0100 | 3.0050 | 6.0000 | AID373209 |
| Beta-lactamase | Acinetobacter baumannii | Km | 16.0000 | 3.0000 | 5.6667 | 9.0000 | AID567279 |
| Beta-lactamase | Burkholderia cenocepacia | Km | 10.0000 | 10.0000 | 10.0000 | 10.0000 | AID541022 |
| Metallo-beta-lactamase type 2 | Klebsiella pneumoniae | Km | 12.0000 | 8.0000 | 9.3333 | 10.0000 | AID563972 |
| Beta-lactamase | Klebsiella pneumoniae | Km | 3.2000 | 3.2000 | 5.8250 | 10.0000 | AID562754 |
| Beta-lactamase | Pseudomonas aeruginosa | Km | 0.3000 | 0.3000 | 2.0063 | 8.0000 | AID495661 |
| Beta-lactamase | Aeromonas allosaccharophila | Km | 4.0000 | 1.5000 | 6.3000 | 10.0000 | AID584846 |
| Beta-lactamase | Acinetobacter baumannii | Km | 25.0000 | 6.0000 | 7.6667 | 10.0000 | AID567280 |
| Beta-lactamase SHV-1 | Klebsiella pneumoniae | Km | 24.0000 | 4.2000 | 4.2500 | 4.3000 | AID519746; AID519983 |
| Beta-lactamase | Pseudomonas aeruginosa PAO1 | Km | 100.0000 | 0.5000 | 4.2444 | 8.0000 | AID546426 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | Km | 90.0000 | 10.0000 | 10.0000 | 10.0000 | AID285442 |
| Beta-lactamase | Salmonella enterica subsp. enterica serovar Westhampton | Km | 12.0000 | 10.0000 | 10.0000 | 10.0000 | AID556340 |
| Metallo-beta-lactamase VIM-2 | Klebsiella pneumoniae | Km | 72.0000 | 5.0000 | 7.5000 | 10.0000 | AID563976 |
| Beta-lactamase | Klebsiella pneumoniae | Km | 8.0000 | 5.0000 | 7.1667 | 10.0000 | AID519982 |
| Beta-lactamase | Pseudomonas luteola | Km | 7.0000 | 7.0000 | 7.5000 | 8.0000 | AID495635 |
| BlaVIM-1 | Escherichia coli | Km | 3,500.0000 | 1.5000 | 1.5000 | 1.5000 | AID495914 |
| Beta-lactamase | Pseudomonas aeruginosa | Km | 40.0000 | 0.5000 | 2.7500 | 5.0000 | AID546429 |
| Carbapenem-hydrolyzing beta-lactamase KPC | Klebsiella pneumoniae | Km | 16.5000 | 1.6000 | 3.8000 | 6.0000 | AID374025; AID548044 |
| Beta-lactamase class B VIM-2 | Pseudomonas aeruginosa | Km | 125.0000 | 2.0000 | 6.6500 | 9.4000 | AID531315 |
| Beta-lactamase VIM-1 | Pseudomonas aeruginosa | Km | 1,377.0000 | 4.0000 | 4.0000 | 4.0000 | AID530340 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID541834 | Antimicrobial activity against Streptococcus pyogenes clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID576333 | Antibacterial activity against plasmid-mediated AmpC beta-Lactamase DHA-1 and ESBL-producing Klebsiella pneumoniae by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1. |
| AID521836 | Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID541533 | Antimicrobial activity against Enterococcus faecalis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574515 | Antimicrobial activity against Bacteroides ovatus assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID516142 | Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 7 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID544925 | Antimicrobial activity against Acinetobacter baumannii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID727657 | Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV-1 K234X protein mutant by CLSI agar dilution method | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID519628 | Antimicrobial activity against beta-lactamase OXA-63 producing Brachyspira pilosicoli isolate BM4442 isolated from feces of patient with diarrhea by disc diffusion method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID559918 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase RTG4 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID573786 | Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID544681 | Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID548011 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Q mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID573824 | Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID549330 | Antimicrobial activity against Escherichia coli isolate 16 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID562820 | Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID573576 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID516145 | Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 11 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID573592 | Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529494 | Antimicrobial activity against Enterobacter cloacae isolate 837 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID520883 | Activity of Achromobacter xylosoxidans CIP69598 beta-lactamase OXA-114a expressed in Escherichia coli TOP10 assessed as compound hydrolysis | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID520968 | Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID521840 | Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID574782 | Antimicrobial activity against Actinomyces odontolyticus after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID533419 | Antimicrobial activity against Micromonas micros by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID533408 | Antimicrobial activity against Clostridium tertium assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID559590 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID544504 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-2 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID573382 | Antibacterial activity against beta lactamase-positive Haemophilus influenzae by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID532439 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-38 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1373284 | Antimicrobial activity against Escherichia coli expressing beta-lactamase IMI-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID324860 | Antimicrobial activity against Acinetobacter baumannii A24B after 4 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID340726 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-15 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID547768 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBR322-catI carrying beta-lactamase KPC-2 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID573371 | Antibacterial activity against ceftazidime-susceptible Serratia marcescens assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID528843 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID573818 | Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID555218 | Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 65 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID533363 | Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID544495 | Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-2 to MIC for Escherichia coli TOP10 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID557431 | Antimicrobial activity in Bacteroides uniformis by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID541519 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557729 | Antimicrobial activity in Finegoldia magna by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID1257069 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after 20 hrs by CLSI broth microdilution method | 2015 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23 | Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID535064 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-7 plasmid by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID561443 | Antibacterial activity against Escherichia coli 34943 harboring beta-lactamase CMY-44 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID561487 | Antibacterial activity against Stenotrophomonas maltophilia by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID285608 | Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID546621 | Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID542628 | Antimicrobial activity against streptomycin-resistant Streptococcus pneumoniae R6 harboring PBP2x2349 mutant gene and Janus disruption at PBP1a and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID574524 | Antimicrobial activity against Prevotella oralis after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID584836 | Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID574023 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID531607 | Ratio of Kcat to Km for Escherichia coli beta-lactamase SHV-11 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID567328 | Antimicrobial activity against Escherichia coli TUM4670 by broth dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID544584 | Antimicrobial activity against Escherichia coli ATCC 25922 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID511387 | Antibacterial activity against ciprofloxacin susceptible Escherichia coli by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. |
| AID541507 | Antimicrobial activity against beta-lactamase-negative Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID495913 | Ratio of Kcat to Km for beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID285580 | Antimicrobial activity against Pseudomonas aeruginosa IC7 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID424320 | Antimicrobial activity against Dialister micraerophilus by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID574534 | Antimicrobial activity against Prevotella buccae assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID519736 | Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method in presence of 4 ug/ml Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID542625 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x2349 mutant gene, disruption in PBP1a and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID544688 | Antimicrobial activity against class A extended spectrum beta-lactamase- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID529000 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID372616 | Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-12 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID573353 | Antibacterial activity against ceftazidime-susceptible Escherichia coli assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID559266 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID541503 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID542623 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x T338P mutant gene, disruption at PBP1a and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID574504 | Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1604438 | Antibacterial activity against Pseudomonas aeruginosa haboring OXA-24/40 assessed as reduction in microbial growth by CLSI based broth microdilution method | 2020 | Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5 | β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs. |
| AID424322 | Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID511300 | Antibacterial activity against Escherichia coli DH5alpha pB-ges-1in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID535650 | Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3 harboring GyrA S83L, ParC S80R mutant, wild-type GyrB and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID541779 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535701 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A by agar dilution method in presence of 4 mg/liter Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID531605 | Activity of Escherichia coli beta-lactamase SHV-11 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID583040 | Antimicrobial activity against Escherichia coli ATCC 25922 by broth macrodilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Mathematical modeling to characterize the inoculum effect. |
| AID541811 | Antimicrobial activity against Enterococcus gallinarum clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID301743 | Antibacterial activity against Bacillus subtilis | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. |
| AID557975 | Antimicrobial activity in Clostridium tertium by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID584559 | Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID373760 | Antibacterial activity against imipenem-intermediate Acinetobacter baumannii ab1297 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID534303 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA483 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID285269 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM28 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID541544 | Antimicrobial activity against Enterococcus avium clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544670 | Antimicrobial activity against Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID562737 | Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID394487 | Activity of Escherichia coli beta-lactamase ACC4 by UV spectrophotometry | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID561286 | Antibacterial activity against Klebsiella oxytoca by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID574529 | Antimicrobial activity against Prevotella intermedia assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID575006 | Antimicrobial activity against Eubacterium sp. after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID521426 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID544690 | Antimicrobial activity against AmpC beta-lactamase-producing Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573845 | Antimicrobial activity against AmpC beta-lactamase producing Pseudomonas aeruginosa GC 1764 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID532998 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P11 exhibiting PFGE A pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID583183 | Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID511398 | Antibacterial activity against Pseudomonas aeruginosa by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID544913 | Antimicrobial activity against Proteus vulgaris clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544697 | Antimicrobial activity against Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID583097 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 A64W mutant beta-lactamase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID530335 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID534911 | Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541509 | Antimicrobial activity against beta-lactamase-negative Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID206991 | Antibacterial activity was determined against the Staphylococcus aureus ATCC 29213 | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID544928 | Antimicrobial activity against Acinetobacter haemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID534388 | Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID1373286 | Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-3 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID373203 | Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique in presence of beta-lactamase inhibitor Tazobactam | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID533379 | Antimicrobial activity against Bacteroides merdae by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID544885 | Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544917 | Antimicrobial activity against Providencia rettgeri clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID532917 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID555450 | Antibacterial activity against Escherichia coli DH5alpha by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID495836 | Antimicrobial activity against Escherichia coli harbouring plasmidBK-CMV expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID522026 | Antimicrobial activity against Escherichia coli isolate J53 harboring pEcA containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID522027 | Antimicrobial activity against Escherichia coli isolate J53 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID535837 | Antimicrobial activity against Pseudomonas aeruginosa GP20KT21 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID548259 | Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by spectrophotometric analysis | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID564695 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID583182 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID409957 | Inhibition of bovine liver MAOA | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. |
| AID529637 | Antimicrobial activity against Escherichia coli T-625 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID495791 | Antimicrobial activity against Pseudomonas fluorescens isolate PF-1 expressing beta-lactamase BIC-1 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID547781 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237I mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID529459 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase Oxa-48 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID574734 | Antimicrobial activity against Fusobacterium necrogenes after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID541501 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID571932 | Antimicrobial activity against Escherichia coli MC4100 harboring a weak promoter in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID557951 | Antimicrobial activity in Propionibacterium acnes by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID495636 | Ratio of kcat/Km for Pseudomonas luteola LAM Beta-lactamase LUT-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID573373 | Antibacterial activity against multidrug-resistant Acinetobacter by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID531509 | Antibacterial activity against Bacteroides fragilis isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID511389 | Antibacterial activity against Enterobacter cloacae by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. |
| AID529505 | Antimicrobial activity against Enterobacter cloacae isolate 293 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID571933 | Antimicrobial activity against Escherichia coli MC4100 harboring strong promoter in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID541532 | Antimicrobial activity against Enterococcus faecalis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544673 | Antimicrobial activity against Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574768 | Antimicrobial activity against Finegoldia magna assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID541511 | Antimicrobial activity against Haemophilus parainfluenzae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544685 | Antimicrobial activity against Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID558785 | Antimicrobial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID574759 | Antimicrobial activity against Peptoniphilus asaccharolyticus after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID495806 | Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID1475190 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12 | Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC. |
| AID573356 | Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID545426 | Antimicrobial activity against Enterobacter aerogenes obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID573558 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID573642 | Antimicrobial activity against penicillinase producing Staphylococcus aureus GC 6468 infected in CD-1 mouse treated 30 and 150 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID573552 | Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574767 | Antimicrobial activity against Finegoldia magna assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID573608 | Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574741 | Antimicrobial activity against Peptostreptococcus anaerobius after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID573840 | Antimicrobial activity against SHV-11 beta-lactamase producing Klebsiella pneumoniae GAR 7693 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID574994 | Antimicrobial activity against Bifidobacterium sp. after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID573794 | Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID573830 | Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID528998 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID530347 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID548019 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237D mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID285591 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID315705 | Antibacterial efficacy against Escherichia coli LSU 80-8 infected ip dosed CD1 mouse model | 2008 | Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4 | 5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of beta-lactamases. |
| AID544421 | Antimicrobial activity against Escherichia coli CU164A expressing beta-lactamase TEM-1 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID545627 | Antimicrobial activity against Pseudomonas aeruginosa PS5 with PFGE phenotype 7A expressing beta-lactamase KPC-2 obtained from sputum of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID573572 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID544920 | Antimicrobial activity against Providencia stuartii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID583186 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID373766 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh14 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID559807 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene complemented with wild type DNA oxidative repair system mutY gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID530346 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID283320 | Antimicrobial activity against Klebsiella pneumoniae KPN15-NL | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands. |
| AID535176 | Antimicrobial activity against imipenem susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541540 | Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID394489 | Activity of Hafnia alvei beta-lactamase ACC-1 | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID574533 | Antimicrobial activity against Prevotella bivia assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID533123 | Antimicrobial activity against Bacteroides distasonis by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID573358 | Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID520780 | Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID285612 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID531496 | Antibacterial activity against Bacteroides uniformis assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID541497 | Antimicrobial activity against Burkholderia cepacia clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574770 | Antimicrobial activity against Clostridium perfringens after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574030 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID285589 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1373298 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID326267 | Antibacterial activity against Escherichia coli DH5-alpha carrying pSCO1 encoding SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. |
| AID373052 | Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID522002 | Antimicrobial activity against Escherichia coli isolate J53 harboring p6A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID519982 | Activity of Klebsiella pneumoniae Beta-Lactamase SHV-55 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. |
| AID544437 | Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring empty plasmid by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID324866 | Antimicrobial activity against Acinetobacter baumannii A24D after 4 days in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID532396 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate FG-17X-08 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID544899 | Antimicrobial activity against AmpC- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID519743 | Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID574458 | Antimicrobial activity against Escherichia coli DH10B by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID524255 | Antimicrobial activity against Escherichia coli INSRA4590 expressing SHV-84 in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID558318 | Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID577233 | Antibacterial activity against intI1-negative tigecycline-intermediate Acinetobacter baumannii AB098 with PFGE subgroup F containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID523890 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID541814 | Antimicrobial activity against Enterococcus hirae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID524003 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-66 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID372322 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by CLSI broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. |
| AID561479 | Antibacterial activity against Pseudomonas aeruginosa by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID535118 | Antimicrobial activity against ceftazidime susceptible Serratia marcescens by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID511579 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID532999 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P9 exhibiting PFGE A pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID541535 | Antimicrobial activity against Enterococcus faecium clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574443 | Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID555557 | Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID573792 | Antibacterial activity against Prevotella bivia by by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID541792 | Antimicrobial activity against Bacteroides thetaiotaomicron clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID584847 | Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER6 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID424863 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID532585 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-11 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID555673 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring recombinant plasmid carrying CTX-M-53 gene by disk diffusion method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID562330 | Antimicrobial activity against Chryseobacterium indologenes 597 expressing metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID555555 | Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID573835 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID533399 | Antimicrobial activity against Clostridium paraputrificum by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID541534 | Antimicrobial activity against Enterococcus faecium clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID511390 | Antibacterial activity against Proteus mirabilis by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. |
| AID521995 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp3A expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID573340 | Antibacterial activity against ceftazidime-susceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID573609 | Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID567331 | Antimicrobial activity against Escherichia coli ML4901 by broth dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID529638 | Antimicrobial activity against Escherichia coli T-781 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID574993 | Antimicrobial activity against Bifidobacterium sp. after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID518522 | Antimicrobial activity against Capnocytophaga sputigena CIP 104301T after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID530350 | Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID574976 | Antimicrobial activity against Actinomyces meyeri after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID544897 | Antimicrobial activity against AmpC- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573364 | Antibacterial activity against ceftazidime-susceptible Morganella morganii by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID555558 | Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID535066 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 by Vitek II system in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID544934 | Antimicrobial activity against Acinetobacter junii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535834 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP62 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID574450 | Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID522388 | Activity of Aeromonas enteropelogenes Beta-lactamase TRU1 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID565669 | Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID574974 | Antimicrobial activity against Actinomyces israelii assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID535069 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-6 plasmid by Vitek II system in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID562225 | Antimicrobial activity against Desulfovibrio sp. in presence of Tazobactam by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID530342 | Ratio of Kcat to Km for Pseudomonas aeruginosa VIM-13 beta-lactamase | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID541797 | Antimicrobial activity against Clostridium perfringens clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573334 | Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID372626 | Ratio of Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-12 to Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-158 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID495634 | Antimicrobial activity against Escherichia coli DH10B by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID574051 | Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID534309 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA483 in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID540965 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBCSK plasmid by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID573599 | Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID1373300 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-16 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID544676 | Antimicrobial activity against Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID565690 | Antimicrobial activity against beta-lactamase negative ampicillin-resistant-Haemophilus influenzae harboring fst1 mutant gene by disk diffusion method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID541812 | Antimicrobial activity against Enterococcus gallinarum clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544696 | Antimicrobial activity against Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID521993 | Antimicrobial activity against Klebsiella pneumoniae isolate KpB expressing OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID532391 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A1 isolate FG-17X-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID562754 | Activity of Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID559920 | Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-S69 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID524252 | Antimicrobial activity against Escherichia coli DH5alpha in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID528996 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID69008 | In vitro synergistic activity against Escherichia coli C600N + (SHV-4) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID535662 | Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID528491 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4663 expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID529303 | Antimicrobial activity against Acinetobacter genospecies 3 isolate Ac057 expressing beta-lactamase Oxa-58 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. |
| AID574988 | Antimicrobial activity against Bifidobacterium adolescentis after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID372612 | Antibacterial activity against rifampin-resistant Escherichia coli C600 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID544678 | Antimicrobial activity against AmpC beta-lactamase-producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID584555 | Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID573344 | Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID373768 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh18 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID564527 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID374022 | Activity of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID495824 | Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID495833 | Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID325447 | Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Polyamine effects on antibiotic susceptibility in bacteria. |
| AID573641 | Antimicrobial activity against OXA-1 beta-lactamase producing Escherichia coli GAR 5946 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID422495 | Antimicrobial activity against Escherichia coli BL21 (DE3) harboring pAT514 by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID559264 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID548258 | Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID532920 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID541523 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573606 | Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID573379 | Antibacterial activity against beta lactamase-negative Haemophilus influenzae by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID585397 | Activity at Stenotrophomonas maltophilia 1SML metallo-beta-lactamase L1 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. |
| AID549338 | Antimicrobial activity against Escherichia coli isolate 16 harboring bla CTX-M-3a gene by broth microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID533407 | Antimicrobial activity against Clostridium tertium by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID532445 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-10 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID573651 | Antimicrobial activity against AmpC beta-lactamase producing Pseudomonas aeruginosa GC 1764 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID544906 | Antimicrobial activity against Morganella morganii clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID541520 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573394 | Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID541783 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID532442 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-07 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID574982 | Antimicrobial activity against Actinomyces naeslundii after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID373752 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab3 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID565425 | Antimicrobial activity against beta-lactamase-producing Pseudomonas aeruginosa clinical isolate by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. |
| AID532992 | Antibacterial activity against PER-1 producing Pseudomonas aeruginosa isolate P170 exhibiting PFGE G pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID541789 | Antimicrobial activity against Bacteroides fragilis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574483 | Antimicrobial activity against Bacteroides fragilis after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574760 | Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID279186 | Activity of Enterobacter cloacae S3 isolate beta lactamase LAP1 expressed in Escherichia coli DH10B | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID562811 | Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID405080 | Antimicrobial activity against Citrobacter freundii 33587 isolate by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID558797 | Antimicrobial activity against extended spectrum beta-lactamase-deficient Escherichia coli assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID429079 | Antibacterial activity against Klebsiella pneumoniae Greece producing KPC-2 beta-lactamase by E test method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. |
| AID529490 | Antimicrobial activity against Enterobacter cloacae isolate 354 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID534619 | Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID571934 | Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 1 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID565689 | Antimicrobial activity against beta-lactamase-positive ampicillin-resistant Haemophilus influenzae harboring fst1 mutant gene assessed as susceptible isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID544687 | Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557733 | Antimicrobial activity in Micromonas micros by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID285266 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM151 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID586057 | Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring plasmid encoded ISAba1-blaOXA-51-like gene with nuc upstream sequence by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. |
| AID573357 | Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID533767 | Antibacterial activity against VEB-1a and OXA-10 producing Pseudomonas aeruginosa isolate P151 exhibiting PFGE I pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID574519 | Antimicrobial activity against Prevotella intermedia after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1373313 | Antimicrobial activity against Escherichia coli expressing beta-lactamase MIR-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID541498 | Antimicrobial activity against Stenotrophomonas maltophilia clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574522 | Antimicrobial activity against Prevotella buccae after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID544907 | Antimicrobial activity against Morganella morganii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544895 | Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID561475 | Antibacterial activity against Serratia marcescens assessed as intermediate isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID544892 | Antimicrobial activity against class A extended spectrum beta-lactamase- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID547797 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237F mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID560130 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 by disk diffusion method in presence of 4 ug/ml Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID422494 | Antimicrobial activity against Escherichia coli BL21 (DE3) by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID587728 | Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-1-pLBII after 18 hrs by microdilution broth method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID574774 | Antimicrobial activity against Clostridium perfringens assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID541517 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557451 | Antimicrobial activity in Prevotella denticola by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID564481 | Antimicrobial activity against Pseudomonas aeruginosa isolate 927 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID567329 | Antimicrobial activity against Escherichia coli TUM4672 by broth dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID394495 | Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc4 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID561444 | Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-33 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID530356 | Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID541505 | Antimicrobial activity against beta-lactamase-producing Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544442 | Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring empty plasmid by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID520898 | Antibacterial activity against Achromobacter xylosoxidans DUC in presence of 4 ug/ml Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID544896 | Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID727795 | Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV-1 K234A protein mutant by CLSI agar dilution method | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID542054 | Antibacterial activity against Klebsiella pneumoniae B expressing CTX-M group 1 beta-lactamase by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID534099 | Antibacterial activity against Acinetobacter baumannii PFGE type A isolate by microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital. |
| AID529483 | Antimicrobial activity against Enterobacter cloacae isolate 151 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID544891 | Antimicrobial activity against class A extended spectrum beta-lactamase- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID560131 | Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID575007 | Antimicrobial activity against Eubacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID533367 | Antimicrobial activity against Bacteroides uniformis by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID535152 | Antimicrobial activity against ceftazidime susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID523268 | Activity at Escherichia coli isolate HN1157 AcrAB-TolC efflux transporter | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. |
| AID574743 | Antimicrobial activity against Peptostreptococcus micros after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1449628 | Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. |
| AID524253 | Antimicrobial activity against Escherichia coli DH5alpha expressing SHV-1 in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID560115 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase RTG3 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID557689 | Antimicrobial activity in Prevotella veroralis by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID544693 | Antimicrobial activity against AmpC beta-lactamase-producing Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557737 | Antimicrobial activity in Peptostreptococcus anaerobius by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID511687 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PA01 deficient in dacB gene by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID560495 | Antibacterial activity against 5 x 10'5 CFU/ml CMY-2 producing Escherichia coli MC4100 harboring plasmid AC-cmy2 by microdilution method in presence of 4 ug/ml Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID574040 | Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID324852 | Antimicrobial activity against Acinetobacter baumannii D54 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID544901 | Antimicrobial activity against Klebsiella oxytoca clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID522021 | Antimicrobial activity against Enterobacter cloacae isolate 2 expressing beta-lactamase OXA-48 and SHV-5 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID573793 | Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID532198 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42 harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID574026 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID541521 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID529201 | Antibacterial activity against ESBL-producing Escherichia coli isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. |
| AID531503 | Antibacterial activity against Bacteroides ovatus isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID545659 | Antimicrobial activity against Acinetobacter sp. assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID405823 | Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID544884 | Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535059 | Antimicrobial activity against Acinetobacter genomic species 13TU by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID530340 | Activity of Pseudomonas aeruginosa VIM-1 beta-lactamase | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID530814 | Antibacterial activity against Klebsiella pneumoniae 11978 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID207191 | In vitro minimum inhibitory concentration against Methicillin-resistant Staphylococcus aureus (GC 4542) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID531491 | Antibacterial activity against Bacteroides spp. assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID544931 | Antimicrobial activity against Acinetobacter johnsonii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID587733 | Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID564219 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID406437 | Volume of distribution at steady state in cystic fibrosis patient with lean body mass of 53 kg at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID573646 | Antimicrobial activity against SHV-11 beta-lactamase producing Klebsiella pneumoniae GAR 7693 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID573588 | Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID520897 | Antibacterial activity against Achromobacter xylosoxidans LOL in presence of 4 ug/ml Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID541786 | Antimicrobial activity against Streptococcus agalactiae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID532403 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone E isolate VA-06X-29 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID532916 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID495830 | Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID541788 | Antimicrobial activity against Bacteroides fragilis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID529504 | Antimicrobial activity against Enterobacter cloacae isolate 185 containing PFGE genetic clone A expressing qnrB2 aac(6')-Ib-cr and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID530829 | Antibacterial activity against Escherichia coli J53 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID540949 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBCSK plasmid by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID522381 | Antimicrobial activity against blaKPC-possessing Klebsiella pneumoniae isolates assessed as susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID560555 | Antimicrobial activity against Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID533395 | Antimicrobial activity against Clostridium innocuum by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID534914 | Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541790 | Antimicrobial activity against Bacteroides thetaiotaomicron clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID559271 | Antimicrobial activity against Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID541795 | Antimicrobial activity against Bacteroides uniformis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID564534 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position and R210P substitution by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID374023 | Activity of Enterobacter cloacae IMI1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID200990 | Synergistic activity of compound was determined against SPM-1 beta lactamase produced by Escherichia coli | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID573625 | Antimicrobial activity against TEM-10 beta-lactamase producing Escherichia coli GC 2022 infected in CD-1 mouse treated 30 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID574978 | Antimicrobial activity against Actinomyces meyeri assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID544924 | Antimicrobial activity against Acinetobacter baumannii clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544669 | Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID541506 | Antimicrobial activity against beta-lactamase-producing Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544675 | Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557745 | Antimicrobial activity in Anaerococcus tetradius by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID532192 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID207368 | In vitro synergistic activity against Staphylococcus aureus (PC1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID535119 | Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541810 | Antimicrobial activity against Enterococcus durans clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID560133 | Ratio of Kcat to Km for recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID574771 | Antimicrobial activity against Clostridium perfringens after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID373753 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab4 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID544911 | Antimicrobial activity against Proteus mirabilis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID584754 | Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID573336 | Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID541835 | Antimicrobial activity against Streptococcus agalactiae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID555199 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox after 18 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID1373308 | Antimicrobial activity against Escherichia coli expressing beta-lactamase SPM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID567279 | Activity of Acinetobacter baumannii ADC-33 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID587729 | Antimicrobial activity against Escherichia coli DH5alpha carrying empty pBC-SK after 18 hrs by microdilution broth method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID545643 | Antimicrobial activity against Pseudomonas aeruginosa PS23 with PFGE phasotype 4A expressing beta-lactamase KPC-2 obtained from blood of patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID573349 | Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID205372 | In vivo inhibitory activity against Serratia marcescens in mice | 1999 | Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7 | 6-(1-Hydroxyalkyl))penam sulfone derivatives as inhibitors of class A and class C beta-lactamases II. |
| AID545631 | Antimicrobial activity against Pseudomonas aeruginosa PS10 with PFGE phenotype 1A expressing beta-lactamase KPC-2 obtained from blood of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID574740 | Antimicrobial activity against Peptostreptococcus anaerobius after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID540958 | Antimicrobial activity against Salmonella enterica serotype Newport AM17274 expressing CMY-31 cephalosporinase by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID544424 | Antimicrobial activity against Escherichia coli CU164A harboring beta-lactamase CTX-M-14 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID532928 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID534304 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA494 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID567585 | Antimicrobial activity against Acinetobacter baumannii by broth dilution method in presence of beta-lactamase inhibitor Sulbactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID516143 | Antibacterial activity against Pulsotype B Acinetobacter genomosp. 3 isolate 8 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID374025 | Activity of Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID520879 | Antibacterial activity against Achromobacter xylosoxidans DUC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID1373287 | Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-4 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID561463 | Antibacterial activity against Proteus mirabilis by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID541547 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID563973 | Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase NDM-1 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID519472 | Antimicrobial activity against Stenotrophomonas maltophilia K279a harboring -121 frameshift mutation in ampR gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator. |
| AID545626 | Antimicrobial activity against Pseudomonas aeruginosa PS4 with PFGE phasotype 9B expressing beta-lactamase IMP-18 obtained from sputum of patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID1373317 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-23 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID373209 | Activity of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID574523 | Antimicrobial activity against Prevotella buccae after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID405089 | Antibacterial activity against blaVIM2-harboring integrons containing Pseudomonas aeruginosa 42 isolate from ventilator-associated pneumonia patient | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence. |
| AID561447 | Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID535178 | Antimicrobial activity against imipenem susceptible Acinetobacter assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID495649 | Antimicrobial activity against Pseudomonas luteola LAM expressing blaLUT-1 by Etest method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID369641 | Antibacterial activity against Acinetobacter baumannii B clone by Etest method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. |
| AID541510 | Antimicrobial activity against Haemophilus parainfluenzae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID576288 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16855 harboring porin OmpK36 and OmpK35 genes by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID545623 | Antimicrobial activity against Pseudomonas aeruginosa PS1 with PFGE phenotype 9C expressing beta-lactamase IMP-18 and OXA-2 obtained from sputum of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID519627 | Antimicrobial activity against Brachyspira pilosicoli 80.10 without producing beta-lactamase OXA-63 by disc diffusion method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID522023 | Antimicrobial activity against Citrobacter freundii isolate expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID373054 | Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID531490 | Antibacterial activity against Bacteroides eggerthii assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID562821 | Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID535060 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID573391 | Antibacterial activity against ceftazidime-susceptible Providencia sp. by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID533383 | Antimicrobial activity against Bacteroides nordii by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID562226 | Antimicrobial activity against Desulfovibrio fairfieldensis in presence of Tazobactam by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID573396 | Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID206379 | In vitro minimum inhibitory concentration against methicillin-resistant Coagulase-negative Staphylococci (MRCNS) (GC 4547) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID544694 | Antimicrobial activity against Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557749 | Antimicrobial activity in Anaerococcus prevotii by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID279183 | Antibacterial activity against Escherichia coli DH10B expressing recombinant beta lactamase LAP1 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID555221 | Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 109 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID574726 | Antimicrobial activity against Prevotella oralis assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574742 | Antimicrobial activity against Peptostreptococcus micros after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID530345 | Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID546622 | Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID511581 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID372614 | Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-158 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID68398 | In vitro minimum inhibitory concentration against vancomycin-susceptible Enterococcus faecium (GC 4556) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID544889 | Antimicrobial activity against Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID325444 | Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Polyamine effects on antibiotic susceptibility in bacteria. |
| AID1373297 | Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-7 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID531772 | Antimicrobial activity against Pseudomonas aeruginosa pleural fluid isolate 4679 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID533865 | Antibacterial activity against toxin-positive Clostridium difficile clinical isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. |
| AID68874 | In vitro synergistic activity against Escherichia coli 4100 + (CCRA) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID519737 | Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID548008 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Q mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID562223 | Antimicrobial activity against Desulfovibrio desulfuricans MB by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID534382 | Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID406436 | Clearance in cystic fibrosis patient with lean body mass of 53 kg at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID577232 | Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB166 with PFGE subgroup A3 containing carbapenemase OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID535375 | Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID285257 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha CL1295 isolate expressing pBK-TEM-151 and CMT by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID557963 | Antimicrobial activity in Clostridium perfringens by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID564692 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID574527 | Antimicrobial activity against Prevotella intermedia assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID542624 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x T338G mutant gene, disruption at PBP1a and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID555215 | Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 14 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID564524 | Antimicrobial activity against Acinetobacter baumannii KI by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID529635 | Antimicrobial activity against Enterobacter cloacae isolate 4469 containing PFGE genetic clone C expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID70901 | In vitro antibacterial activity against AmpC producing Escherichia coli (GC2894) | 2001 | Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8 | Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors. |
| AID529577 | Ratio of Kcat to Km for Pseudomonas maltophilia ULA-511 beta-Lactamase L-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID541499 | Antimicrobial activity against Stenotrophomonas maltophilia clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535124 | Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID545450 | Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella oxytoca assessed as percent susceptible isolates be agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID285573 | Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573836 | Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID573345 | Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID574987 | Antimicrobial activity against Bifidobacterium adolescentis after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID573597 | Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID531499 | Antibacterial activity against Bacteroides stercoris isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID285439 | Antimicrobial activity against Citrobacter gillenii CIP 106783 after 18 hrs by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID533371 | Antimicrobial activity against Bacteroides vulgatus by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID541529 | Antimicrobial activity against Staphylococcus haemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID561471 | Antibacterial activity against Serratia marcescens by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID530349 | Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID544689 | Antimicrobial activity against AmpC beta-lactamase-producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID519633 | Ratio of Kcat to Km for Brachyspira pilosicoli beta-lactamase OXA-63 expressed in Escherichia coli BL21 (DE3) assessed as compound hydrolysis by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID530817 | Antibacterial activity against Escherichia coli J53 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID373770 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh26 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID565204 | Antimicrobial activity against Klebsiella pneumoniae isolate T-1780 expressing VIM-1 and KPC-2 genes by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID520775 | Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID529145 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID562738 | Antimicrobial activity against Escherichia coli K-12 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID557713 | Antimicrobial activity in Fusobacterium nucleatum by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID542106 | Antibacterial activity against Escherichia coli TrC C expressing Klebsiella pneumoniae C blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID574050 | Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID495915 | Ratio of Kcat to Km for beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID326266 | Antibacterial activity against Escherichia coli K12 carrying pR3521 encoding SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. |
| AID573848 | Antimicrobial activity against penicillinase producing Staphylococcus aureus GC 6468 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID543427 | Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID544926 | Antimicrobial activity against Acinetobacter baumannii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID540960 | Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pA172 plasmid expressing cephalosporinase CMY-31 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID559274 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID584835 | Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID567312 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2203 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID544434 | Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring beta-lactamase AmpC by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID544905 | Antimicrobial activity against Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID567578 | Antimicrobial activity against Acinetobacter baumannii assessed as resistant isolate by broth dilution method in presence of beta-lactamase inhibitor Sulbactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID548263 | Selectivity index, Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant to ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID43898 | In vitro antibacterial activity against Serratia marcescens GC4132 Beta-lactamase AmpC of class C enzyme | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone. |
| AID531502 | Antibacterial activity against Bacteroides spp. isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID561278 | Antibacterial activity against Klebsiella pneumoniae by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID584566 | Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID531773 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4688 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID520895 | Antibacterial activity against Achromobacter xylosoxidans CIP69598 in presence of 4 ug/ml Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID584753 | Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID544439 | Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring beta-lactamase CTX-M-14 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID571937 | Antimicrobial activity against Escherichia coli MC4100 harboring strong promoter and active promoter P2 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID727655 | Activity of Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID495802 | Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID533380 | Antimicrobial activity against Bacteroides merdae assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID557459 | Antimicrobial activity in Prevotella nigrescens by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID575005 | Antimicrobial activity against Eubacterium sp. after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID406432 | Volume of distribution at steady state in healthy human at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID541539 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID571220 | Antimicrobial activity against Pseudomonas aeruginosa isolate 164CD obtained from patient with non-cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID573355 | Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID560489 | Antibacterial activity against 5 x 10'5 CFU/ml CMY-2 producing Escherichia coli MC4100 harboring plasmid AC-cmy2 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID68871 | In vitro synergistic activity against Escherichia coli 300 + (TEM-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID373771 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh29 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID574025 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574991 | Antimicrobial activity against Bifidobacterium adolescentis assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID573565 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574455 | Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID285601 | Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1373299 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-10 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID562781 | Antimicrobial activity against Escherichia coli DH10B by Etest in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate. |
| AID535121 | Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID542613 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x T338A mutant gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID519630 | Antimicrobial activity against Escherichia coli JM83 harboring beta-lactamase OXA-63 after 3 days by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID524245 | Antimicrobial activity against Escherichia coli DH5alpha expressing SHV-1 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID535373 | Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient assessed as intermediate isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541787 | Antimicrobial activity against Bacteroides fragilis clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID283219 | Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. |
| AID372640 | Ratio of Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-35 to Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-158 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID547776 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237A mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID340734 | Antimicrobial activity against Escherichia coli HB101 harboring pBC-SK plasmid assessed as drug level at which microbial resistance was observed by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID544888 | Antimicrobial activity against Citrobacter koseri clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574485 | Antimicrobial activity against Bacteroides thetaiotaomicron after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID573366 | Antibacterial activity against ceftazidime-susceptible Morganella morganii assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID563970 | Antibacterial activity against Escherichia coli J53 harboring beta-lactamase NDM-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID573628 | Antimicrobial activity against SHV-1and SHV-5 beta-lactamase producing Klebsiella pneumoniae GAR 7978 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID519635 | Activity of Brachyspira pilosicoli beta-lactamase OXA-63 expressed in Escherichia coli BL21 (DE3) assessed as compound hydrolysis by spectrophotometry relative to oxacillin | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID544919 | Antimicrobial activity against Providencia stuartii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID495799 | Ratio of Kcat to Km of KPC-2 using nitrocefin hydrolysis | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID530341 | Ratio of Kcat to Km for Pseudomonas aeruginosa VIM-1 beta-lactamase | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID530339 | Activity of Pseudomonas aeruginosa VIM-13 beta-lactamase | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID541815 | Antimicrobial activity against Enterococcus hirae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573590 | Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID545456 | Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID534639 | Antimicrobial activity against ESBL producing Escherichia coli assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541538 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535863 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47 harboring qnrB and qnrS genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID498872 | Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate. |
| AID571035 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA22 obtained from patient with cystic fibrosis by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID518732 | Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase DIM-1 by agar dilution method in presence of beta-lactam inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID567304 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2202 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID530828 | Antibacterial activity against Escherichia coli J53 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID529507 | Antimicrobial activity against Enterobacter cloacae isolate 622 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID530332 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID544671 | Antimicrobial activity against Citrobacter koseri clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID528990 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID544903 | Antimicrobial activity against Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573823 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID207199 | In vitro minimum inhibitory concentration against Methicillin-susceptible Staphylococcus aureus(GC 4545) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID520782 | Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 in presence of Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID576061 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 71697 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID544937 | Antimicrobial activity against Acinetobacter lwoffii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID562334 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pBC-SK after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID574521 | Antimicrobial activity against Prevotella bivia after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID584759 | Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID561489 | Antibacterial activity against Acinetobacter baumannii by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID534618 | Antimicrobial activity against ceftazidime non-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID558535 | Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P843 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID558539 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P1826 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID535153 | Antimicrobial activity against ceftazidime non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID565685 | Antimicrobial activity against beta-lactamase-positive ampicillin-resistant Haemophilus influenzae harboring fst1 mutant gene by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID546429 | Activity at Pseudomonas aeruginosa PDC-5 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID544938 | Antimicrobial activity against Acinetobacter lwoffii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID522001 | Antimicrobial activity against Escherichia coli isolate J53 harboring p5A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID573640 | Antimicrobial activity against OXA-1 beta-lactamase producing Escherichia coli GAR 5946 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID541793 | Antimicrobial activity against Bacteroides uniformis clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID495911 | Antimicrobial activity in Escherichia coli J53 strain | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID542614 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x T338P mutant gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID542626 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x T338G and PBP1a2349 mutant gene and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID206381 | In vitro minimum inhibitory concentration against methicillin-resistant Coagulase-negative Staphylococci (MRCNS) (GC 4548) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID573556 | Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529481 | Antimicrobial activity against Enterobacter cloacae isolate 18 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID557427 | Antimicrobial activity in Bacteroides distasonis by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID574981 | Antimicrobial activity against Actinomyces naeslundii after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID584760 | Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID544922 | Antimicrobial activity against Acinetobacter calcoaceticus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID203143 | In vitro inhibitory activity against Serratia marcescens | 1999 | Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7 | 6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C beta-lactamases I. |
| AID533133 | Antimicrobial activity against Bacteroides fragilis by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID541531 | Antimicrobial activity against Enterococcus faecalis clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID559586 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID555190 | Ratio of MIC for Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox deltaampDh3::lox deltanagZ::Gm in presence of beta-lactamase inhibitor Tazobactam to MIC for nagZ gene-deficient Pseudomonas aeruginosa PAO1 in presence of beta-lactama | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID521842 | Antibacterial activity against Escherichia coli J53 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID522008 | Antimicrobial activity against Escherichia coli isolate J53 harboring pI-2 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID564476 | Antimicrobial activity against Pseudomonas aeruginosa isolate 896 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID68399 | In vitro minimum inhibitory concentration against vancomycin-susceptible Enterococcus faecium (GC 4557) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID562224 | Antimicrobial activity against Desulfovibrio piger by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID285606 | Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID574518 | Antimicrobial activity against Prevotella intermedia after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID541527 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID519012 | Activity of Beta-lactamase TEM-10 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID541508 | Antimicrobial activity against beta-lactamase-negative Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID541809 | Antimicrobial activity against Enterococcus durans clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535147 | Antimicrobial activity against ceftazidime non-susceptible Pseudomonas aeruginosa by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID544933 | Antimicrobial activity against Acinetobacter junii clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535836 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP37 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID573626 | Antimicrobial activity against SHV-1and SHV-5 beta-lactamase producing Klebsiella pneumoniae GAR 7978 infected in CD-1 mouse treated 30 and 150 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID529155 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1373280 | Antimicrobial activity against wild type Escherichia coli by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID396032 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID528991 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID534913 | Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID544429 | Antimicrobial activity against Escherichia coli MC4100A harboring beta-lactamase L2 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID516146 | Antibacterial activity against Pulsotype J Acinetobacter genomosp. 3 isolate 15 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID727796 | Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV-1 K234R protein mutant by CLSI agar dilution method | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID531315 | Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID68870 | In vitro synergistic activity against Escherichia coli 300 (no beta-lactamase, imp mutant) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID541514 | Antimicrobial activity against Moraxella catarrhalis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID332075 | Antibacterial activity against Pseudomonas aeruginosa by agar dilution method | 2008 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11 | Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors. |
| AID573657 | Antimicrobial activity against TEM-10 beta-lactamase producing Escherichia coli GC 2022 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID200364 | Beta-Lactamase inhibitory activity against representative class C (AmpC) serine enzyme from Escherichia coli P99 | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID533411 | Antimicrobial activity against Finegoldia magna by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID544679 | Antimicrobial activity against AmpC beta-lactamase-producing Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID576306 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 287942 harboring porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID508741 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent nonsusceptible isolates by broth microdilution assay | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID548027 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237H mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID535712 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 S287N mutant protein by agar dilution method in presence of 4 mg/liter Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID541530 | Antimicrobial activity against Staphylococcus haemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID163429 | The compound was evaluated for antimicrobial activity against Pseudomonas aeruginosa OC 4270 by inhibiting enzyme AmpC(ind) | 2000 | Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19 | The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. |
| AID535146 | Antimicrobial activity against ceftazidime susceptible Pseudomonas aeruginosa by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID425863 | Antimicrobial activity against Carnobacterium divergens CIP101029 at 0.5 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID560591 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID535180 | Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID322317 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID559643 | Antimicrobial activity against Extended-spectrum beta-lactamase producing Escherichia coli clinical isolate assessed as resistant isolate in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. |
| AID541799 | Antimicrobial activity against Peptostreptococcus anaerobius clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID530326 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID541780 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID583158 | Antimicrobial activity against ampC::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID574489 | Antimicrobial activity against Bacteroides distasonis after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID555559 | Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID544912 | Antimicrobial activity against Proteus vulgaris clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID555214 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID564228 | Activity of Escherichia coli TOP10 beta-lactamase OXA-143 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID573643 | Antimicrobial activity against penicillinase producing Staphylococcus aureus GC 6468 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID429078 | Antibacterial activity against Escherichia coli J53 expressing Klebsiella pneumoniae Greece blaKPC-2 gene by E test method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. |
| AID573377 | Antibacterial activity against imipenem-susceptible Acinetobacter assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID576291 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 6267 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID519749 | Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-72 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID530323 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID544695 | Antimicrobial activity against Citrobacter koseri clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557979 | Antimicrobial activity in Clostridium ramosum by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID574488 | Antimicrobial activity against Bacteroides distasonis after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID544420 | Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 expressing beta-lactamase TEM-1 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID301748 | Apparent permeability across Caco-2 cells | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. |
| AID541516 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID528835 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID564480 | Antimicrobial activity against Pseudomonas aeruginosa isolate 913 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID584848 | Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER2 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID68875 | In vitro synergistic activity against Escherichia coli ATCC 25922 (no beta-lactamase) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID574764 | Antimicrobial activity against Finegoldia magna after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID541542 | Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID585402 | Ratio of Kcat to Km for Chryseobacterium meningosepticum NCTC 10585 metallo-beta-lactamase GOB-1 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. |
| AID545630 | Antimicrobial activity against Pseudomonas aeruginosa PS9 with PFGE phenotype 3B obtained from sputum of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID523892 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-23 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID574042 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529579 | Ratio of Kcat to Km for Legionella gormanii ATCC 33297T beta-Lactamase FEZ-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID529632 | Antimicrobial activity against Enterobacter cloacae isolate 658 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID496593 | Activity at Escherichia coli DH10B beta-lactamase KPC-2 by diode array spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. |
| AID544936 | Antimicrobial activity against Acinetobacter lwoffii clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID562328 | Antimicrobial activity against Chryseobacterium indologenes 597 expressing metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID574977 | Antimicrobial activity against Actinomyces meyeri assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID324858 | Antimicrobial activity against Acinetobacter baumannii A24A after 4 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID563975 | Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase IMP1 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID547788 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237L mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID541512 | Antimicrobial activity against Haemophilus parainfluenzae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID405083 | Inhibition of Citrobacter freundii PER2 beta lactamase | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID519007 | Antimicrobial activity against Escherichia coli HB101 expressing plasmid encoded TEM-149 T182M mutant by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID529147 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID285584 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID547995 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Y mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID529203 | Antibacterial activity against AmpC-producing Escherichia coli isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. |
| AID575001 | Antimicrobial activity against Eubacterium lentum assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1824273 | Antimicrobial activity against Escherichia coli clinical isolate T2228 expressing VIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay | 2022 | European journal of medicinal chemistry, Jan-15, Volume: 228 | Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases. |
| AID373202 | Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor Tazobactam | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID544909 | Antimicrobial activity against Proteus mirabilis clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID584846 | Activity at Aeromonas allosaccharophila AL-1 beta-lactamase PER6 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID285590 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID585214 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-1 E104, G170 mutant in presence of at 4 ug/ml Tazobactam by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID544668 | Antimicrobial activity against class A extended spectrum beta-lactamase- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574482 | Antimicrobial activity against Bacteroides fragilis after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID541546 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID533134 | Antimicrobial activity against Bacteroides fragilis assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID544585 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8133 expressing bla TEM-55 gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID535833 | Antimicrobial activity against Pseudomonas aeruginosa GP62KT41 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID324864 | Antimicrobial activity against Acinetobacter baumannii A24D after 4 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID541782 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID555212 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID561627 | Antimicrobial activity against Stenotrophomonas maltophilia KJ by twofold serial agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID531965 | Antibacterial activity against Klebsiella pneumoniae urine isolate A28009 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID561457 | Antibacterial activity against Enterobacter cloacae assessed as susceptible isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID583150 | Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID545852 | Antimicrobial activity against Pseudomonas aeruginosa PS44 with PFGE phenotype 13 expressing beta-lactamase IMP-18 obtained from blood of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID557955 | Antimicrobial activity in Actinomyces by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID565661 | Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID511668 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID574491 | Antimicrobial activity against Bacteroides vulgatus after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574997 | Antimicrobial activity against Bifidobacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID535374 | Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient assessed as resistant isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573550 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID545624 | Antimicrobial activity against Pseudomonas aeruginosa PS2 with PFGE phenotype 10B obtained from urine of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID541522 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574756 | Antimicrobial activity against Anaerococcus prevotii assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID519983 | Activity of Klebsiella pneumoniae Beta-Lactamase SHV-1 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. |
| AID574727 | Antimicrobial activity against Prevotella oralis assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID531313 | Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID495635 | Activity of Pseudomonas luteola LAM Beta-lactamase LUT-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID576264 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 19039 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID582983 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID534291 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-G plasmid and ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID587530 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml NXL104 beta-lactamase inhibitor | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID583098 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 beta-lactamase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID564018 | Antibacterial activity against Pseudomonas aeruginosa isolated from wound infection of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID574492 | Antimicrobial activity against Bacteroides ovatus after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID535061 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pYMAb3 plasmid by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID584565 | Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID574964 | Antimicrobial activity against Actinomyces odontolyticus after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID573567 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID542055 | Antibacterial activity against Klebsiella pneumoniae A expressing CTX-M group 1 beta-lactamase by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID1373319 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-48 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID574031 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID559263 | Antimicrobial activity against Providencia stuartii Ps5 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID1373288 | Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-8 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID574765 | Antimicrobial activity against Finegoldia magna after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID534285 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID583190 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID540961 | Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pH205 plasmid expressing cephalosporinase CMY-36 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID548003 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237N mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID559275 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID519748 | Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-1 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID322315 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID529572 | Antimicrobial activity against Erwinia carotovora subsp. atroseptica DSM 30184 after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID574967 | Antimicrobial activity against Actinomyces odontolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID511290 | Antibacterial activity against Escherichia coli DH5alpha | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID573348 | Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID534890 | Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID535890 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41T harboring qnrB gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID574777 | Antimicrobial activity against Clostridium difficile after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID396026 | Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID534872 | Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID544683 | Antimicrobial activity against Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID1373320 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-51 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID532400 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-17 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID533391 | Antimicrobial activity against Clostridium perfringens by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID534917 | Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID529487 | Antimicrobial activity against Enterobacter cloacae isolate 622 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID540962 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c31 plasmid expressing cephalosporinase CMY-31 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID424328 | Antimicrobial activity against Dialister invisus by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID541801 | Antimicrobial activity against Peptostreptococcus anaerobius clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557411 | Antimicrobial activity in Bacteroides fragilis by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID549339 | Antimicrobial activity against Escherichia coli isolate 32 harboring bla CTX-M-3a gene by broth microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID573433 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection in presence of 6:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID1373295 | Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID532390 | Antibacterial activity against VIM-1 producing Pseudomonas putida isolate RM-11X-11 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID532923 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID575417 | Antimicrobial activity against anrB-deficient Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics. |
| AID573581 | Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID531507 | Antibacterial activity against Bacteroides uniformis isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID544677 | Antimicrobial activity against class A extended spectrum beta-lactamase- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID322319 | Antibacterial activity against Escherichia coli DH5 alpha isolates by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID573370 | Antibacterial activity against ceftazidime-susceptible Serratia marcescens by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID535068 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-5 plasmid by Vitek II system in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID541528 | Antimicrobial activity against Staphylococcus haemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID542591 | Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. |
| AID557947 | Antimicrobial activity in Bifidobacterium by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID544680 | Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID531506 | Antibacterial activity against Bacteroides vulgatus isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID531779 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4677 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID555678 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring phagemid pBK-CMV by disk diffusion method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID567327 | Antimicrobial activity against Proteus mirabilis TUM4660 by broth dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID562823 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID571031 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID573368 | Antibacterial activity against ceftazidime-susceptible Proteus mirabilis assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID372619 | Activity of Escherichia coli DH5alpha beta-lactamase TEM-1 by microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID467876 | Antibacterial activity against Staphylococcus aureus by NCCLS method | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12 | Methicillin-resistant Staphylococcus aureus (MRSA)-active metabolites from Platanus occidentalis (American Sycamore). |
| AID544882 | Antimicrobial activity against AmpC beta-lactamase-producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID577231 | Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB127 with PFGE subgroup I containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID541796 | Antimicrobial activity against Clostridium perfringens clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID576312 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29830 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID535860 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40T harboring qnrB gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID529015 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID529460 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, SHV-12 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID585400 | Ratio of Kcat to Km for Fluoribacter gormanii 1K07 metallo-beta-lactamase FEZ-1 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. |
| AID495810 | Antimicrobial activity against Escherichia coli harbouring plasmid BK-CMV expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID522187 | Antimicrobial activity against Klebsiella pneumoniae isolate KpL expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID531505 | Antibacterial activity against Bacteroides caccae isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID520899 | Antibacterial activity against Achromobacter xylosoxidans TB1 in presence of 4 ug/ml Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID529146 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID574490 | Antimicrobial activity against Bacteroides vulgatus after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1209734 | Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4 | Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. |
| AID534633 | Antimicrobial activity against Non-ESBL Escherichia coli by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID562956 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone E expressing beta-lactamase KPC-2 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID559587 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as microbial doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID544692 | Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID532410 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate CR-04X-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID561630 | Antimicrobial activity against ampD1-, ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID535857 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID562744 | Antimicrobial activity against Escherichia coli K-12 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID535148 | Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID285600 | Antimicrobial activity against Pseudomonas aeruginosa 2C2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID374024 | Ratio of Kcat to Km for Enterobacter cloacae IMI1 beta lactamase Escherichia coli DH5alpha by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID557971 | Antimicrobial activity in Clostridium sp. by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID557959 | Antimicrobial activity in Eggerthella lenta by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID565206 | Antimicrobial activity against Klebsiella pneumoniae isolate T-1504 expressing VIM-1 and KPC-2 genes by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID573644 | Antimicrobial activity against penicillinase producing Staphylococcus aureus GC 6468 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID68396 | In vitro minimum inhibitory concentration against vancomycin-resistant Enterococcus faecium (GC 2243) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID542621 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring wild type PBP2x, disruption in PBP1a and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID541800 | Antimicrobial activity against Peptostreptococcus anaerobius clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID532932 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID574503 | Antimicrobial activity against Bacteroides caccae assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID534771 | Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. |
| AID534637 | Antimicrobial activity against Non-ESBL Escherichia coli assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID529639 | Antimicrobial activity against Escherichia coli GeneHogs by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID586060 | Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring chromosomally encoded ISAba1-blaOXA-51-like gene with fxsA upstream sequence by agar dilution method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. |
| AID535175 | Antimicrobial activity against imipenem non-susceptible Acinetobacter by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID544890 | Antimicrobial activity against Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573557 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID557725 | Antimicrobial activity in Fusobacterium varium by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID544916 | Antimicrobial activity against Providencia rettgeri clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID542051 | Antibacterial activity against Klebsiella pneumoniae expressing CTX-M group 1 beta-lactamase by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID563603 | Antimicrobial activity against Klebsiella pneumoniae isolate 048 expressing beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA. |
| AID574525 | Antimicrobial activity against Prevotella oralis after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID405820 | Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID531606 | Ratio of Kcat to Km for Escherichia coli Inhibitor-resistant beta-lactamase SHV-56 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID544682 | Antimicrobial activity against AmpC beta-lactamase-producing Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573783 | Antibacterial activity against Prevotella buccae by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID544886 | Antimicrobial activity against AmpC beta-lactamase-producing Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID285256 | Antimicrobial activity against Escherichia coli DH5-alpha CF1295 isolate expressing CMT and TEM1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID545638 | Antimicrobial activity against Pseudomonas aeruginosa PS18A with PFGE phenotype 11D obtained from CSF of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID1373311 | Antimicrobial activity against Escherichia coli expressing beta-lactamase DHA by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID574975 | Antimicrobial activity against Actinomyces meyeri after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID532204 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99 harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID563976 | Activity of Klebsiella pneumoniae 05-560 beta-lactamase VIM2 by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID405086 | Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase relative to cephalothin | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID530330 | Antimicrobial activity against Escherichia coli XL1-Blue by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID541806 | Antimicrobial activity against Enterococcus casseliflavus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID567584 | Antimicrobial activity against Acinetobacter baumannii by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID540948 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c2 plasmid expressing cephalosporinase CMY-2 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID573361 | Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID573634 | Antimicrobial activity against AmpC beta-lactamase producing Pseudomonas aeruginosa GC 1764 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID532420 | Antibacterial activity against VIM-1 producing Pseudomonas putida isolate RM-11X-11 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID584757 | Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID529002 | Antimicrobial activity against Haemophilus influenzae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID524256 | Activity at Escherichia coli beta-lactamase SHV-1 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID529149 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID544921 | Antimicrobial activity against Acinetobacter calcoaceticus clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID207196 | In vitro minimum inhibitory concentration against Methicillin-susceptible Staphylococcus aureus (GC 2216) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID541816 | Antimicrobial activity against Enterococcus hirae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID567280 | Activity of Acinetobacter baumannii ADC-11 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID535174 | Antimicrobial activity against imipenem susceptible Acinetobacter by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID544423 | Antimicrobial activity against Escherichia coli MC4100A harboring beta-lactamase CTX-M-14 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID562220 | Antimicrobial activity against Desulfovibrio sp. by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID584838 | Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID557967 | Antimicrobial activity in Clostridium difficile by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID207204 | In vitro minimum inhibitory concentration against Staphylococcus aureus (10strains, including MRSA) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID541805 | Antimicrobial activity against Enterococcus casseliflavus clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573591 | Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID508734 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID561455 | Antibacterial activity against Enterobacter cloacae by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID574034 | Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529514 | Antibacterial activity against Pseudomonas aeruginosa 1750J expressing beta-lactamase IMP-15 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico. |
| AID535122 | Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID285268 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM152 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID541502 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574493 | Antimicrobial activity against Bacteroides ovatus after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID511388 | Antibacterial activity against Klebsiella pneumoniae by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. |
| AID1373289 | Antimicrobial activity against Escherichia coli expressing beta-lactamase NMC-A by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID372617 | Activity of Escherichia coli CF0042 beta-lactamase TEM-35 by microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID541785 | Antimicrobial activity against Streptococcus agalactiae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID562756 | Ratio of Kcat to Km for Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID573561 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID562741 | Antimicrobial activity against Escherichia coli DH5[alpha] by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID43730 | In vitro antibacterial activity against Escherichia coli GC4206 Beta-lactamase TEM-1 of class A enzyme | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone. |
| AID519008 | Activity of Beta-lactamase TEM-149 expressed in Escherichia coli HB101 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID541545 | Antimicrobial activity against Enterococcus avium clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID547789 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237M mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID574047 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID557423 | Antimicrobial activity in Bacteroides vulgatus by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID574041 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID544893 | Antimicrobial activity against class A extended spectrum beta-lactamase- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544497 | Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-5 to MIC for Escherichia coli TOP10 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID531975 | Antibacterial activity against Escherichia coli DH10B by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID1225388 | Antibacterial activity against Escherichia coli transformed with plasmid carrying MG1655 deltaBC/pABM by p-iodonitrotetrazolium chloride colorimetric assay | 2015 | Journal of natural products, Mar-27, Volume: 78, Issue:3 | Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp. |
| AID573563 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID571217 | Antimicrobial activity against Pseudomonas aeruginosa isolate TX291 obtained from patient with non-cystic fibrosis by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID554991 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID285260 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-28 and ESBL by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID574781 | Antimicrobial activity against Clostridium difficile assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID564477 | Antimicrobial activity against Pseudomonas aeruginosa isolate 988 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID1592957 | Antibacterial activity against multi-drug resistant Escherichia coli NMI 3548/14 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID541537 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID571043 | Antimicrobial activity against Pseudomonas aeruginosa isolate GB57 obtained from patient with non-cystic fibrosis by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID574990 | Antimicrobial activity against Bifidobacterium adolescentis assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID565199 | Antimicrobial activity against Klebsiella pneumoniae isolate T-1780 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID583185 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID577243 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB096 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID203170 | The compound was evaluated for antimicrobial activity against Serratia marcescens OC 4101 by inhibiting enzyme AmpC(ind) | 2000 | Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19 | The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. |
| AID495793 | Antimicrobial activity against Escherichia coli DH10B by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID574970 | Antimicrobial activity against Actinomyces israelii after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID495663 | Activity at Pseudomonas aeruginosa 51170 beta-lactamase BEL-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID531603 | Antimicrobial activity against Escherichia coli JM109 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID573367 | Antibacterial activity against ceftazidime-susceptible Proteus mirabilis by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID557443 | Antimicrobial activity in Prevotella buccae by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID573617 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 min postinfection in presence of 12:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID574735 | Antimicrobial activity against Fusobacterium necrogenes after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574776 | Antimicrobial activity against Clostridium difficile after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID535710 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 S287N mutant protein by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID540943 | Antimicrobial activity against Klebsiella pneumoniae HP205 expressing CMY-36 cephalosporinase by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID394488 | Activity of Hafnia alvei beta-lactamase ACC-1 assessed as nmol of compound hydrolysis per ug of protein | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID518816 | Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID535177 | Antimicrobial activity against imipenem susceptible Acinetobacter assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541525 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID548039 | Antimicrobial activity against Escherichia coli DH10B by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID529461 | Antimicrobial activity against Escherichia coli J53 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID529016 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID727656 | Activity of wild type Beta-lactamase SHV-1 in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID544900 | Antimicrobial activity against Klebsiella oxytoca clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID567317 | Antimicrobial activity against Proteus mirabilis TUM4660 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID285609 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID518733 | Antimicrobial activity against Escherichia coli TOP10 by agar dilution method in presence of beta-lactam inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID544425 | Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring beta-lactamase CTX-M-14 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID534283 | Antimicrobial activity against Stenotrophomonas maltophilia KJ by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID529644 | Antimicrobial activity against Pseudomonas aeruginosa 9551 expressing beta-lactamase VIM-15 obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID558333 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P790 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID511301 | Antibacterial activity against Escherichia coli DH5alpha in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID574971 | Antimicrobial activity against Actinomyces israelii assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574773 | Antimicrobial activity against Clostridium perfringens assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID544918 | Antimicrobial activity against Providencia stuartii clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID529478 | Antimicrobial activity against Klebsiella pneumoniae isolate 11 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-1 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID541802 | Antimicrobial activity against Peptostreptococcus micros clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID529204 | Antibacterial activity against AmpC-producing Escherichia coli assessed as sensitive isolates by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. |
| AID372615 | Activity of Escherichia coli DH5alpha beta-lactamase TEM-12 by microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID555202 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID373772 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh36 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID549345 | Antimicrobial activity against Escherichia coli ATCC 25922 harboring bla CTX-M-3a gene by broth microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID533403 | Antimicrobial activity against Clostridium subterminale by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID511391 | Antibacterial activity against Citrobacter freundii by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. |
| AID531500 | Antibacterial activity against Bacteroides merdae isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID573800 | Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574737 | Antimicrobial activity against Fusobacterium nucleatum after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID322313 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID541549 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID547777 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237G mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID520966 | Antibacterial activity against Klebsiella pneumoniae YC by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID587644 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at 1024 mg/kg, sc after 24 hrs by acute | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID573776 | Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID575340 | Antimicrobial activity against Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics. |
| AID531504 | Antibacterial activity against Bacteroides distasonis isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID573825 | Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574779 | Antimicrobial activity against Clostridium difficile assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID532914 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID555686 | Antimicrobial activity against Escherichia coli ATCC 25922 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID565423 | Antimicrobial activity against beta-lactamase-producing Pseudomonas aeruginosa clinical isolate assessed as susceptible isolate by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. |
| AID544914 | Antimicrobial activity against Proteus vulgaris clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID541541 | Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID541813 | Antimicrobial activity against Enterococcus gallinarum clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID495661 | Activity at Pseudomonas aeruginosa 531 beta-lactamase BEL-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID529161 | FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID574972 | Antimicrobial activity against Actinomyces israelii assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID541833 | Antimicrobial activity against Streptococcus pyogenes clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID574732 | Antimicrobial activity against Fusobacterium varium after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID69001 | In vitro synergistic activity against Escherichia coli C600N + (Imi-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID541798 | Antimicrobial activity against Clostridium perfringens clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID555216 | Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 20 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID535181 | Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID529573 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pLBII carrying beta-lactamase CAR-1 gene after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID545644 | Antimicrobial activity against Pseudomonas aeruginosa PS25 with PFGE phenotype 1A obtained from sputum of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID529158 | Antimicrobial activity against Haemophilus influenzae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID546618 | Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID528606 | Activity of Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID558332 | Antibacterial activity against Campylobacter jejuni isolate P338 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID1373307 | Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-5 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID565285 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID534910 | Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541526 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID564479 | Antimicrobial activity against Pseudomonas aeruginosa isolate 856 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID576309 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29459 harboring porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID534301 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA460 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID582966 | Antimicrobial activity against beta-lactamase A-deficient Yersinia enterocolitica GY5717 after 20 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B. |
| AID535149 | Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID495905 | Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-19 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID567582 | Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolate by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID322325 | Antibacterial activity against Escherichia coli DH5 alpha-URA5924 isolates expressing CTX-M-32 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID495909 | Antimicrobial activity in Escherichia coli J53 transconjugate with Escherichia coli DIH-1 expressing natural plasmid containing beta-lactamase VIM-19 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID529486 | Antimicrobial activity against Enterobacter cloacae isolate 533 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID547991 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237W mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID542052 | Antibacterial activity against Klebsiella pneumoniae D expressing CTX-M group 1 beta-lactamase by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID574442 | Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID523273 | Antimicrobial activity against Escherichia coli HN1157/pHSG576oxa7 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. |
| AID561469 | Antibacterial activity against Proteus mirabilis assessed as resistant isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID585396 | Ratio of Kcat to Km for Bradyrhizobium japonicum metallo-beta-lactamase BJP-1 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. |
| AID547780 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237G mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID573341 | Antibacterial activity against ceftazidime-susceptible Citrobacter freundii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID565681 | Antimicrobial activity against beta-lactamase negative ampicillin-susceptible Haemophilus influenzae harboring fst1 mutant gene assessed as susceptible isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID520781 | Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 in presence of Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID565677 | Antimicrobial activity against beta-lactamase negative ampicillin-susceptible Haemophilus influenzae harboring fst1 mutant gene by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID532422 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-21 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID531508 | Antibacterial activity against Bacteroides thetaiotaomicron isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID562955 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone D expressing beta-lactamase KPC-2 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID519746 | Activity of Klebsiella pneumoniae Beta-Lactamase SHV-1 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID341596 | Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID532428 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D1 isolate VA-06X-63 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID562745 | Antimicrobial activity against Escherichia coli DH5alpha harboring pBC-CTX-M-71 plasmid by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID532930 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID1373309 | Antimicrobial activity against Escherichia coli expressing beta-lactamase VIM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID535123 | Antimicrobial activity against ceftazidime non-susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID405081 | Antimicrobial activity against Escherichia coli CAG12177 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID574440 | Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID573784 | Antibacterial activity against Prevotella bivia by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523888 | Antimicrobial activity against Acinetobacter baumannii 6AB11 harboring ISAba1-blaOXA-66 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID535125 | Antimicrobial activity against ceftazidime non-susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID564484 | Antimicrobial activity against Pseudomonas aeruginosa isolate 821 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID587641 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at 2048 mg/kg, sc after 24 hrs by acute | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID534296 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID564535 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position and R210P substitution by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID113523 | In vivo inhibitory activity against Escherichia coli in mice | 1999 | Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7 | 6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C beta-lactamases I. |
| AID322323 | Antibacterial activity against Escherichia coli DH5 alpha-URA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID557419 | Antimicrobial activity in Bacteroides ovatus by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID583095 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87A mutant beta-lactamase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID558805 | Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID529009 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID544887 | Antimicrobial activity against Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID520884 | Inhibition of Achromobacter xylosoxidans CIP69598 beta-lactamase OXA-114a expressed in Escherichia coli TOP10 assessed as reduction of benzyl-penicillin hydrolysis | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID573777 | Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID522011 | Antimicrobial activity against Klebsiella pneumoniae isolate KpE expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID425864 | Antimicrobial activity against Carnobacterium divergens CIP101029 at 3 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID534656 | Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID534877 | Antimicrobial activity against ESBL producing Proteus mirabilis assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID534634 | Antimicrobial activity against ESBL producing Escherichia coli by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID285265 | Antimicrobial activity against Escherichia coli DH5-alpha isolate expressing pBK-CMV by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID534654 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID583651 | Antibacterial activity against Escherichia coli isolate 271 | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. |
| AID573630 | Antimicrobial activity against CTX-M-5 beta-lactamase producing Salmonella enterica serovar Typhimurium GC 4195 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID531623 | Antimicrobial activity against Escherichia coli JM109 harboring pE1MD plasmid expressing beta-lactamase SHV-56 by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID541013 | Antimicrobial activity against Burkholderia cenocepacia 5007902 expressing beta-lactamase PenB4 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID558787 | Antimicrobial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID285604 | Antimicrobial activity against Pseudomonas aeruginosa 2A6 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID534193 | Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. |
| AID573814 | Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID373051 | Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID532994 | Antibacterial activity against OXA-30, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P19 exhibiting PFGE F pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID519742 | Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method in presence of 4 ug/ml Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID96429 | In vitro synergistic activity against Klebsiella pneumoniae GC 6269 clinical isolate | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID301746 | Antibacterial activity against Pseudomonas aeruginosa | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. |
| AID562742 | Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID541791 | Antimicrobial activity against Bacteroides thetaiotaomicron clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID560124 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG4 gene by disk diffusion method in presence of 4 ug/ml Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID584557 | Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID520971 | Antibacterial activity against Klebsiella pneumoniae 633 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID541495 | Antimicrobial activity against Burkholderia cepacia clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID373773 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh37 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID396029 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID541007 | Antimicrobial activity against Burkholderia cenocepacia 09-54 expressing beta-lactamase PenB2 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID574447 | Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID324359 | Antibacterial activity against Escherichia coli DH10B by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID561629 | Antimicrobial activity against ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID574502 | Antimicrobial activity against Bacteroides caccae assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID530325 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID511667 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID529482 | Antimicrobial activity against Enterobacter cloacae isolate 140 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID424858 | Antimicrobial activity against Pseudomonas aeruginosa GY3 producing blaVIM-2 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID534616 | Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID574999 | Antimicrobial activity against Eubacterium lentum after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID544910 | Antimicrobial activity against Proteus mirabilis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID529580 | Ratio of Kcat to Km for Caulobacter crescentus beta-Lactamase CAU-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID541524 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID495632 | Antimicrobial activity against Pseudomonas luteola expressing blaLUT-2 to blaLUT-6 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID534617 | Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID529456 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID559265 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID545646 | Antimicrobial activity against Pseudomonas aeruginosa PS28 with PFGE phenotype 6 expressing beta-lactamase KPC-5 obtained from skin of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID541784 | Antimicrobial activity against Streptococcus pyogenes clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544929 | Antimicrobial activity against Acinetobacter haemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID534891 | Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573619 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID564533 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID583205 | Antimicrobial activity against Escherichia coli ATCC 25922 by broth macrodilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Mathematical modeling to characterize the inoculum effect. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID532997 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P122 exhibiting PFGE A pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID529828 | Antimicrobial activity against Acinetobacter baumannii by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. |
| AID531314 | Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID560127 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG3 gene by disk diffusion method in presence of 4 ug/ml Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID574486 | Antimicrobial activity against Bacteroides caccae after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574984 | Antimicrobial activity against Actinomyces naeslundii assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID530290 | Antimicrobial activity against Escherichia coli J53 harboring blaKPC-2 and blaTEM-1 gene by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID576332 | Antibacterial activity against ESBL-producing Klebsiella pneumoniae by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1. |
| AID69003 | In vitro synergistic activity against Escherichia coli C600N + (MIR-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID1373316 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-18 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID576303 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 26077 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID549333 | Antimicrobial activity against Escherichia coli isolate 36 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID1373303 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-121 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID557455 | Antimicrobial activity in Prevotella intermedia by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID535844 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTS harboring mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID424324 | Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CA-SFM method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID544505 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-4 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID559583 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID519631 | Activity of Brachyspira pilosicoli beta-lactamase OXA-63 expressed in Escherichia coli BL21 (DE3) assessed as compound hydrolysis by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID530550 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID573831 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID541548 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535905 | Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12 harboring GyrA S83L mutant, wild-type GyrB, ParC and qnrS genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID564530 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID573659 | Antimicrobial activity against CTX-M-5 beta-lactamase producing Salmonella enterica serovar Typhimurium GC 4195 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID586059 | Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring plasmid encoded ISAba1-blaOXA-51-like gene with nuc upstream sequence by agar dilution method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. |
| AID529491 | Antimicrobial activity against Enterobacter cloacae isolate 649 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID573817 | Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID565666 | Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID532406 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B1 isolate SS-09X-45 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID535179 | Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID544579 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8133 expressing bla TEM-55 gene by microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID574752 | Antimicrobial activity against Anaerococcus prevotii after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID522004 | Antimicrobial activity against Escherichia coli isolate J53 harboring p7A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID564218 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring plasmid PH98 by Etest method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID396028 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID496592 | Antimicrobial activity against Escherichia coli DH10B by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. |
| AID584750 | Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID557995 | Antimicrobial activity in Clostridium sordellii by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID544930 | Antimicrobial activity against Acinetobacter johnsonii clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID564554 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID531604 | Activity of Escherichia coli Inhibitor-resistant beta-lactamase SHV-56 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID531494 | Antibacterial activity against Bacteroides caccae assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID558329 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P305 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID70724 | In vitro inhibitory activity against Escherichia coli | 1999 | Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7 | 6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C beta-lactamases I. |
| AID548032 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237R mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID396027 | Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID565665 | Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae assessed as susceptible isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID1209735 | Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4 | Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. |
| AID563966 | Antibacterial activity against Klebsiella pneumoniae 05-560 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID540944 | Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pA172 plasmid expressing cephalosporinase CMY-31 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID541804 | Antimicrobial activity against Peptostreptococcus micros clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID529011 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID520783 | Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 in presence of Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID562474 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase SHV-12 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID340727 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-2 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID1824272 | Antimicrobial activity against Klebsiella pneumoniae clinical isolate T2301 expressing NDM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay | 2022 | European journal of medicinal chemistry, Jan-15, Volume: 228 | Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases. |
| AID543411 | Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID373759 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1316 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID559277 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID208747 | In vitro minimum inhibitory concentration against Streptococcus agalactiae (GC4564) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID542588 | Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. |
| AID373055 | Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID521991 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp11978 expressing beta-lactamase OXA-48, SHV-2a and TEM-1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID373764 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh11 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID545651 | Antimicrobial activity against Pseudomonas aeruginosa PS34 with PFGE phenotype 4A obtained from blood of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID529010 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID549343 | Antimicrobial activity against Escherichia coli isolate Z1 harboring bla CTX-M-3a gene by broth microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID285597 | Antimicrobial activity against Pseudomonas aeruginosa 2A1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573436 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection in presence of 12:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID285581 | Antimicrobial activity against Pseudomonas aeruginosa ID7 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID532426 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate FG-17X-08 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID562480 | Antimicrobial activity against Klebsiella pneumoniae isolate 2641/08 obtained from urine of patient with ischemic cardiomyopathy and several comorbidities by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID565284 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID533126 | Antimicrobial activity against Bacteroides caccae assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID533634 | Antimicrobial activity against Propionibacterium acnes assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID534894 | Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID565424 | Antimicrobial activity against beta-lactamase-producing Pseudomonas aeruginosa clinical isolate assessed as susceptible isolates by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. |
| AID495804 | Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID563967 | Antibacterial activity against Escherichia coli TOP10 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID541808 | Antimicrobial activity against Enterococcus durans clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID547761 | Antimicrobial activity against Klebsiella pneumoniae 1534 expressing beta-lactamase KPC-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID285443 | Ratio of kcat to Km of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B relative to benzyl-penicillin | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID544894 | Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID534620 | Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID208130 | In vitro minimum inhibitory concentration against Penicillin susceptible Streptococcus pneumoniae (GC 6242) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID545637 | Antimicrobial activity against Pseudomonas aeruginosa PS17B with PFGE phenotype 11D expressing beta-lactamase KPC-2 obtained from blood of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID573352 | Antibacterial activity against ceftazidime-susceptible Escherichia coli by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID520977 | Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID518523 | Antimicrobial activity against Escherichia coli TOP10 after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID67553 | In vitro minimum inhibitory concentration against vancomycin-resistant Enterococcus faecalis (GC 2242) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID563159 | Antibacterial activity against Pseudomonas aeruginosa isolate 19BR by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. |
| AID544674 | Antimicrobial activity against Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544426 | Antimicrobial activity against Escherichia coli MC4100A harboring beta-lactamase L1 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID394494 | Antimicrobial activity against Escherichia coli MC4100 harboring pACYC184 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID535872 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51T harboring qnrA gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID533528 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID1373321 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-146 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID558808 | Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID68374 | In vitro synergistic activity against Enterobacter cloacae (Imi-1+AmpC) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID529576 | Ratio of Kcat to Km for Erwinia carotovora subsp. atroseptica DSM 30184 beta-Lactamase CAR-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID574506 | Antimicrobial activity against Bacteroides distasonis assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID535709 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 by agar dilution method in presence of 4 mg/liter Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID574487 | Antimicrobial activity against Bacteroides caccae after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID369642 | Antibacterial activity against Acinetobacter baumannii C clone by Etest method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. |
| AID518726 | Antimicrobial activity against Escherichia coli TOP10 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID532180 | Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID574532 | Antimicrobial activity against Prevotella bivia assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID528482 | Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4696 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID561445 | Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-44 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID567270 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID534874 | Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573376 | Antibacterial activity against imipenem-susceptible Acinetobacter by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID519011 | Ratio of Kcat to Km for Beta-lactamase TEM-149 T182M mutant expressed in Escherichia coli HB101 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID533525 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID534876 | Antimicrobial activity against ESBL producing Proteus mirabilis assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID547999 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237C mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID519734 | Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID560490 | Antibacterial activity against 5 x 10'5 CFU/ml Escherichia coli MC4100 harboring plasmid ACYC184 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID534875 | Antimicrobial activity against ESBL producing Proteus mirabilis assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID530551 | Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID555193 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox deltaampDh3::lox deltanagZ::Gm after 18 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID546431 | Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-2 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID558789 | Antimicrobial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID544927 | Antimicrobial activity against Acinetobacter haemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID564526 | Antimicrobial activity against Acinetobacter baumannii AYE expressing VEB-1 gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID69012 | In vitro synergistic activity against Escherichia coli C600N + (ampR ampC) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID285442 | Activity of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID544935 | Antimicrobial activity against Acinetobacter junii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544932 | Antimicrobial activity against Acinetobacter johnsonii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID584562 | Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID574456 | Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID560132 | Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay relative to benzylpenicillin | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID534895 | Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID561461 | Antibacterial activity against Enterobacter cloacae assessed as resistant isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID524254 | Antimicrobial activity against Escherichia coli DH5alpha expressing SHV-84 in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID573655 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID541536 | Antimicrobial activity against Enterococcus faecium clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID496594 | Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase KPC-2 | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. |
| AID544533 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8130 expressing bla SHV-1 gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID564216 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring plasmid PH98 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID571939 | Antimicrobial activity against Escherichia coli MC4100 expressing promoterless beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID372613 | Activity of Escherichia coli DH5alpha beta-lactamase TEM-158 by microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID529152 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID544904 | Antimicrobial activity against Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID562475 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID564229 | Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase OXA-143 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID528993 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID573812 | Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID522022 | Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc2 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID574509 | Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID406442 | Central volume of distribution in healthy human with lean body mass of 53 kg at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID573791 | Antibacterial activity against Prevotella buccae by by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID544915 | Antimicrobial activity against Providencia rettgeri clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID555210 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID522380 | Antimicrobial activity against blaKPC-possessing Klebsiella pneumoniae isolates in presence of 4 ug/ml by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID122906 | In vitro minimum inhibitory concentration against Micrococcus lutea (GC 4562) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID528986 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID559269 | Antimicrobial activity against Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID565281 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID529633 | Antimicrobial activity against Enterobacter cloacae isolate 781 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID549335 | Antimicrobial activity against Escherichia coli isolate Z1 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID562472 | Antimicrobial activity against Klebsiella pneumoniae isolate 2641/08 obtained from urine of patient with ischemic cardiomyopathy and several comorbidities by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID535156 | Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573393 | Antibacterial activity against ceftazidime-susceptible Providencia sp. assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID584839 | Antimicrobial activity against Escherichia coli DH10B by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID574753 | Antimicrobial activity against Anaerococcus prevotii after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID548015 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237S mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID587528 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 1 ug/ml NXL104 beta-lactamase inhibitor | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID532929 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID535696 | Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID573435 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection in presence of 10:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID532441 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-02 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID555676 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring phagemid pBK-CMV by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID531774 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4703 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID324868 | Antimicrobial activity against Acinetobacter baumannii B46 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID583181 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID587730 | Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID681769 | TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Piperacillin: 2000 uM) in Xenopus laevis oocytes | 1999 | The Journal of pharmacology and experimental therapeutics, Aug, Volume: 290, Issue:2 | The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. |
| AID574744 | Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID66133 | In vitro minimum inhibitory concentration against Enterococcus species; 0.25->64 | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Synthesis and evaluation of ether and halogenated derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID561467 | Antibacterial activity against Proteus mirabilis assessed as intermediate isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID533427 | Antimicrobial activity against Peptostreptococcus sp. by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID1373281 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-3 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID573564 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID424327 | Antimicrobial activity against Dialister propionicifaciens by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID573607 | Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID545648 | Antimicrobial activity against Pseudomonas aeruginosa PS30 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID495664 | Ratio of Kcat to Km for Pseudomonas aeruginosa 51170 beta-lactamase BEL-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID529575 | Activity of Erwinia carotovora subsp. atroseptica DSM 30184 beta-lactamase CAR-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID557415 | Antimicrobial activity in Bacteroides thetaiotaomicron by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID394486 | Ratio of Kcat to Km for Escherichia coli beta-lactamase ACC4 by UV spectrophotometry | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID558007 | Antimicrobial activity in Clostridium hastiforme by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID560125 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG3 gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID524259 | Ratio of Kcat to Km in Escherichia coli beta-lactamase SHV-84 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID576073 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 harboring pSHA2-encoded porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID534385 | Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID518519 | Antimicrobial activity against Capnocytophaga sputigena isolate NOR after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID557717 | Antimicrobial activity in Fusobacterium necrophorum by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID541543 | Antimicrobial activity against Enterococcus avium clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID217329 | Synergistic activity of compound was determined against VIM-7 beta lactamase produced by Escherichia coli; R = Resistant | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID545441 | Antimicrobial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID532589 | Antibacterial activity against metallo-beta-lactamase positive Pseudomonas aeruginosa assessed as percent susceptible isolates by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID545629 | Antimicrobial activity against Pseudomonas aeruginosa PS7A with PFGE phenotype 11D obtained from urine of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID285441 | Antimicrobial activity against Escherichia coli DH10B after 18 hrs by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID554987 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID562954 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone C expressing beta-lactamase KPC-2 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID561284 | Antibacterial activity against Klebsiella pneumoniae assessed as resistant isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID534653 | Antimicrobial activity against Non-ESBL Klebsiella pneumoniae by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID540946 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c31 plasmid expressing cephalosporinase CMY-31 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID573780 | Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID534613 | Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID544531 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 7668 expressing bla SHV-48 gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID521838 | Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID522005 | Antimicrobial activity against Klebsiella pneumoniae isolate KpI-1 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID542053 | Antibacterial activity against Klebsiella pneumoniae C expressing CTX-M group 1 beta-lactamase by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID523266 | Activity at Escherichia coli isolate 7181 beta-lactamase OXA-7 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. |
| AID529154 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID544436 | Antimicrobial activity against Escherichia coli CU164A harboring empty plasmid by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID557701 | Antimicrobial activity in Prevotella loescheii by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID545640 | Antimicrobial activity against Pseudomonas aeruginosa PS20A with PFGE phenotype 11D obtained from skin of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID522385 | Antimicrobial activity against Aeromonas enteropelogenes M1 hyperproducing beta-lactamase AmpC | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID535847 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID587612 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID565288 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID406429 | Terminal half life in cystic fibrosis patient at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID518724 | Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase DIM-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID340728 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-9 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID495907 | Antimicrobial activity in Escherichia coli TOP10 strain harbouring recombinant plasmid VIM-1 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID587524 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml NXL104 beta-lactamase inhibitor | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID573785 | Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID322322 | Antibacterial activity against Escherichia coli INSRA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID541781 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID560496 | Antibacterial activity against 5 x 10'5 CFU/ml Escherichia coli MC4100 harboring plasmid ACYC184 by microdilution method in presence of 4 ug/ml Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID206384 | In vitro minimum inhibitory concentration against methicillin-susceptible Coagulase-negative Staphylococci (MSCNS) (GC 4549) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID70946 | In vitro antibacterial activity against TEM-1 producing Escherichia coli (GC2206) | 2001 | Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8 | Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors. |
| AID531768 | Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4696 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID545649 | Antimicrobial activity against Pseudomonas aeruginosa PS31 with PFGE phenotype 11B obtained from skin of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID511299 | Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID560224 | Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing stm3031 gene deletion mutant by CLSI M7-A7 agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium. |
| AID541794 | Antimicrobial activity against Bacteroides uniformis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573601 | Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID535376 | Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID422498 | Ratio of Kcat to Km of Carnobacterium divergens BM4489 penicillinase Cad-1 relative to benzyl-penicillin | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID573392 | Antibacterial activity against ceftazidime-susceptible Providencia sp. assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID562736 | Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID559267 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID535843 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 IPM46 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID562333 | Antimicrobial activity against Escherichia coli DH5alpha harboring metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID574441 | Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID565200 | Antimicrobial activity against Klebsiella pneumoniae isolate A-1760 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID373755 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab12 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID279184 | Antibacterial activity against Escherichia coli DH10B | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID533568 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID69006 | In vitro synergistic activity against Escherichia coli C600N + (PSE-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID406439 | Central volume of distribution in cystic fibrosis patient with lean body mass of 53 kg at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID533521 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID534492 | Antimicrobial activity against ampN deficient Stenotrophomonas maltophilia KJ by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID564531 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid with entire blaAmpC gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID217323 | Synergistic activity of compound was determined against VIM-1 beta lactamase produced by Escherichia coli | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID571042 | Antimicrobial activity against Pseudomonas aeruginosa isolate GB57 obtained from patient with non-cystic fibrosis by Etest | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID542622 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x T338A mutant gene, disruption at PBP1a and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID574032 | Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID557753 | Antimicrobial activity in Lactobacillus by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID574056 | Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID563160 | Antibacterial activity against Pseudomonas aeruginosa isolate 213BR by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. |
| AID587642 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at 2048 mg/kg, sc after 24 hrs by acute | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID532389 | Antibacterial activity against VIM-1 producing Enterobacter cloacae isolate TO-16X-51 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID574058 | Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID91392 | Synergic activity of compound was determined against IMP-1 beta lactamase produced by Escherichia coli | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID533637 | Antimicrobial activity against Propionibacterium sp. by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID541803 | Antimicrobial activity against Peptostreptococcus micros clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID567268 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-50 plasmid by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID573380 | Antibacterial activity against beta lactamase-negative Haemophilus influenzae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID534298 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID531488 | Antibacterial activity against Bacteroides stercoris assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID301807 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 | 2007 | Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23 | Direct diazo-transfer reaction on beta-lactam: synthesis and preliminary biological activities of 6-triazolylpenicillanic acids. |
| AID522379 | Antimicrobial activity against blaKPC-possessing Klebsiella pneumoniae isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID542612 | Antimicrobial activity against Streptococcus pneumoniae R6 after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID573656 | Antimicrobial activity against SHV-11 beta-lactamase producing Klebsiella pneumoniae GAR 7693 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID529554 | Antimicrobial activity against Bacillus anthracis MurA1 AS clone 2G2 assessed as growth inhibition in presence of xylose by antisense-induced hypersensitive testing | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis. |
| AID574778 | Antimicrobial activity against Clostridium difficile assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID558533 | Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1698 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID495808 | Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID495841 | Ratio of Kcat to Km for beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID533526 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID533359 | Antimicrobial activity against Bacteroides ovatus by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID529654 | Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID574983 | Antimicrobial activity against Actinomyces naeslundii assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1373302 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-47 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID520878 | Antibacterial activity against Achromobacter xylosoxidans LOL by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID573350 | Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID565202 | Antimicrobial activity against Klebsiella pneumoniae isolate H-1406 expressing VIM-1 and KPC-2 genes by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID285267 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM29 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID532991 | Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P60 exhibiting PFGE H pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID587531 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID520876 | Antibacterial activity against Achromobacter xylosoxidans CIP69598 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID530336 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-1 gene by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID326265 | Antibacterial activity against Escherichia coli 3521r carrying pR352 encoding SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. |
| AID573841 | Antimicrobial activity against TEM-10 beta-lactamase producing Escherichia coli GC 2022 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID285583 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID521427 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID560494 | Antibacterial activity against 5 x 10'5 CFU/ml CMY-30 producing Escherichia coli MC4100 harboring plasmid AC-cmy30 by microdilution method in presence of 4 ug/ml Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID524258 | Activity at Escherichia coli beta-lactamase SHV-84 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID557999 | Antimicrobial activity in Clostridium butyricum by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID530357 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID583187 | Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID495798 | Ratio of Kcat to Km of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B using nitrocefin hydrolysis | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID373774 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh39 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID532995 | Antibacterial activity against OXA-28 producing Pseudomonas aeruginosa isolate P174 exhibiting PFGE E pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID544684 | Antimicrobial activity against Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557721 | Antimicrobial activity in Fusobacterium mortiferum by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID583155 | Antimicrobial activity against ampD::lox, ampDh2::lox and ampDh3::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID266539 | Antibacterial activity against Escherichia coli expressing TEM1 in iv dosed murine acute lethal infection model | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15 | Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods. |
| AID573346 | Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID573637 | Antimicrobial activity against ACT-1 beta-lactamase producing Escherichia coli GC 2814 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID1373293 | Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV-12 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID534614 | Antimicrobial activity against ceftazidime non-susceptible Enterobacteriaceae by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID495910 | Antimicrobial activity in Escherichia coli TOP10 strain | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID324311 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. |
| AID374363 | Activity of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID574980 | Antimicrobial activity against Actinomyces meyeri assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID564471 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1050 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID1769951 | Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 43300 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms. |
| AID511669 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID564021 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID511288 | Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID373210 | Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID322320 | Antibacterial activity against Escherichia coli INSRA5776 isolates expressing CTX-M-14 and TEM-1B enzymes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID532419 | Antibacterial activity against VIM-1 producing Enterobacter cloacae isolate TO-16X-51 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID285575 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID545654 | Antimicrobial activity against Pseudomonas aeruginosa PS37 with PFGE phasotype 11D obtained from sputum of patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID573650 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID574762 | Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID535151 | Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID531601 | Antimicrobial activity against Escherichia coli JM109 harboring pSC1 plasmid expressing beta-lactamase SHV-56 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID532915 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID564469 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1036 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID547773 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237A mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID573593 | Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID535697 | Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID521997 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp4A expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID573648 | Antimicrobial activity against SHV-1and SHV-5 beta-lactamase producing Klebsiella pneumoniae GAR 7978 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID518823 | Antibacterial activity against Pulsotype C Acinetobacter genomosp. 3 isolate 1 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID324870 | Antimicrobial activity against Acinetobacter baumannii B46 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID531318 | Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID529480 | Antimicrobial activity against Enterobacter cloacae isolate 1 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID424319 | Antimicrobial activity against Dialister pneumosintes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID285691 | Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID574979 | Antimicrobial activity against Actinomyces meyeri assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID531622 | Antimicrobial activity against Escherichia coli JM109 harboring pSC1 plasmid expressing beta-lactamase SHV-56 by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID373050 | Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID528483 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4698 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID582981 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID546620 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID558814 | Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID1257070 | Antibacterial activity against methicillin-resistant Staphylococcus aureus XJ 75302 after 20 hrs by CLSI broth microdilution method | 2015 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23 | Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities. |
| AID547785 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237L mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID587523 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 2 ug/ml NXL104 beta-lactamase inhibitor | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID549332 | Antimicrobial activity against Escherichia coli isolate 86 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID533375 | Antimicrobial activity against Bacteroides eggerthii by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID535070 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-7 plasmid by Vitek II system in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID557447 | Antimicrobial activity in Prevotella melaninogenica by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID573374 | Antibacterial activity against multidrug-resistant Acinetobacter assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID563969 | Antibacterial activity against Escherichia coli J53 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID373758 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1254 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID535154 | Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID69002 | In vitro synergistic activity against Escherichia coli C600N + (L1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID573397 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID533420 | Antimicrobial activity against Micromonas micros assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID561497 | Antibacterial activity against Moraxella catarrhalis by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID372606 | Antibacterial activity against rifampin-resistant Escherichia coli C600 transconjugant producing beta-lactamase of pI 5.2 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID531501 | Antibacterial activity against Bacteroides eggerthii isolate by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID584756 | Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID544440 | Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring beta-lactamase L1 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID540947 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c36 plasmid expressing cephalosporinase CMY-36 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID1592959 | Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 2697/14 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID529578 | Ratio of Kcat to Km for Chryseobacterium meningosepticum beta-Lactamase GOB-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID534312 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA509 in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID33217 | In vitro synergistic activity against Aeromonas sobria (Asb A, OXA-12, Asb M) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID535875 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID583192 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID69021 | In vivo synergistic activity against Escherichia coli GC6265 (TEM-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID396033 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID574043 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529499 | Antimicrobial activity against Escherichia coli GeneHogs by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID574747 | Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574520 | Antimicrobial activity against Prevotella bivia after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID529648 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-15 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID208128 | In vitro minimum inhibitory concentration against Penicillin resistant Streptococcus pneumoniae (GC 1894) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID565280 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID558319 | Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID532394 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-32 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID534379 | Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID561270 | Antibacterial activity against Escherichia coli by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID573813 | Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID541504 | Antimicrobial activity against beta-lactamase-producing Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID555683 | Antimicrobial activity against Escherichia coli DH10B by disk diffusion method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID567581 | Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolate by broth dilution method in presence of beta-lactamase inhibitor Sulbactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID405817 | Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID573618 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 min postinfection in presence of 14:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID524247 | Antimicrobial activity against Escherichia coli INSRA4590 expressing SHV-84 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID534299 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID528484 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4706 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID532413 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C1 isolate AV-13X-28 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID727798 | Antimicrobial activity against Escherichia coli DH10B by CLSI agar dilution method | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID495927 | Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-19 by Etest in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID565504 | Antimicrobial activity against beta-lactamase negative ampicillin-resistant -Haemophilus influenzae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID573343 | Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID573434 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID575009 | Antimicrobial activity against Eubacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID533387 | Antimicrobial activity against Clostridium difficile by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID529496 | Antimicrobial activity against Escherichia coli T-622 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID545642 | Antimicrobial activity against Pseudomonas aeruginosa PS22 with PFGE phenotype 3A obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID577229 | Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB095 with PFGE subgroup E containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID547769 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBC SK(+) carrying wild type beta-lactamase KPC-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID528999 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID496590 | Antimicrobial activity against Klebsiella pneumoniae 1534 harboring beta lactamase KPC-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. |
| AID574027 | Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID495656 | Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-2 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID516144 | Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 10 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID532924 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID555192 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox deltaampDh3::lox deltanagZ::Gm after 18 hrs by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID564017 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID529472 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID557677 | Antimicrobial activity in Prevotella disiens by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID374361 | Antimicrobial activity against Escherichia coli DH5alpha expressing pJDB2 containing Aeromonas caviae A324R metallo-beta-lactamase gene by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID531769 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4698 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID528995 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID574965 | Antimicrobial activity against Actinomyces odontolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID529489 | Antimicrobial activity against Enterobacter cloacae isolate 656 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID541513 | Antimicrobial activity against Moraxella catarrhalis clinical isolate after 18 to 22 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID561441 | Antibacterial activity against Escherichia coli 1285 harboring beta-lactamase CMY-33 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID424332 | Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CA-SFM method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID573629 | Antimicrobial activity against CTX-M-5 beta-lactamase producing Salmonella enterica serovar Typhimurium GC 4195 infected in CD-1 mouse treated 30 and 150 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID587527 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID528600 | Antimicrobial activity against Escherichia coli TOP10 harboring blaKPC-2 and blaTEM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID544427 | Antimicrobial activity against Escherichia coli CU164A harboring beta-lactamase L1 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID545635 | Antimicrobial activity against Pseudomonas aeruginosa PS14 with PFGE phenotype 10C obtained from sputum of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID549337 | Antimicrobial activity against Escherichia coli ATCC 25922 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID522392 | Ratio of Kcat Km for Aeromonas enteropelogenes Beta-lactamase TRU1 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID532922 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID546427 | Activity at Pseudomonas aeruginosa PDC-2 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID577235 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB106 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID574736 | Antimicrobial activity against Fusobacterium nucleatum after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574738 | Antimicrobial activity against Fusobacterium mortiferum after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID522016 | Antimicrobial activity against Escherichia coli isolate J53 harboring pL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID520979 | Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID533127 | Antimicrobial activity against Bacteroides caccae by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID535715 | Antibacterial activity against Escherichia coli TOP10 by agar dilution method in presence of 4 mg/liter Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID540963 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c36 plasmid expressing cephalosporinase CMY-36 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID560117 | Antibacterial activity against Escherichia coli TOP10 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID564022 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-161 by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID495827 | Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID574038 | Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID575000 | Antimicrobial activity against Eubacterium lentum after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID533416 | Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID576270 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18567 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID541807 | Antimicrobial activity against Enterococcus casseliflavus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID558322 | Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni NCTC 11168 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID528985 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID533424 | Antimicrobial activity against Anaerococcus prevotii assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID573585 | Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID532425 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate NA-14X-34 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID200366 | Beta-Lactamase inhibitory activity against represent active class A (TEM-1) serine enzyme from Escherichia coli ATCC 35218 | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID521996 | Antimicrobial activity against Escherichia coli isolate J53 harboring p3A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID574020 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529014 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID557991 | Antimicrobial activity in Clostridium innocuum by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID542049 | Antibacterial activity against rifampicin resistant Escherichia coli J53-2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID285688 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID544506 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-5 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID555668 | Antimicrobial activity against Escherichia coli DH10B harboring natural plasmid pWES-1 carrying CTX-M-53 gene by disk diffusion method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID557693 | Antimicrobial activity in Prevotella bergensis by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID564222 | Antimicrobial activity against Escherichia coli TOP10 harboring plasmid PH1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID210429 | In vitro minimum inhibitory concentration against Streptococcus species; | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Synthesis and evaluation of ether and halogenated derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID583652 | Antibacterial activity against Escherichia coli TOP10 expressing metallo-beta-lactamase NDM-1 | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. |
| AID561280 | Antibacterial activity against Klebsiella pneumoniae assessed as susceptible isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID532418 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C3 isolate PG-12X-03 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID583653 | Antibacterial activity against Escherichia coli TOP10 | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. |
| AID541518 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID285577 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID555681 | Antimicrobial activity against Escherichia coli DH10B by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID573579 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID573832 | Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574015 | Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529153 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID587727 | Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-18-pLBII after 18 hrs by microdilution broth method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID542047 | Antibacterial activity against Escherichia coli TrC A expressing Klebsiella pneumoniae A blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID541500 | Antimicrobial activity against Stenotrophomonas maltophilia clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID521425 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID558537 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P321 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID571218 | Antimicrobial activity against Pseudomonas aeruginosa isolate TX292 obtained from patient with non-cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID394490 | Ratio of Vmax to Km for Hafnia alvei beta-lactamase ACC-1 | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID562739 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-71 plasmid by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID548044 | Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID283218 | Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent susceptible isolates | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. |
| AID373757 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1308 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID528987 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID544443 | Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring beta-lactamase L2 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID565205 | Antimicrobial activity against Klebsiella pneumoniae isolate A-1760 expressing VIM-1 and KPC-2 genes by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID561459 | Antibacterial activity against Enterobacter cloacae assessed as intermediate isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID571038 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA24 obtained from patient with cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID564552 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID544500 | Antibacterial activity against Pseudomonas aeruginosa PR100 harboring beta-lactamase KPC-2 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID495912 | Hydrolytic activity of beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID574057 | Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID555209 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID573574 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID340730 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase TEM-ES by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID555220 | Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 103 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID585216 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-2 E104, N170 mutant in presence of at 4 ug/ml Tazobactam by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID548031 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237K mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID520882 | Antibacterial activity against Escherichia coli TOP10 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID558327 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P285 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID519747 | Activity of Klebsiella pneumoniae Beta-Lactamase SHV-72 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID325445 | Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Polyamine effects on antibiotic susceptibility in bacteria. |
| AID544578 | Antimicrobial activity against Escherichia coli ATCC 25922 by microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID571219 | Antimicrobial activity against Pseudomonas aeruginosa isolate TX292 obtained from patient with non-cystic fibrosis by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID560119 | Antimicrobial activity against Acinetobacter baumannii by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID341595 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID534870 | Antimicrobial activity against Non-ESBL Proteus mirabilis by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID529484 | Antimicrobial activity against Enterobacter cloacae isolate 185 containing PFGE genetic clone A expressing qnrB2 aac(6')-Ib-cr and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID567276 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position and R210P substitution by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID573582 | Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID530813 | Antibacterial activity against Escherichia coli J53 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID561477 | Antibacterial activity against Serratia marcescens assessed as resistant isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID573822 | Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID584560 | Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID285607 | Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID324862 | Antimicrobial activity against Acinetobacter baumannii A24C after 4 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID544898 | Antimicrobial activity against AmpC- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID544498 | Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-2 to MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-4 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID532183 | Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22T harboring qnrS gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID396030 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID534288 | Antimicrobial activity against Stenotrophomonas maltophilia KJ harboring pRK415 plasmid by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID113524 | In vivo inhibitory activity against Serratia marcescens in mice | 1999 | Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7 | 6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C beta-lactamases I. |
| AID406428 | Peak drug level in cystic fibrosis patient at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID542627 | Antimicrobial activity against streptomycin-resistant Streptococcus pneumoniae R6 harboring PBP2x T338G and PBP1a2349 mutant gene and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID562763 | Antimicrobial activity against Escherichia coli NO8-1503 harboring blaTEM-168 gene by Etest in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate. |
| AID405084 | Activity of Citrobacter freundii PER2 beta lactamase | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID69004 | In vitro synergistic activity against Escherichia coli C600N + (OXA-10) {PSE-2} | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID574484 | Antimicrobial activity against Bacteroides thetaiotaomicron after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID544902 | Antimicrobial activity against Klebsiella oxytoca clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557439 | Antimicrobial activity in Prevotella bivia by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID558536 | Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P854 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID565286 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID573781 | Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID548261 | Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by spectrophotometric analysis | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID573337 | Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID557705 | Antimicrobial activity in Prevotella sp.by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID508735 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring acquired beta-lactamase OXA-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID562953 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone B expressing beta-lactamase KPC-2 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID557709 | Antimicrobial activity in Porphyromonas asaccharolytica by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID573819 | Antibacterial activity against Veillonella parvula by by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529463 | Antimicrobial activity against Klebsiella pneumoniae isolate 21 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID533404 | Antimicrobial activity against Clostridium subterminale assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID511397 | Antibacterial activity against Acinetobacter baumannii by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. |
| AID495651 | Antimicrobial activity against Escherichia coli DH10B transfected with pBK-L3 expressing blaLUT-1 by Etest method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID535846 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID562331 | Antimicrobial activity against Escherichia coli DH5alpha harboring metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID532165 | Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12T harboring wild-type GyrA, GyrB, ParC and qnrS genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID584755 | Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID530322 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID533633 | Antimicrobial activity against Propionibacterium acnes by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID564693 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID285689 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID557435 | Antimicrobial activity in Bacteroides stercoris by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID544672 | Antimicrobial activity against Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID573595 | Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID534289 | Antimicrobial activity against Stenotrophomonas maltophilia KJ harboring pRK-NG plasmid by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID1373290 | Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID529503 | Antimicrobial activity against Enterobacter cloacae isolate 151 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID531620 | Antimicrobial activity against Klebsiella pneumoniae Kp2792 expressing beta-lactamase SHV-56 by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID562232 | Antimicrobial activity against Desulfovibrio piger in presence of Tazobactam by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID574758 | Antimicrobial activity against Peptoniphilus asaccharolyticus after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID554986 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID544686 | Antimicrobial activity against Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID556341 | Ratio of Kcat/Km for Salmonella enterica serotype Westhampton beta-lactamase CTX-M-53 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID574052 | Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID583153 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID573363 | Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID561493 | Antibacterial activity against Acinetobacter baumannii assessed as intermediate isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID301745 | Antibacterial activity against Klebsiella aerogenes | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. |
| AID534640 | Antimicrobial activity against ESBL producing Escherichia coli assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541515 | Antimicrobial activity against Moraxella catarrhalis clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID67558 | In vitro minimum inhibitory concentration against vancomycin-susceptible Enterococcus faecalis (GC 2691) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID565203 | Antimicrobial activity against Klebsiella pneumoniae isolate A-1797 expressing VIM-1 and KPC-2 genes by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID322316 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID529629 | Antimicrobial activity against Enterobacter cloacae isolate 656 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID557463 | Antimicrobial activity in Prevotella corporis by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID558331 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P338 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID560113 | Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-S69-V49 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID574969 | Antimicrobial activity against Actinomyces israelii after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID406430 | Mean residence time in cystic fibrosis patient at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID545636 | Antimicrobial activity against Pseudomonas aeruginosa PS15A with PFGE phasotype 10A obtained from blood of patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID585393 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-13 K104, N170 mutant in presence of at 4 ug/ml Tazobactam by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID544422 | Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A expressing beta-lactamase TEM-1 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID544691 | Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID520900 | Antibacterial activity against Escherichia coli TOP10 harboring recombinant p6S3 expressing beta lactamase OXA-114a in presence of 4 ug/ml Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID545634 | Antimicrobial activity against Pseudomonas aeruginosa PS13 with PFGE phenotype 11E obtained from sputum of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID285271 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM1 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID535704 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A S287N mutant protein by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID511586 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in ampD gene by selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution metho | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID531492 | Antibacterial activity against Bacteroides ovatus assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID518817 | Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID530825 | Antibacterial activity against Klebsiella pneumoniae 11978 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID532408 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-28 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID541496 | Antimicrobial activity against Burkholderia cepacia clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID535150 | Antimicrobial activity against ceftazidime susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541006 | Antimicrobial activity against Burkholderia cenocepacia 07-34 expressing beta-lactamase PenB in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID1209733 | Binding affinity to mouse OAT3 expressed in CHO cells at 10 to 1000 uM measured over 20 mins | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4 | Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. |
| AID1373323 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-181 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID495821 | Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID535062 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-5 plasmid by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID285258 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha CL1179 isolate expressing pBK-TEM-152 and CMT by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID406438 | Clearance in healthy human with lean body mass of 53 kg at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID544908 | Antimicrobial activity against Morganella morganii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID557741 | Antimicrobial activity in Peptoniphilus asaccharolyticus by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID544923 | Antimicrobial activity against Acinetobacter calcoaceticus clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID516141 | Antibacterial activity against Pulsotype K Acinetobacter genomosp. 3 isolate 6 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID528486 | Antimicrobial activity against Pseudomonas aeruginosa pleural fluid isolate 4679 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID574003 | Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID558324 | Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P835 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID372641 | Ratio of Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-1 to Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-158 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID529001 | Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID561491 | Antibacterial activity against Acinetobacter baumannii assessed as susceptible isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID373754 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab8 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID558335 | Antibacterial activity against Campylobacter jejuni isolate P1093 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID66069 | The compound was evaluated for antimicrobial activity against Enterobacter cloacae OC 4080 by inhibiting enzyme P99 | 2000 | Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19 | The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. |
| AID573652 | Antimicrobial activity against ACT-1 beta-lactamase producing Escherichia coli GC 2814 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID574494 | Antimicrobial activity against Bacteroides fragilis assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID541022 | Activity at Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10 by UV-spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID533565 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID573844 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID511386 | Antibacterial activity against ciprofloxacin resistant Escherichia coli by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. |
| AID573833 | Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID324361 | Activity of Acinetobacter johnsonii SCO1 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID495839 | Ratio of Kcat to Km for Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID573432 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection in presence of 4:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID519005 | Antimicrobial activity against Escherichia coli HB101 expressing recombinant plasmid encoded TEM-149 by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID558538 | Antibacterial activity against bla-positive and beta-lactamase-weakly positive Campylobacter coli isolate P1627 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID554984 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID533360 | Antimicrobial activity against Bacteroides ovatus assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID68375 | In vitro synergistic activity against Enterobacter cloacae SC12629 (AmpC inducible) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID422496 | Activity of Carnobacterium divergens BM4489 penicillinase Cad-1 assessed as initial rate of hydrolysis by spectrophotometer | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID585193 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-1 E104, G170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID519745 | Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations in presence of 4 ug/ml Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID69011 | In vitro synergistic activity against Escherichia coli C600N + (TEM-10) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID574731 | Antimicrobial activity against Porphyromonas asaccharolytica after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID207193 | In vitro minimum inhibitory concentration against Methicillin-resistant Staphylococcus aureus(GC 4541) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID544883 | Antimicrobial activity against AmpC beta-lactamase-producing Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method in presence of beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. |
| AID519006 | Antimicrobial activity against Escherichia coli HB101 harboring empty vector pBK-SK by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID467877 | Antibacterial activity against methicillin-resistant Staphylococcus aureus at 100 ug/ml by NCCLS method | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12 | Methicillin-resistant Staphylococcus aureus (MRSA)-active metabolites from Platanus occidentalis (American Sycamore). |
| AID530815 | Antibacterial activity against human urinary Klebsiella pneumoniae UCL-1 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID548007 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237P mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID573362 | Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID285603 | Antimicrobial activity against Pseudomonas aeruginosa 2B5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID574531 | Antimicrobial activity against Prevotella bivia assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID340731 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase SHV-ES by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID573834 | Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID406426 | Total clearance in cystic fibrosis patient at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID425867 | Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID532427 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D isolate VA-06X-69 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID535659 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61T harboring qnrS gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID285611 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573598 | Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID548035 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237R mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID521436 | Ratio of induction of xylE gene expression in Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene to induction of xylE gene expression in Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene assessed as catec | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID583154 | Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID561465 | Antibacterial activity against Proteus mirabilis assessed as susceptible isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID534660 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID532401 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D3 isolate VA-06X-65 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID542618 | Antimicrobial activity against streptomycin-resistant Streptococcus pneumoniae R6 harboring PBP2x T338G and PBP1a2349 mutant gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID562746 | Antimicrobial activity against Escherichia coli DH5alpha harboring pBC-CTX-M-15 plasmid by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID534302 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA479 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID563974 | Activity of Klebsiella pneumoniae 05-560 beta-lactamase IMP1 by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID562772 | Antimicrobial activity against Escherichia coli DH10B transformant harboring blaTEM-168 gene by Etest in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate. |
| AID573338 | Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID567283 | Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase to Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID573799 | Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID559922 | Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-V49 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID522387 | Antimicrobial activity against Escherichia coli TOP10 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID546426 | Activity at Pseudomonas aeruginosa PDC-1 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID394492 | Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc4 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID531624 | Antimicrobial activity against Escherichia coli JM109 by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID548043 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBK SK(+) by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID573631 | Antimicrobial activity against CTX-M-5 beta-lactamase producing Salmonella enterica serovar Typhimurium GC 4195 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID573555 | Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID540959 | Antimicrobial activity against Klebsiella pneumoniae HP205 expressing CMY-36 cephalosporinase by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID373761 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1265 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID562221 | Antimicrobial activity against Desulfovibrio fairfieldensis by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID583156 | Antimicrobial activity against ampD::lox, ampDh2::lox,ampDh3::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID573846 | Antimicrobial activity against ACT-1 beta-lactamase producing Escherichia coli GC 2814 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID369640 | Antibacterial activity against Acinetobacter baumannii A clone expressing carbapenemase-encoding blaOXA-40 gene by Etest method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. |
| AID495906 | Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID535866 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47T harboring qnrB gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID372605 | Antibacterial activity against Escherichia coli BER1 producing beta-lactamase pI 5.2 and pI 5.4 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID554985 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID544441 | Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring beta-lactamase AmpC by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID573627 | Antimicrobial activity against SHV-1and SHV-5 beta-lactamase producing Klebsiella pneumoniae GAR 7978 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID372607 | Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-158 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID555560 | Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID405818 | Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID545848 | Antimicrobial activity against Pseudomonas aeruginosa PS39 with PFGE phenotype 8 expressing beta-lactamase IMP-18 obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID529200 | Antibacterial activity against ESBL-producing Escherichia coli assessed as sensitive isolates by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. |
| AID532434 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone F isolate RM-11X-09 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID374365 | Antimicrobial activity against Escherichia coli DH5alpha expressing pIP19 containing Aeromonas caviae A324R metallo-beta-lactamase blaIMP-19 gene by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID396031 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID535854 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67T harboring qnrS gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID522006 | Antimicrobial activity against Klebsiella pneumoniae isolate KpI-2 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID529582 | Ratio of Kcat to Km for Bradyrhizobium japonicum beta-Lactamase BJP-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID534311 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA507 in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID574968 | Antimicrobial activity against Actinomyces odontolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID495928 | Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-4 by Etest in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID531493 | Antibacterial activity against Bacteroides distasonis assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID564483 | Antimicrobial activity against Pseudomonas aeruginosa isolate 971 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID556336 | Antimicrobial activity against Escherichia coli ATCC 25922 by disk diffusion method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID529458 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, CTX-M-15 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID583206 | Bactericidal activity against Escherichia coli ATCC 25922 using 10'5 CFU/ml inoculum assessed as log reduction in bacterial count at 4 times MIC after 24 hrs by time-kill study | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Mathematical modeling to characterize the inoculum effect. |
| AID495633 | Antimicrobial activity against Escherichia coli DH10B transfected with pBK-L3 expressing blaLUT-1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID555195 | Antimicrobial activity against nagZ gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID91387 | Synergic activity of compound was determined against IMP-1 beta lactamase produced by Escherichia coli; R = Resistant | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID535063 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-6 plasmid by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID533527 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID576276 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17834 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID564016 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA isolated from wound infection of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID546619 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID548012 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237S mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID545622 | Antimicrobial activity against OprD overproducing Pseudomonas aeruginosa PAO1 expressing mexA and oprD by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID520784 | Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 in presence of Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID69013 | In vitro synergistic activity against Escherichia coli GC 6266 clinical isolate | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID544501 | Antibacterial activity against Enterobacter cancerogenus E624 harboring beta-lactamase KPC-4 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID495792 | Antimicrobial activity against Escherichia coli DH10B harbouring recombinant plasmid pSau1 expressing beta-lactamase BIC-1 from Pseudomonas fluorescens PF-1 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID562812 | Antimicrobial activity against Escherichia coli DH5[alpha] | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID1373306 | Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID573839 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID547800 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237F mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID285598 | Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID529492 | Antimicrobial activity against Enterobacter cloacae isolate 658 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID530827 | Antibacterial activity against human urinary Klebsiella pneumoniae UCL-1 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID67562 | In vitro minimum inhibitory concentration against vancomycin-susceptible Enterococcus faecalis (GC 4555) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID532412 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-07 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID529004 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID533768 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa isolate P67 exhibiting PFGE J pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID555219 | Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 69 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID532927 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID406441 | Volume of distribution at steady state in healthy human with lean body mass of 53 kg at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID511584 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID369643 | Antibacterial activity against Acinetobacter haemolyticus expressing carbapenemase-encoding blaOXA-40 gene by Etest method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID584563 | Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID340736 | Activity of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID567311 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2202 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID542615 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x T338G mutant gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID544503 | Antibacterial activity against Escherichia coli TOP10 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID571033 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID1373282 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-15 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID577242 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB097 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID574017 | Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID207189 | In vitro minimum inhibitory concentration against Methicillin-resistant Staphylococcus aureus (GC 1131) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID207198 | In vitro minimum inhibitory concentration against Methicillin-susceptible Staphylococcus aureus(GC 4544) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID534287 | Antimicrobial activity against ampN deficient Stenotrophomonas maltophilia KJ harboring ampG with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID531968 | Antibacterial activity against Klebsiella pneumoniae blood isolate A28008 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID560121 | Antimicrobial activity against Acinetobacter baumannii by disk diffusion method in presence of 4 ug/ml Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID518730 | Antimicrobial activity against Pseudomonas stutzeri clinical isolate expressing beta-lactamase DIM-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID43897 | In vitro antibacterial activity against Pseudomonas aeruginosa Beta-lactamase AmpC of class C enzyme | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone. |
| AID532432 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D4 isolate VA-06X-47 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1373294 | Antimicrobial activity against Escherichia coli expressing beta-lactamase SME-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID532421 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A1 isolate FG-17X-14 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1373304 | Antimicrobial activity against Escherichia coli expressing beta-lactamase GIM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID530553 | Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID562222 | Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID546428 | Activity at Pseudomonas aeruginosa PDC-3 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID511298 | Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID529497 | Antimicrobial activity against Escherichia coli T-625 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID561485 | Antibacterial activity against Pseudomonas aeruginosa assessed as resistant isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID557983 | Antimicrobial activity in Clostridium cadaveris by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID520974 | Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID545633 | Antimicrobial activity against Pseudomonas aeruginosa PS12 with PFGE phasotype 7B obtained from sputum of patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID406435 | Mean residence time in healthy human at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID541019 | Antimicrobial activity against Escherichia coli TOP10 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID528488 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4703 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID495908 | Antimicrobial activity in Escherichia coli TOP10 harbouring recombinant plasmid VIM-1-N215K by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID541010 | Antimicrobial activity against Burkholderia cenocepacia 212 expressing beta-lactamase PenB3 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID576064 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69928 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID495797 | Activity at Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID68872 | In vitro synergistic activity against Escherichia coli 300 + (ampR ampC) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID534636 | Antimicrobial activity against Non-ESBL Escherichia coli assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID563977 | Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase VIM2 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID583189 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID571936 | Antimicrobial activity against Escherichia coli MC4100 harboring weak promoter and active promoter P2 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID573622 | Antimicrobial activity against SHV-11beta-lactamase producing Klebsiella pneumoniae GAR 7693 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID549331 | Antimicrobial activity against Escherichia coli isolate 32 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID535159 | Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID562959 | Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID528988 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID555201 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID533415 | Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID567273 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID577227 | Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB018 with PFGE subgroup G containing carbapenemase OXA-58 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID530321 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID325448 | Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Polyamine effects on antibiotic susceptibility in bacteria. |
| AID547764 | Antimicrobial activity against Klebsiella pneumoniae 1534 expressing beta-lactamase KPC-2 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID534892 | Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID429077 | Antibacterial activity against Escherichia coli J53 by E test method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. |
| AID68693 | In vitro inhibitory activity against Escherichia coli | 1999 | Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7 | 6-(1-Hydroxyalkyl))penam sulfone derivatives as inhibitors of class A and class C beta-lactamases II. |
| AID324874 | Antimicrobial activity against Acinetobacter baumannii C75 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID560488 | Antibacterial activity against 5 x 10'5 CFU/ml CMY-30 producing Escherichia coli MC4100 harboring plasmid AC-cmy30 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID394497 | Antimicrobial activity against Escherichia coli MC4100 harboring pBCSK plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID574729 | Antimicrobial activity against Prevotella oralis assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID532189 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID529501 | Antimicrobial activity against Enterobacter cloacae isolate 18 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID576282 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID576294 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 11932 harboring porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID548004 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237P mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID528604 | Antimicrobial activity against Escherichia coli J53 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID555663 | Antimicrobial activity against Salmonella enterica serotype Westhampton isolate 04CEB8273SAL expressing CTX-M-53 gene by disk diffusion method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID535835 | Antimicrobial activity against Pseudomonas aeruginosa GP37KT31 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID532443 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C1 isolate AV-13X-28 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID544428 | Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring beta-lactamase L1 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID529160 | Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay in presence of 250 ug/ml polyethylenimine | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID573600 | Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID573658 | Antimicrobial activity against SHV-1and SHV-5 beta-lactamase producing Klebsiella pneumoniae GAR 7978 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID520777 | Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID574745 | Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID584317 | Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. |
| AID531602 | Antimicrobial activity against Escherichia coli JM109 harboring pE1MD plasmid expressing beta-lactamase SHV-56 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID573623 | Antimicrobial activity against TEM-10 beta-lactamase producing Escherichia coli GC 2022 infected in CD-1 mouse treated 30 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID529013 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID324310 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolate | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. |
| AID585395 | Activity at Bradyrhizobium japonicum metallo-beta-lactamase BJP-1 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. |
| AID535694 | Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID405082 | Antimicrobial activity against Escherichia coli 33587-TC9 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID583151 | Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID565691 | Antimicrobial activity against beta-lactamase negative ampicillin-clavulanic acid-resistant-Haemophilus influenzae harboring fst1 mutant gene by disk diffusion method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID528602 | Antimicrobial activity against blaKPC-2, blaKLUC-2 and blaTEM-1 producing Enterobacter cloacae 7506 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID523274 | Activity at Escherichia coli isolate 7181 beta-lactamase OXA-7 measured per mg of protein | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. |
| AID560593 | Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID573342 | Antibacterial activity against ceftazidime-susceptible Citrobacter freundii assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID571034 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA22 obtained from patient with cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID583188 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID573438 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 min postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID406443 | Peripheral volume of distribution in healthy human with lean body mass of 53 kg at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID555661 | Antimicrobial activity against Salmonella enterica serotype Westhampton isolate 04CEB8273SAL expressing CTX-M-53 gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID534195 | Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. |
| AID495655 | Antimicrobial activity against Pseudomonas aeruginosa 51170 expressing beta-lactamase BEL-1 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID519629 | Antimicrobial activity against Escherichia coli JM83 without producing beta-lactamase OXA-63 after 3 days by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID535706 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A S287N mutant protein by agar dilution method in presence of 4 mg/liter Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID373053 | Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID522384 | Antimicrobial activity against Aeromonas enteropelogenes ATCC 49803 producing endogenous class C beta-lactamase TRU-1 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID495926 | Antimicrobial activity in Klebsiella pneumoniae DIH-2 clinical isolate expressing beta-lactamase VIM-19 by Etest in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID529636 | Antimicrobial activity against Escherichia coli T-622 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID559417 | Antimicrobial activity against Acinetobacter baumannii 3208 expressing multiple-antibiotic resistance gene AbaR5 by Viek 2 system in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AbaR5, a large multiple-antibiotic resistance region found in Acinetobacter baumannii. |
| AID285593 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID520881 | Antibacterial activity against Escherichia coli TOP10 harboring recombinant p6S3 expressing beta lactamase OXA-114a by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID584751 | Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID522391 | Inhibition of Aeromonas enteropelogenes Beta-lactamase TRU1 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID424862 | Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID373769 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh20 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID574454 | Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID544580 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8128 expressing bla SHV-105 gene by microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID285263 | Antimicrobial activity against Escherichia coli DH5-alpha TC1295 isolate expressing TEM-1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID529634 | Antimicrobial activity against Enterobacter cloacae isolate 837 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID585215 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-7 K104, G170 mutant in presence of at 4 ug/ml Tazobactam by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID559262 | Antimicrobial activity against Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID545423 | Antimicrobial activity against Citrobacter freundii obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID573660 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID373767 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh17 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID558534 | Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1699 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID584554 | Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID533523 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID67559 | In vitro minimum inhibitory concentration against vancomycin-susceptible Enterococcus faecalis (GC 4552) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID587640 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=8:2 mg/kg, sc compound to NXL104 b | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID727653 | Ratio of Kcat to Km for Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID565201 | Antimicrobial activity against Klebsiella pneumoniae isolate T-1504 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID528481 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4682-1 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID573638 | Antimicrobial activity against ACT-1 beta-lactamase producing Escherichia coli GC 2814 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID217319 | Synergistic activity of compound was determined against VIM-1 beta lactamase produced by Escherichia coli; R = Resistant | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID562481 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase KPC-2/TEM-1 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID548036 | Antimicrobial activity against Escherichia coli DH10B by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID528489 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4659 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID341594 | Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID585399 | Activity at Fluoribacter gormanii 1K07 metallo-beta-lactamase FEZ-1 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. |
| AID511585 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID573662 | Antimicrobial activity against ACT-1 beta-lactamase producing Escherichia coli GC 2814 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID530324 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-13 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID530331 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID534873 | Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573551 | Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID69007 | In vitro synergistic activity against Escherichia coli C600N + (SHV-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID372610 | Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-1 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID529502 | Antimicrobial activity against Enterobacter cloacae isolate 140 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID561446 | Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-2 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID528493 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID564529 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID535884 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132T harboring qnrB gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID585198 | Antimicrobial activity against Escherichia coli DH5[alpha] by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID576285 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17049 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID283217 | Antimicrobial activity against Burkholderia cepacia complex isolated from cystic fibrosis patient by broth microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. |
| AID532409 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-38 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID558338 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1730 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID564486 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1093 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID529574 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid BC-SK after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID495812 | Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID557987 | Antimicrobial activity in Clostridium bifermentans by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID534306 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA509 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID544583 | Antimicrobial activity against Escherichia coli DH5[alpha] by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID564227 | Antimicrobial activity against Escherichia coli TOP10 by Etest method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID522382 | Antimicrobial activity against blaKPC-possessing Klebsiella pneumoniae isolates assessed as susceptible isolates in presence of 4 ug/ml by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID563158 | Antibacterial activity against Pseudomonas aeruginosa isolate 9BR by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. |
| AID573801 | Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID576297 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16830 harboring porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID65041 | In vitro antibacterial activity against Escherichia coli GC6265 | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone. |
| AID573842 | Antimicrobial activity against SHV-1and SHV-5 beta-lactamase producing Klebsiella pneumoniae GAR 7978 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID574446 | Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID573375 | Antibacterial activity against multidrug-resistant Acinetobacter assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID529508 | Antimicrobial activity against Enterobacter cloacae isolate 625 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID564215 | Antimicrobial activity against Acinetobacter baumannii ATCC 135040 by Etest method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID529631 | Antimicrobial activity against Enterobacter cloacae isolate 649 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID521998 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp5A expressing beta-lactamase OXA-48 and SHV-5 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID548016 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237D mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID531600 | Antimicrobial activity against Escherichia coli JM109 harboring pE1 plasmid expressing beta-lactamase SHV-11 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID546430 | Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-1 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID520973 | Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID68877 | In vitro synergistic activity against Escherichia coli C600N (no beta-lactamase) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID574453 | Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID544581 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 7668 expressing bla SHV-48 gene by microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID567282 | Ratio of Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID574528 | Antimicrobial activity against Prevotella intermedia assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID573647 | Antimicrobial activity against TEM-10 beta-lactamase producing Escherichia coli GC 2022 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID562228 | Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 in presence of Tazobactam by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID1207762 | Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits | 2013 | Scientific reports, , Volume: 3 | MICE models: superior to the HERG model in predicting Torsade de Pointes. |
| AID495662 | Ratio of Kcat to Km for Pseudomonas aeruginosa 531 beta-lactamase BEL-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID530106 | Antimicrobial activity against Escherichia coli TOP10 harboring blaKPC-2 and blaTEM-1 gene by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID573570 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID531777 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4663 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID394493 | Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc1 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID584752 | Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID301744 | Antibacterial activity against Escherichia coli | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. |
| AID530552 | Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID545650 | Antimicrobial activity against Pseudomonas aeruginosa PS33 with PFGE phasotype 9A obtained from blood of patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID582965 | Antimicrobial activity against Yersinia enterocolitica Biovar 1B 8081 after 20 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B. |
| AID405821 | Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID573378 | Antibacterial activity against imipenem-susceptible Acinetobacter assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID564694 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID574507 | Antimicrobial activity against Bacteroides distasonis assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1373314 | Antimicrobial activity against Escherichia coli expressing beta-lactamase P99 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID562957 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone F expressing beta-lactamase KPC-2 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID340729 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-14 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID573802 | Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID558011 | Antimicrobial activity in Porphyromonas gingivalis by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID574445 | Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID531498 | Antibacterial activity against Bacteroides fragilis assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID495805 | Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID1373285 | Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-2 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID533412 | Antimicrobial activity against Finegoldia magna assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID727654 | Ratio of Kcat to Km for wild type Beta-lactamase SHV-1 in Escherichia coli DH10B | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID574772 | Antimicrobial activity against Clostridium perfringens assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID567580 | Antimicrobial activity against Acinetobacter baumannii assessed as resistant isolate by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID574996 | Antimicrobial activity against Bifidobacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID585197 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-13 K104, N170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID96430 | In vitro synergistic activity against Klebsiella pneumoniae KC2 (TEM-10) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID529652 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-2 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID529488 | Antimicrobial activity against Enterobacter cloacae isolate 625 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID564015 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA lung biopsy specimen of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID583184 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID532996 | Antibacterial activity against OXA-2 and OXA-19 producing Pseudomonas aeruginosa isolate P66 exhibiting PFGE C pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID301805 | Antibacterial activity against Staphylococcus aureus ATCC 29213 | 2007 | Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23 | Direct diazo-transfer reaction on beta-lactam: synthesis and preliminary biological activities of 6-triazolylpenicillanic acids. |
| AID585401 | Activity at Chryseobacterium meningosepticum NCTC 10585 metallo-beta-lactamase GOB-1 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. |
| AID577234 | Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB099 with PFGE subgroup H containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID545465 | Antimicrobial activity against Pseudomonas fluorescens assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID561495 | Antibacterial activity against Acinetobacter baumannii assessed as resistant isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID576076 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 harboring pSHA2-encoded porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID1373318 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-40 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID520880 | Antibacterial activity against Achromobacter xylosoxidans TB1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID573580 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID285270 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM36 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID571938 | Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 1 and active promoter P2 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID561628 | Antimicrobial activity against ampD1-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID573782 | Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID405819 | Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID520776 | Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID533569 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID529630 | Antimicrobial activity against Enterobacter cloacae isolate 354 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1257072 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA 300 LAC after 20 hrs by CLSI broth microdilution method | 2015 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23 | Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities. |
| AID340737 | Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID534912 | Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573596 | Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID322324 | Antibacterial activity against Escherichia coli INSRA5924 isolates expressing CTX-M-32 and TEM-1B enzymes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID528601 | Antimicrobial activity against Escherichia coli TOP10 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID530291 | Antimicrobial activity against Escherichia coli J53 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID573632 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID495654 | Antimicrobial activity against Pseudomonas aeruginosa 531 expressing beta-lactamase BEL-2 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID549342 | Antimicrobial activity against Escherichia coli isolate 100 harboring bla CTX-M-3a gene by broth microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID558323 | Antibacterial activity against Campylobacter jejuni isolate P270 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID511577 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID567275 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID424331 | Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CA-SFM method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID1604436 | Antibacterial activity against Pseudomonas aeruginosa haboring KPC-2 assessed as reduction in microbial growth by CLSI based broth microdilution method | 2020 | Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5 | β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs. |
| AID207210 | In vitro minimum inhibitory concentration against glycopeptide tntermediate Staphylococcus aureus (GC 3051) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID584556 | Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID573439 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 min postinfection in presence of 2:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID163430 | The compound was evaluated for antimicrobial activity against Pseudomonas aeruginosa OC 4290 by inhibiting enzyme AmpC(const) | 2000 | Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19 | The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. |
| AID564224 | Antimicrobial activity against Escherichia coli TOP10 harboring plasmid PH1 by Etest method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID547796 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237V mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID374366 | Antimicrobial activity against Escherichia coli DH5alpha by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID535840 | Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID573837 | Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID285578 | Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID549336 | Antimicrobial activity against Escherichia coli isolate 49 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID573797 | Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID555208 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID573815 | Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574989 | Antimicrobial activity against Bifidobacterium adolescentis assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID534308 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA479 in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID532430 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-17 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID574496 | Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID285595 | Antimicrobial activity against Pseudomonas aeruginosa 1B9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID531971 | Antibacterial activity against Klebsiella pneumoniae blood isolate A28006 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID545453 | Antimicrobial activity against extended-spectrum beta-lactamase-positive Proteus mirabilis assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID532404 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone F isolate RM-11X-09 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID69005 | In vitro synergistic activity against Escherichia coli C600N + (P99) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID394496 | Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc1 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID533396 | Antimicrobial activity against Clostridium innocuum assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID66130 | In vitro minimum inhibitory concentration against Enterococcus species (11 strains, including VRE) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID518521 | Antimicrobial activity against Capnocytophaga sputigena CRBIP 17.39 after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID544496 | Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-4 to MIC for Escherichia coli TOP10 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID574508 | Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID727797 | Antimicrobial activity against Escherichia coli DH10B expressing wild type Beta-lactamase SHV-1 by CLSI agar dilution method | 2013 | Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3 | Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. |
| AID574526 | Antimicrobial activity against Prevotella intermedia assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID495815 | Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID584318 | Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. |
| AID584758 | Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID574730 | Antimicrobial activity against Porphyromonas asaccharolytica after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574499 | Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID582982 | Antimicrobial activity against nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID534896 | Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID574501 | Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID576268 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18918 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID577241 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB173 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID564485 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1080 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID324872 | Antimicrobial activity against Acinetobacter baumannii C75 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID544432 | Antimicrobial activity against Escherichia coli MC4100A harboring beta-lactamase AmpC by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID285440 | Antimicrobial activity against Escherichia coli DH10B expressing GIL1 after 18 hrs by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID540942 | Antimicrobial activity against Salmonella enterica serotype Newport AM17274 expressing CMY-31 cephalosporinase by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID558336 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1618 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID564475 | Antimicrobial activity against Pseudomonas aeruginosa isolate 878 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID531317 | Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID561453 | Antibacterial activity against Klebsiella oxytoca assessed as resistant isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID324854 | Antimicrobial activity against Acinetobacter baumannii A24 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID533372 | Antimicrobial activity against Bacteroides vulgatus assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID567305 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2203 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID584761 | Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID531489 | Antibacterial activity against Bacteroides merdae assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID559278 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Providencia stuartii Ps5 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID532402 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D4 isolate VA-06X-47 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID563605 | Antimicrobial activity against lacZ-negative, Nalidixic acid-, rifampicin-resistant Escherichia coli EC600 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA. |
| AID574019 | Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID564482 | Antimicrobial activity against Pseudomonas aeruginosa isolate 968 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID534635 | Antimicrobial activity against Non-ESBL Escherichia coli assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573437 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection in presence of 14:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID534871 | Antimicrobial activity against ESBL producing Proteus mirabilis by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID545639 | Antimicrobial activity against Pseudomonas aeruginosa PS19A with PFGE phenotype 11C obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID567303 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2201 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID532397 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D isolate VA-06X-69 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID567310 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2201 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID340733 | Antimicrobial activity against Chryseobacterium indologenes NF16 isolate assessed as drug level at which microbial resistance was observed by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID518824 | Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 2 containing IMP-8, OXA-58, ADC-43, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID531775 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4659 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID531770 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4706 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID532931 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID533766 | Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P102 exhibiting PFGE H pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID285587 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID574766 | Antimicrobial activity against Finegoldia magna assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID547792 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237M mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID567277 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position and R210P substitution by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID528490 | Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4680 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID567278 | Antimicrobial activity against Escherichia coli TOP10 harboring pTOPO plasmid by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID495803 | Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID545652 | Antimicrobial activity against Pseudomonas aeruginosa PS35 with PFGE phenotype 11A obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID522025 | Antimicrobial activity against Escherichia coli isolate A expressing beta-lactamase OXA-48 and TEM-150 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID562482 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase SHV-12 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID573573 | Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574021 | Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID564473 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1095 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID535161 | Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID534305 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA507 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID529485 | Antimicrobial activity against Enterobacter cloacae isolate 293 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID206387 | In vitro minimum inhibitory concentration against methicillin-susceptible Coagulase-negative Staphylococci (MSCNS) (GC 6257) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID372603 | Antibacterial activity against Escherichia coli BER1 producing beta-lactamase TEM-158 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID532407 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-20 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID535845 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL1 harboring oprD, mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID573616 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 min postinfection in presence of 10:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID587731 | Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID495807 | Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID535699 | Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID577228 | Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB039 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID531316 | Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID557681 | Antimicrobial activity in Prevotella baroniae by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID533428 | Antimicrobial activity against Peptostreptococcus sp. assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID567319 | Antimicrobial activity against Escherichia coli TUM4672 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID531767 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4682-1 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID422497 | Ratio of Kcat to Km of Carnobacterium divergens BM4489 penicillinase Cad-1 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID532921 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID530334 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-13 gene by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID69014 | In vitro synergistic activity against Escherichia coli GC6267 clinical isolate | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID406433 | Peak drug level in healthy human at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID561473 | Antibacterial activity against Serratia marcescens assessed as susceptible isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID573663 | Antimicrobial activity against OXA-1 beta-lactamase producing Escherichia coli GAR 5946 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID529462 | Antimicrobial activity against Klebsiella pneumoniae isolate 11 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID560134 | Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 assessed as Ratio of Kcat to Km by nitrocefin hydrolysis assay relative to benzylpenicillin | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID535653 | Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID574751 | Antimicrobial activity against Peptostreptococcus micros assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID518520 | Antimicrobial activity against Escherichia coli TOP10(pNOR-1) expressing CSP-1 gene after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID405825 | Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID530338 | Antimicrobial activity against Escherichia coli XL1-Blue by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID534292 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-NG plasmid and ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID574530 | Antimicrobial activity against Prevotella bivia assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID564532 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene with alanine residue deletion at 215 position by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID495652 | Antimicrobial activity against Escherichia coli DH10B by Etest method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID535656 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID285596 | Antimicrobial activity against Pseudomonas aeruginosa 1C9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID528994 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID533384 | Antimicrobial activity against Bacteroides nordii assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID561288 | Antibacterial activity against Klebsiella oxytoca assessed as susceptible isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID534391 | Antibacterial activity against Escherichia coli JM109 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID555198 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox after 18 hrs by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID529150 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID573621 | Antimicrobial activity against SHV-11beta-lactamase producing Klebsiella pneumoniae GAR 7693 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID573775 | Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID548000 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237N mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID583157 | Antimicrobial activity against ampR::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID301806 | Antibacterial activity against Escherichia coli ATCC 25922 | 2007 | Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23 | Direct diazo-transfer reaction on beta-lactam: synthesis and preliminary biological activities of 6-triazolylpenicillanic acids. |
| AID542619 | Antimicrobial activity against streptomycin- resistant Streptococcus pneumoniae R6 harboring PBP2x2349 mutant gene and Janus disruption at PBP1a after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID297186 | Antibacterial activity against multidrug resistant Staphylococcus aureus 49589 | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. |
| AID540945 | Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pH205 plasmid expressing cephalosporinase CMY-36 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID424330 | Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID425865 | Antimicrobial activity against Carnobacterium divergens BM4489 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID587643 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at 1024 mg/kg, sc after 24 hrs by acute | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID1373296 | Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-4 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID524246 | Antimicrobial activity against Escherichia coli DH5alpha expressing SHV-84 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID529506 | Antimicrobial activity against Enterobacter cloacae isolate 533 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID528485 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4658 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID1225389 | Antibacterial activity against Escherichia coli transformed with plasmid carrying MG1655 deltaBC/pXYM by p-iodonitrotetrazolium chloride colorimetric assay | 2015 | Journal of natural products, Mar-27, Volume: 78, Issue:3 | Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp. |
| AID544430 | Antimicrobial activity against Escherichia coli CU164A harboring beta-lactamase L2 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID531765 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4667 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID534300 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA459 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID567320 | Antimicrobial activity against Escherichia coli ML4909 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID373063 | Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique in presence of beta-lactamase inhibitor Tazobactam | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID533376 | Antimicrobial activity against Bacteroides eggerthii assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID495929 | Antimicrobial activity in Escherichia coli TOP10 strain harbouring recombinant plasmid VIM-1 by Etest in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID535065 | Antimicrobial activity against Acinetobacter genomic species 13TU by Vitek II system in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID532417 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-12 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID534897 | Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID535832 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP61 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID545429 | Antimicrobial activity against Enterobacter cloacae obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID68876 | In vitro synergistic activity against Escherichia coli ATCC 35218 (TEM-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID533522 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID209618 | In vitro minimum inhibitory concentration against Streptococcus pyogenes (GC 4563) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID424323 | Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CA-SFM method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID535158 | Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573365 | Antibacterial activity against ceftazidime-susceptible Morganella morganii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID326268 | Antibacterial activity against Escherichia coli DH5-alpha by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. |
| AID564553 | Antimicrobial activity against Acinetobacter baumannii AYE expressing VEB-1 gene by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID518731 | Antimicrobial activity against Pseudomonas stutzeri clinical isolate expressing beta-lactamase DIM-1 by agar dilution method in presence of beta-lactam inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID574039 | Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID573796 | Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID573661 | Antimicrobial activity against AmpC beta-lactamase producing Pseudomonas aeruginosa GC 1764 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID535841 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP4 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID558330 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P316 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID522383 | Inhibition of Beta-lactamase KPC-2 in Klebsiella pneumoniae isolates assessed as reduction in antimicrobial MIC of beta-lactams by agar dilution method relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID285264 | Antimicrobial activity against Escherichia coli DH5-alpha TC1179 isolate expressing TEM-1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID555556 | Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID542044 | Antibacterial activity against Escherichia coli TrC B expressing Klebsiella pneumoniae B blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID556340 | Activity of Salmonella enterica serotype Westhampton beta-lactamase CTX-M-53 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID571935 | Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 2 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID573636 | Antimicrobial activity against ACT-1 beta-lactamase producing Escherichia coli GC 2814 infected in CD-1 mouse treated 30 and 150 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID520785 | Antibacterial activity against Escherichia coli EC600 in presence of Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID1194547 | Antibacterial activity against TolC-deficient Escherichia coli AB1157 | 2015 | Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9 | Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors. |
| AID535067 | Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pYMAb3 plasmid by Vitek II system in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. |
| AID563972 | Activity of Klebsiella pneumoniae 05-560 beta-lactamase NDM-1 by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID571036 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA367 obtained from patient with cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID585398 | Ratio of Kcat to Km for Stenotrophomonas maltophilia 1SML metallo-beta-lactamase L1 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. |
| AID534916 | Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID541012 | Antimicrobial activity against Burkholderia cenocepacia 212 expressing beta-lactamase PenB3 in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID573633 | Antimicrobial activity against AmpC beta-lactamase producing Pseudomonas aeruginosa GC 1764 infected in CD-1 mouse treated 30 and 150 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID555561 | Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID532438 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-28 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID574016 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID562743 | Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID534638 | Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID545432 | Antimicrobial activity against Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID1225387 | Antibacterial activity against Escherichia coli AG102 overexpressing AcrAB-TolC by p-iodonitrotetrazolium chloride colorimetric assay | 2015 | Journal of natural products, Mar-27, Volume: 78, Issue:3 | Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp. |
| AID555554 | Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID546433 | Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-5 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID373062 | Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor Tazobactam | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID547801 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237W mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID542616 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x2349 mutant gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID516140 | Antibacterial activity against Pulsotype M Acinetobacter genomosp. 3 isolate 5 containing IMP-1, OXA-58, ADC-43, ISAba2, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID522386 | Antimicrobial activity against Escherichia coli NI540 carrying cloned class C beta-lactamase TRU-1 gene | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID574500 | Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID583093 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pBC-SK plasmid by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID520967 | Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID573339 | Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID547784 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237I mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID519981 | Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-1 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. |
| AID531621 | Antimicrobial activity against Escherichia coli JM109 harboring pE1 plasmid expressing beta-lactamase SHV-11 by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID535881 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID532925 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID545851 | Antimicrobial activity against Pseudomonas aeruginosa PS43 with PFGE phasotype 2 expressing beta-lactamase KPC-2, OXA-2 obtained from skin of ICU patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID562958 | Antimicrobial activity against Klebsiella oxytoca expressing beta-lactamase KPC-2 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID558337 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1650 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID495843 | Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID535893 | Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64 harboring GyrA T83I, wild-type ParC, GyrB and qnrA genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID285574 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID285592 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID285610 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID519014 | Antimicrobial activity against Enterobacter aerogenes isolate SS-13 by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID561274 | Antibacterial activity against Escherichia coli assessed as intermediate isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID529495 | Antimicrobial activity against Enterobacter cloacae isolate 4469 containing PFGE genetic clone C expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID532201 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42T harboring qnrA gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID522014 | Antimicrobial activity against Escherichia coli isolate J53 harboring pBEL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID519739 | Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method in presence of 4 ug/ml Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID584316 | Antimicrobial activity against beta-lactamase AmpC producing meropenem-resistant Serratia marcescens by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. |
| AID511578 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID520975 | Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID535869 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51 harboring qnrA gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID543423 | Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID529473 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID535155 | Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method in presence of tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573589 | Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID495914 | Hydrolytic activity of beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID1194546 | Antibacterial activity against wild-type Escherichia coli AB1157 | 2015 | Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9 | Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors. |
| AID529156 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID547765 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBR322-catI carrying beta-lactamase KPC-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID575002 | Antimicrobial activity against Eubacterium lentum assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID511289 | Antibacterial activity against Escherichia coli DH5alpha pB-ges-1 | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID573635 | Antimicrobial activity against AmpC beta-lactamase producing Pseudomonas aeruginosa GC 1764 infected in CD-1 mouse treated 30 and 150 mins postinfection in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID495933 | Antimicrobial activity in Escherichia coli J53 strain in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID325443 | Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Polyamine effects on antibiotic susceptibility in bacteria. |
| AID575010 | Antimicrobial activity against Eubacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID561481 | Antibacterial activity against Pseudomonas aeruginosa assessed as susceptible isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID532993 | Antibacterial activity against OXA-10, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P22 exhibiting PFGE F pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID582968 | Antimicrobial activity against beta-lactamase A and B-deficient Yersinia enterocolitica GY5718 after 20 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B. |
| AID495842 | Hydrolytic activity of Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID406434 | Terminal half life in healthy human at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID534290 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK415 plasmid and ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID564019 | Antibacterial activity against Pseudomonas aeruginosa isolated from lung biopsy specimen of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID564225 | Antimicrobial activity against Escherichia coli TOP10 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID534307 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA460 in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID560590 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID561483 | Antibacterial activity against Pseudomonas aeruginosa assessed as intermediate isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID208129 | In vitro minimum inhibitory concentration against Penicillin susceptible Streptococcus pneumoniae (GC 4565) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID508736 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID523270 | Permeability across Escherichia coli HN1157/pHSG576oxa7 assessed as permeability coefficient in presence of proton uncoupler carbonyl cyanide meta-chlorophenylhydrazone | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. |
| AID532431 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D3 isolate VA-06X-65 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID528615 | Antimicrobial activity against blaKPC-2 and blaTEM-1 producing Escherichia coli 2138 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID532918 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID559273 | Antimicrobial activity against Providencia stuartii Ps5 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID68878 | In vitro synergistic activity against Escherichia coli C600N + (IRT-2) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID562747 | Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID533392 | Antimicrobial activity against Clostridium perfringens assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID373762 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1266 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID532210 | Antimicrobial activity against Escherichia coli J53 harboring wild-type GyrA, ParC, GyrB genes by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID562230 | Antimicrobial activity against Desulfovibrio desulfuricans MB in presence of Tazobactam by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Susceptibilities of 23 Desulfovibrio isolates from humans. |
| AID532934 | Antimicrobial activity against Escherichia coli Genehogs by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID532437 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-20 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID529479 | Antimicrobial activity against Klebsiella pneumoniae isolate 21 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-9 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID535157 | Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID567330 | Antimicrobial activity against Escherichia coli ML4909 by broth dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID535899 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33 harboring GyrA T83I mutant, wild-type ParC, GyrB, qnrA and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID574511 | Antimicrobial activity against Bacteroides vulgatus assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID534658 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID372609 | Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-35 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID567315 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2206 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID571214 | Antimicrobial activity against Pseudomonas aeruginosa isolate GB61 obtained from patient with non-cystic fibrosis by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID567316 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2207 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID563971 | Antibacterial activity against Escherichia coli NF-NDM-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID424859 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID567281 | Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID545849 | Antimicrobial activity against Pseudomonas aeruginosa PS40 with PFGE phenotype 5 expressing beta-lactamase KPC-2, OXA-2 obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID511582 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID559585 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID584564 | Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID207197 | In vitro minimum inhibitory concentration against Methicillin-susceptible Staphylococcus aureus (GC 4543) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID323690 | Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase. |
| AID532933 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID585194 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-7 K104, G170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID532415 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-10 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID573360 | Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID574750 | Antimicrobial activity against Peptostreptococcus micros assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID555666 | Antimicrobial activity against Escherichia coli DH10B harboring natural plasmid pWES-1 carrying CTX-M-53 gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID532393 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-26 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1373310 | Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID529474 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, CTX-M-15 and Oxa-1 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID519013 | Ratio of Kcat to Km for Beta-lactamase TEM-10 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID583207 | Bactericidal activity against Escherichia coli ATCC 25922 using 10'8 CFU/ml inoculum assessed as log reduction in bacterial count at 256 times MIC after 24 hrs by time-kill study | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Mathematical modeling to characterize the inoculum effect. |
| AID573620 | Antimicrobial activity against SHV-11 beta-lactamase producing Klebsiella pneumoniae GAR 7693 infected in CD-1 mouse treated 30 and 150 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID535380 | Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID405085 | Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID573847 | Antimicrobial activity against OXA-1 beta-lactamase producing Escherichia coli GAR 5946 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID522020 | Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID522012 | Antimicrobial activity against Escherichia coli isolate J53 harboring pE containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID562809 | Antimicrobial activity against Escherichia coli J53 | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID535120 | Antimicrobial activity against ceftazidime susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID573347 | Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID520976 | Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID534655 | Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID528603 | Antimicrobial activity against Escherichia coli J53 harboring blaKPC-2 and blaTEM-1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID520970 | Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID535665 | Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63T harboring qnrS gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID565673 | Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae assessed as susceptible isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re |
| AID555671 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring recombinant plasmid carrying CTX-M-53 gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID285605 | Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID574512 | Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID534893 | Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID301747 | Antibacterial activity against Staphylococcus aureus | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. |
| AID559261 | Antimicrobial activity against Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID1373291 | Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-2 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID577236 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB113 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID373200 | Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor Tazobactam | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID564525 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID573562 | Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID532444 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-02 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID573654 | Antimicrobial activity against penicillinase producing Staphylococcus aureus GC 6468 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID544433 | Antimicrobial activity against Escherichia coli CU164A harboring beta-lactamase AmpC by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID535851 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67 harboring wild-type GyrA S83I and qnrS genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID532586 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-12 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID576067 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69036 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID1373305 | Antimicrobial activity against Escherichia coli expressing beta-lactamase IMP-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID529008 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID545647 | Antimicrobial activity against Pseudomonas aeruginosa PS29 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID573369 | Antibacterial activity against ceftazidime-susceptible Proteus mirabilis assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID545447 | Antimicrobial activity against extended-spectrum beta-lactamase-negative Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID567318 | Antimicrobial activity against Escherichia coli TUM4670 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID531771 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4658 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID285576 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID529493 | Antimicrobial activity against Enterobacter cloacae isolate 781 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID374026 | Ratio of Kcat to Km for Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID495838 | Hydrolytic activity of Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID548024 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237H mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID524257 | Ratio of Kcat to Km in Escherichia coli beta-lactamase SHV-1 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID545438 | Antimicrobial activity against extended-spectrum beta-lactamase-negative Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhib | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID534293 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-EcG plasmid and ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID584837 | Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID576315 | Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 299332 harboring porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID535838 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP20 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID405090 | Antimicrobial activity against integron carrying Enterobacteriaceae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. |
| AID574513 | Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1373301 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-24 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID571037 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA367 obtained from patient with cystic fibrosis by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID520778 | Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID495818 | Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID548028 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237K mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID520779 | Antibacterial activity against Escherichia coli EC600 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID545459 | Antimicrobial activity against Serratia marcescens assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID324358 | Antibacterial activity against Escherichia coli DH10B expressing SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID574966 | Antimicrobial activity against Actinomyces odontolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID559588 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID564536 | Antimicrobial activity against Escherichia coli TOP10 harboring pTOPO plasmid by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID1373315 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-10 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID522000 | Antimicrobial activity against Escherichia coli isolate J53 harboring p4A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID558334 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1093 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID545435 | Antimicrobial activity against extended-spectrum beta-lactamase-positive Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhib | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID531778 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4667 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID576273 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID573381 | Antibacterial activity against beta lactamase-negative Haemophilus influenzae assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID511583 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID372611 | Antibacterial activity against Escherichia coli DH5alpha by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID557697 | Antimicrobial activity in Prevotella salivae by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID574985 | Antimicrobial activity against Actinomyces naeslundii assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID279187 | Ratio of kcat to Km of Enterobacter cloacae S3 isolate beta lactamase LAP1 expressed in Escherichia coli DH10B | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID495658 | Antimicrobial activity against Escherichia coli TOP10 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID283321 | Antimicrobial activity against Escherichia coli XL10/vector | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands. |
| AID529202 | Antibacterial activity against ESBL-producing Escherichia coli assessed as resistant isolates by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. |
| AID571040 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA113 obtained from patient with cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID576318 | Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 30018 harboring porin OmpK35 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID67560 | In vitro minimum inhibitory concentration against vancomycin-susceptible Enterococcus faecalis (GC 4553) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID325449 | Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Polyamine effects on antibiotic susceptibility in bacteria. |
| AID528599 | Antimicrobial activity against blaKPC-2 and blaTEM-1 producing Escherichia coli 2138 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID519471 | Antimicrobial activity against Stenotrophomonas maltophilia K279a expressing beta-lactamase L1 and L2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator. |
| AID529498 | Antimicrobial activity against Escherichia coli T-781 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID532398 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D1 isolate VA-06X-63 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID70152 | Minimum inhibitory concentration against 30 strains of Escherichia coli | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8 | Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives. |
| AID372604 | Antibacterial activity against Escherichia coli BER1 producing TEM-158 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID567309 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2207 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID529006 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient urine assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID203171 | The compound was evaluated for antimicrobial activity against Serratia marcescens OC 4294 by inhibiting enzyme AmpC(const) | 2000 | Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19 | The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. |
| AID496591 | Antimicrobial activity against Escherichia coli DH10B harboring beta lactamase KPC-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. |
| AID374021 | Ratio of Kcat to Km for Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID574992 | Antimicrobial activity against Bifidobacterium adolescentis assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574049 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID285594 | Antimicrobial activity against Pseudomonas aeruginosa 1A9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID529476 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, SHV-12 and Oxa-9 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID571045 | Antimicrobial activity against Pseudomonas aeruginosa isolate GB61 obtained from patient with non-cystic fibrosis by Etest | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID68828 | In vivo inhibitory activity against Escherichia coli in mice | 1999 | Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7 | 6-(1-Hydroxyalkyl))penam sulfone derivatives as inhibitors of class A and class C beta-lactamases II. |
| AID424321 | Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID495840 | Hydrolytic activity of beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID341597 | Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID549340 | Antimicrobial activity against Escherichia coli isolate 86 harboring bla CTX-M-3a gene by broth microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID522009 | Antimicrobial activity against Klebsiella pneumoniae isolate KpBIC expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID542620 | Antimicrobial activity against streptomycin-resistant Streptococcus pneumoniae R6 harboring PBP2x T338G mutant gene and Janus disruption at PBP1a after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID521433 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene at 50 ug/ml | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID1592960 | Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 3081/09 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID523269 | Binding affinity to Escherichia coli isolate HN1157 AcrAB-TolC efflux transporter | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. |
| AID564474 | Antimicrobial activity against Pseudomonas aeruginosa isolate 22 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID530333 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-1 gene by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID529304 | Antimicrobial activity against Acinetobacter baumannii isolate Ac058 expressing beta-lactamase Oxa-58 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. |
| AID529457 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID571221 | Antimicrobial activity against Pseudomonas aeruginosa isolate 164CD obtained from patient with non-cystic fibrosis by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID562952 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone A expressing beta-lactamase KPC-2 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID535896 | Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64T harboring qnrA gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID285599 | Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID511666 | Antimicrobial activity against beta-lactam resistant beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID532919 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523transformant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID532414 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-02 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID554990 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID573431 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection in presence of 2:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID529159 | Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID532416 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-11 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID558328 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P286 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID574998 | Antimicrobial activity against Bifidobacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID373201 | Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique in presence of beta-lactamase inhibitor Tazobactam | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID576321 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 31750 harboring porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID541021 | Antimicrobial activity against Escherichia coli TOP10 in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID520972 | Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID529005 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID495903 | Antimicrobial activity in Escherichia coli DIH-1 expressing beta-lactamase VIM-19 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID564221 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID545632 | Antimicrobial activity against Pseudomonas aeruginosa PS11A with PFGE phasotype 7A obtained from sputum of ICU patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID545625 | Antimicrobial activity against Pseudomonas aeruginosa PS3 with PFGE phenotype 12 obtained from sputum of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID534310 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA494 in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID564478 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1006 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID495657 | Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-1 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID532399 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-16 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID547772 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBC SK(+) carrying wild type beta-lactamase KPC-2 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID406431 | Total clearance in healthy human at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID535842 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 SO20 harboring mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID559589 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID534284 | Antimicrobial activity against Stenotrophomonas maltophilia KJN1 harboring ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID532395 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate NA-14X-34 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID574986 | Antimicrobial activity against Actinomyces naeslundii assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID373214 | Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 to ratio of Kcat/Km for Bacillus anthracis beta-lactamase Bla1 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID549344 | Antimicrobial activity against Escherichia coli isolate 49 harboring bla CTX-M-3a gene by broth microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID532174 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID587525 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID541023 | Ratio of Kcat to Km for Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID207346 | In vitro minimum inhibitory concentration against Staphylococcus aureus; 0.5->64 | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Synthesis and evaluation of ether and halogenated derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID543415 | Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID535691 | Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID301808 | Antibacterial activity against Bacillus anthracis AMES | 2007 | Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23 | Direct diazo-transfer reaction on beta-lactam: synthesis and preliminary biological activities of 6-triazolylpenicillanic acids. |
| AID534286 | Antimicrobial activity against Stenotrophomonas maltophilia KJG harboring ampG with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID522010 | Antimicrobial activity against Escherichia coli isolate TOP10 harboring pBIC containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID574769 | Antimicrobial activity against Finegoldia magna assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID562740 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-15 plasmid by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID584561 | Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID528982 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID69010 | In vitro synergistic activity against Escherichia coli C600N + (TEM-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID285690 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID217333 | Synergistic activity of compound was determined against VIM-7 beta lactamase produced by Escherichia coli | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID567313 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2204 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID67555 | In vitro minimum inhibitory concentration against vancomycin-resistant Enterococcus faecalis (GC 6189) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID574748 | Antimicrobial activity against Peptostreptococcus micros assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID68873 | In vitro synergistic activity against Escherichia coli 4100 (no beta-lactamase) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID1373324 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-225 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID583152 | Antimicrobial activity against dacB::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID516139 | Antibacterial activity against Pulsotype F Acinetobacter genomosp. 3 isolate 4 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS18, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID495930 | Antimicrobial activity in Escherichia coli TOP10 harbouring recombinant plasmid VIM-1-N215K by Etest in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID562810 | Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID562336 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pBC-SK after 18 hrs by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID529581 | Ratio of Kcat to Km for Janthinobacterium lividum THIN-B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID535693 | Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID285588 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID544438 | Antimicrobial activity against Escherichia coli MC4100A expressing beta-lactamase TEM-1 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID571041 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA113 obtained from patient with cystic fibrosis by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID576300 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 25008 by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID547992 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Y mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID520885 | Ratio of Kcat to Km for Achromobacter xylosoxidans CIP69598 beta-lactamase OXA-114a expressed in Escherichia coli TOP10 | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID532177 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39T harboring qnrA gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID529157 | Antimicrobial activity against Haemophilus influenzae assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID523889 | Antimicrobial activity against Acinetobacter baumannii 6AB15 harboring ISAba1-blaOXA-23 and blaOXA-66 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID549341 | Antimicrobial activity against Escherichia coli isolate 36 harboring bla CTX-M-3a gene by broth microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID374364 | Antimicrobial activity against Aeromonas caviae A324R expressing metallo-beta-lactamase IMP-19 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID573430 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 infected in CD-1 mouse treated 30 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID587627 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=1024:256 mg/kg, sc compound to NXL | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID69009 | In vitro synergistic activity against Escherichia coli C600N + (Sme-1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID533566 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID573816 | Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID522013 | Antimicrobial activity against Klebsiella pneumoniae isolate KpBEL expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID535887 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID535878 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1T by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID522017 | Antimicrobial activity against Providencia rettgeri isolate expressing beta-lactamase OXA-48 and TEM-101 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID495650 | Antimicrobial activity against Pseudomonas luteola expressing blaLUT-2 to blaLUT-6 by Etest method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID560554 | Antimicrobial activity against Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID573779 | Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574498 | Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID558811 | Antimicrobial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID523891 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring plasmid AT801 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID531495 | Antibacterial activity against Bacteroides vulgatus assessed as percent resistant isolates by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID546432 | Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-3 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID574754 | Antimicrobial activity against Anaerococcus prevotii assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID583191 | Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID68397 | In vitro minimum inhibitory concentration against vancomycin-resistant Enterococcus faecium (GC 4558) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID1257071 | Antibacterial activity against methicillin-resistant Staphylococcus aureus Mu50 ATCC 700699 after 20 hrs by CLSI broth microdilution method | 2015 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23 | Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities. |
| AID543419 | Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID522019 | Antimicrobial activity against Enterobacter cloacae isolate 1 expressing beta-lactamase OXA-48 and SHV-5 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID574516 | Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID207211 | In vitro minimum inhibitory concentration against glycopeptide tntermediate Staphylococcus aureus (GC 3066) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID574449 | Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID521992 | Antimicrobial activity against Escherichia coli isolate J53 harboring pA-1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID532423 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-26 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID585199 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-5 E104, S170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID555217 | Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 56 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID565197 | Antimicrobial activity against Klebsiella pneumoniae isolate H-1406 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID573811 | Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID520969 | Antibacterial activity against Klebsiella pneumoniae GR by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID521999 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp6A expressing beta-lactamase OXA-48 and TEM-150 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID573615 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 min postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID564472 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1060 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID574725 | Antimicrobial activity against Prevotella buccae assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID522028 | Antimicrobial activity against Escherichia coli isolate TOP10 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID285262 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-1 and TEM1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID495931 | Antimicrobial activity in Escherichia coli J53 transconjugate with Escherichia coli DIH-1 expressing natural plasmid containing beta-lactamase VIM-19 in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID574033 | Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID523272 | Antimicrobial activity against Escherichia coli HN1157/pHSG576oxa7 assessed as minimal drug concentration | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. |
| AID567269 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID533638 | Antimicrobial activity against Propionibacterium sp. assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID285582 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID285586 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573383 | Antibacterial activity against beta lactamase-positive Haemophilus influenzae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID574018 | Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID530337 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-13 gene by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID576070 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 50748 harboring porin OmpK36 gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID528992 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID532440 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate CR-04X-14 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID545653 | Antimicrobial activity against Pseudomonas aeruginosa PS36 with PFGE phenotype 11B obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID660261 | Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM120 | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics. |
| AID424857 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pV2GY3 with blaVIM-2 and aac(6)'-32 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID562813 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID372349 | Antibacterial activity against Pseudomonas aeruginosa PAO1/CAZ mutant by CLSI broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. |
| AID422493 | Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID67554 | In vitro minimum inhibitory concentration against vancomycin-resistant Enterococcus faecalis (GC 3059) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID532186 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID533769 | Antibacterial activity against IMP-18 producing Pseudomonas aeruginosa isolate P85 exhibiting PFGE K pattern by 2-fold agar dilution method in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID547996 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237C mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID574457 | Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID1209736 | Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4 | Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. |
| AID576279 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17830 harboring porin OmpK36V mutant gene by Etest in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID532171 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55T harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID511580 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD, ampDh3 and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID532195 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15T harboring wild-type GyrA, ParC, GyrB genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID574733 | Antimicrobial activity against Fusobacterium varium after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID532433 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone E isolate VA-06X-29 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID511287 | Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID541009 | Antimicrobial activity against Burkholderia cenocepacia 09-54 expressing beta-lactamase PenB2 in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID587529 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 2 ug/ml NXL104 beta-lactamase inhibitor | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID577240 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB168 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID574724 | Antimicrobial activity against Prevotella buccae assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID532436 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B1 isolate SS-09X-45 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID533519 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA459 in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID534657 | Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID1592958 | Antibacterial activity against multi-drug resistant Escherichia coli NMI 3898/15 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID573653 | Antimicrobial activity against OXA-1 beta-lactamase producing Escherichia coli GAR 5946 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID520786 | Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 in presence of Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID559276 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID562483 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID533423 | Antimicrobial activity against Anaerococcus prevotii by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID574749 | Antimicrobial activity against Peptostreptococcus micros assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID554989 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID535379 | Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID577237 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB118 with PFGE subgroup B2 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID573372 | Antibacterial activity against ceftazidime-susceptible Serratia marcescens assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID533368 | Antimicrobial activity against Bacteroides uniformis assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID528989 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID535726 | Antibacterial activity against Klebsiella pneumoniae urine isolate A28011 PFGE pattern A expressing KPC-2, CTX-M-2 beta-lactamase by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID562473 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase KPC-2/TEM-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID324856 | Antimicrobial activity against Acinetobacter baumannii A24 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID565282 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID574761 | Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID203144 | In vitro inhibitory activity against Serratia marcescens | 1999 | Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7 | 6-(1-Hydroxyalkyl))penam sulfone derivatives as inhibitors of class A and class C beta-lactamases II. |
| AID532168 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrA genes by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID528997 | Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID574780 | Antimicrobial activity against Clostridium difficile assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID574746 | Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID567274 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID573645 | Antimicrobial activity against TEM-1 beta-lactamase producing Escherichia coli GC 6265 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID406427 | Volume of distribution at steady state in cystic fibrosis patient at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID283322 | Antimicrobial activity against Escherichia coli XL10/pSHV-31 | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands. |
| AID545462 | Antimicrobial activity against Pasteurella sp. assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID573798 | Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID532207 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99T harboring qnrB gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID535902 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33T harboring qnrA gene by agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID574510 | Antimicrobial activity against Bacteroides vulgatus assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID586058 | Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring chromosomally encoded ISAba1-blaOXA-51-like gene with fxsA upstream sequence by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. |
| AID574006 | Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574495 | Antimicrobial activity against Bacteroides fragilis assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID534915 | Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID544431 | Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring beta-lactamase L2 by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID524593 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. |
| AID285602 | Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID574995 | Antimicrobial activity against Bifidobacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID560222 | Antibacterial activity against Salmonella enterica serovar Typhimurium 01-4 by CLSI M7-A7 agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium. |
| AID208002 | In vitro minimum inhibitory concentration against Streptococcus Species (5 strains, including PRSP) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID574452 | Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID544435 | Antimicrobial activity against Escherichia coli MC4100A harboring empty plasmid by liquid microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane. |
| AID574755 | Antimicrobial activity against Anaerococcus prevotii assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID560223 | Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing Outer membrane protein STM3031 by CLSI M7-A7 agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium. |
| AID548040 | Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBK SK(+) by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID530289 | Antimicrobial activity against blaKPC-2, blaKLUC-2 and blaTEM-1 producing Enterobacter cloacae 7506 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID285579 | Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID575004 | Antimicrobial activity against Eubacterium lentum assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID285261 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-36 and IRT by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID574775 | Antimicrobial activity against Clostridium perfringens assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID548262 | Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by spectrophotometric analysis | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID529148 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient blood assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID574723 | Antimicrobial activity against Prevotella buccae assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID374362 | Ratio of Kcat to Km of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID324362 | Ratio of kcat to Km for Acinetobacter johnsonii SCO1 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID67716 | In vitro synergistic activity against Enterobacter aerogenes GC 6268 clinical isolate | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID1373322 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-160 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID531977 | Antibacterial activity against Escherichia coli DH10B expressing KPC-2 CTX-M-2 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID533567 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID574004 | Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID560592 | Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID562822 | Antimicrobial activity against Escherichia coli DH5[alpha] in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID567314 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2205 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID573351 | Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID565279 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID495904 | Antimicrobial activity in Klebsiella pneumoniae DIH-2 clinical isolate expressing beta-lactamase VIM-19 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID549334 | Antimicrobial activity against Escherichia coli isolate 100 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID533388 | Antimicrobial activity against Clostridium difficile assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID573384 | Antibacterial activity against beta lactamase-positive Haemophilus influenzae assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID373211 | Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) relative to benzyl-penicillin | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID519010 | Activity of Beta-lactamase TEM-149 T182M mutant expressed in Escherichia coli HB101 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID560128 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID573440 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 min postinfection in presence of 4:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID531766 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4677 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID545641 | Antimicrobial activity against Pseudomonas aeruginosa PS21 with PFGE phenotype 11F obtained from skin of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID70153 | Minimum inhibitory concentration against 30 strains of Escherichia coli | 1987 | Journal of medicinal chemistry, Aug, Volume: 30, Issue:8 | Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives. |
| AID542629 | Antimicrobial activity against streptomycin-resistant Streptococcus pneumoniae R6 harboring PBP2x T338G mutant gene, Janus disruption at PBP1a and aad9 disruption in CiaR gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID531776 | Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4680 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID372618 | Ratio of Kcat to Km for Escherichia coli CF0042 beta-lactamase TEM-35 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID521994 | Antimicrobial activity against Escherichia coli isolate J53 harboring pBb containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID529830 | Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolates by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. |
| AID574728 | Antimicrobial activity against Prevotella oralis assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID547793 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237V mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID561272 | Antibacterial activity against Escherichia coli assessed as susceptible isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID573843 | Antimicrobial activity against CTX-M-5 beta-lactamase producing Salmonella enterica serovar Typhimurium GC 4195 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID373763 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh9 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID529475 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase Oxa-48 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID1373283 | Antimicrobial activity against Escherichia coli expressing beta-lactamase GES-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID564470 | Antimicrobial activity against Pseudomonas aeruginosa isolate 944 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID520978 | Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID425866 | Antimicrobial activity against Carnobacterium divergens BM4489 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID567307 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2205 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID573614 | Antimicrobial activity against AmpC beta-lactamase producing Enterobacter cloacae GC 4142 infected in CD-1 mouse treated 30 and 150 min postinfection in presence of 6:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID533364 | Antimicrobial activity against Bacteroides thetaiotaomicron assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID574448 | Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID162788 | In vitro synergistic activity against Pseudomonas aeruginosa Ps505A1 (AmpC derepressed) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID532392 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-21 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID531599 | Antimicrobial activity against Klebsiella pneumoniae Kp2792 expressing beta-lactamase SHV-56 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID67561 | In vitro minimum inhibitory concentration against vancomycin-susceptible Enterococcus faecalis (GC 4554) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID521432 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene at 50 ug/ml | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID521834 | Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID574005 | Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID534659 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID285585 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523271 | Lipophilicity, log P of the compound | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. |
| AID560122 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG4 gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID564528 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-50 plasmid by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID563604 | Antimicrobial activity against Escherichia coli isolate CKP048 transconjugant harboring beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA. |
| AID573639 | Antimicrobial activity against OXA-1 beta-lactamase producing Escherichia coli GAR 5946 infected in CD-1 mouse treated 30 and 150 mins postinfection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID203148 | In vivo synergistic activity against Serratia marcescens GC 4132 (Amp C) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID266540 | Antibacterial activity against Enterobacter aerogenes expressing AmpC in iv dosed murine acute lethal infection model | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15 | Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods. |
| AID532411 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-02 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID565287 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID405824 | Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID574497 | Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID660265 | Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics. |
| AID545645 | Antimicrobial activity against Pseudomonas aeruginosa PS26 with PFGE phenotype 3A expressing beta-lactamase OXA-2 obtained from sputum of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID574517 | Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID206386 | In vitro minimum inhibitory concentration against methicillin-susceptible Coagulase-negative Staphylococci (MSCNS) (GC 4551) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID535378 | Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID571216 | Antimicrobial activity against Pseudomonas aeruginosa isolate TX291 obtained from patient with non-cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID545850 | Antimicrobial activity against Pseudomonas aeruginosa PS41 with PFGE phenotype 11D obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID584558 | Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID528492 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID534297 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID564551 | Antimicrobial activity against Acinetobacter baumannii KI by Etest method in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID574514 | Antimicrobial activity against Bacteroides ovatus assessed as percent susceptible isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID519009 | Ratio of Kcat to Km for Beta-lactamase TEM-149 expressed in Escherichia coli HB101 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID541016 | Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase PenB1 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID575008 | Antimicrobial activity against Eubacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID1266408 | Binding affinity to penicillin-binding protein (unknown origin) | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | New Frontiers in Druggability. |
| AID559268 | Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Providencia stuartii Ps5 expressing beta-lactamase PER-1 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID573335 | Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID565283 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID584749 | Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient in presence of Tazobactam by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID558326 | Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1962 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID340738 | Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID522007 | Antimicrobial activity against Escherichia coli isolate J53 harboring pI-1 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID522018 | Antimicrobial activity against Escherichia coli isolate TOP10 harboring pPR containing beta-lactamase and TEM-101 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID541004 | Antimicrobial activity against Burkholderia cenocepacia 07-34 expressing beta-lactamase PenB1 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID573838 | Antimicrobial activity against penicillinase producing Staphylococcus aureus GC 6468 by broth microdilution method in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID535702 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID238858 | Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells | 2005 | Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13 | Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. |
| AID529012 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID532405 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone G isolate NA-14X-13 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID564213 | Antimicrobial activity against Acinetobacter baumannii ATCC 135040 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID574048 | Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID495809 | Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID561282 | Antibacterial activity against Klebsiella pneumoniae assessed as intermediate isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID520901 | Antibacterial activity against Escherichia coli TOP10 in presence of 4 ug/ml Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID279182 | Antibacterial activity against Enterobacter cloacae S3 isolate by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID574763 | Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID206377 | In vitro minimum inhibitory concentration against methicillin-resistant Coagulase-negative Staphylococci (MRCNS) (GC 4546) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID559272 | Antimicrobial activity against Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID567306 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2204 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID520877 | Antibacterial activity against Achromobacter xylosoxidans MER by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID585392 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-6 K104, S170 mutant in presence of at 4 ug/ml Tazobactam by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID573359 | Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID424329 | Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial susceptibilities and clinical sources of Dialister species. |
| AID548020 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237E mutant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID322321 | Antibacterial activity against Escherichia coli DH5 alpha-URA5776 isolates expressing CTX-M-14 enzyme by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID1373292 | Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-4 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID561451 | Antibacterial activity against Klebsiella oxytoca assessed as intermediate isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID530348 | Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID200986 | Synergistic activity of compound was determined against SPM-1 beta lactamase produced by Escherichia coli bacteria; R = Resistant | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5 | Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases. |
| AID557685 | Antimicrobial activity in Prevotella oralis group by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID519980 | Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-55 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. |
| AID405091 | Antimicrobial activity against non-integron carrying Enterobacteriaceae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. |
| AID535839 | Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID574973 | Antimicrobial activity against Actinomyces israelii assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID558325 | Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P850 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID582967 | Antimicrobial activity against beta-lactamase B-deficient Yersinia enterocolitica GY5542 after 20 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B. |
| AID532424 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-32 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID548260 | Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by spectrophotometric analysis | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID40322 | In vitro minimum inhibitory concentration against Bacillus cereus (GC 4561) assay organism | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. |
| AID285255 | Antimicrobial activity against Escherichia coli DH5-alpha CF1179 isolate expressing CMT and TEM1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID585391 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-5 E104, S170 mutant in presence of at 4 ug/ml Tazobactam by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID533524 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID532435 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone G isolate NA-14X-13 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1373312 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CMY-2 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID555211 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID585196 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-6 K104, S170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID1604437 | Antibacterial activity against Pseudomonas aeruginosa haboring AmpC assessed as reduction in microbial growth by CLSI based broth microdilution method | 2020 | Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5 | β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs. |
| AID541015 | Antimicrobial activity against Burkholderia cenocepacia 5007902 expressing beta-lactamase PenB4 in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID522003 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp7A expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID533520 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase in presence of Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID516147 | Antibacterial activity against Pulsotype D Acinetobacter genomosp. 3 isolate 18 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, repAcil, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID341593 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID545444 | Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID573583 | Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574444 | Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID577230 | Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB110 with PFGE subgroup C containing carbapenemase OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID529007 | Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID555196 | Antimicrobial activity against nagZ gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID563599 | Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolates by Etest in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. |
| AID532926 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID548023 | Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237E mutant by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. |
| AID558794 | Antimicrobial activity against extended spectrum beta-lactamase-expressing Escherichia coli assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID530327 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-13 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID535713 | Antibacterial activity against Escherichia coli TOP10 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID573821 | Antibacterial activity against Veillonella parvula by by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID529151 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID495932 | Antimicrobial activity in Escherichia coli TOP10 strain in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID532429 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-16 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID372620 | Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-1 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID530826 | Antibacterial activity against Escherichia coli J53 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID559591 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutL mutant gene complemented with wild type DNA oxidative repair system mutY gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID573594 | Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID542617 | Antimicrobial activity against Streptococcus pneumoniae R6 harboring PBP2x2349 and PBP1a2349 mutant gene after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. |
| AID531497 | Antibacterial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates by agar dilution me in presence of Tazobactam thod | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. |
| AID575003 | Antimicrobial activity against Eubacterium lentum assessed as percent resistant isolates after 48 hrs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID529646 | Antimicrobial activity against Pseudomonas aeruginosa 166301 expressing beta-lactamase VIM-16 obtained from urine of patient by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID573778 | Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID541018 | Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase PenB1 in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID495925 | Antimicrobial activity in Escherichia coli DIH-1 expressing beta-lactamase VIM-19 by Etest in presence of 4 ug/ml Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID544577 | Antimicrobial activity against Escherichia coli DH5[alpha] by microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID573354 | Antibacterial activity against ceftazidime-susceptible Escherichia coli assessed as resistant isolates by CLSI M7-A7 broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. |
| AID555222 | Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 195 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID529477 | Antimicrobial activity against Escherichia coli J53 by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID528608 | Ratio of Kcat to Km for Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID565198 | Antimicrobial activity against Klebsiella pneumoniae isolate A-1797 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID535848 | Antimicrobial activity against Pseudomonas aeruginosa GP61KT51 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID522024 | Antimicrobial activity against Escherichia coli isolate J53 harboring pCF containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID585195 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-2 E104, N170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID573649 | Antimicrobial activity against CTX-M-5 beta-lactamase producing Salmonella enterica serovar Typhimurium GC 4195 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID533130 | Antimicrobial activity against Bacteroides distasonis assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID544582 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8130 expressing bla SHV-1 gene by microdilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID535377 | Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as resistant isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID545656 | Antimicrobial activity against Stenotrophomonas maltophilia assessed as percent susceptible isolates by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID207123 | In vitro synergistic activity against Stenotrophomonas maltophilia 1712(L1) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID545628 | Antimicrobial activity against Pseudomonas aeruginosa PS6A with PFGE phenotype 11A obtained from sputum of ICU patient by agar dilution method in presence of beta-lactamase inhibitor tazobactam | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. |
| AID554988 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID519004 | Antimicrobial activity against Serratia marcescens isolate CT-118 by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID322314 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID558800 | Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID571039 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA24 obtained from patient with cystic fibrosis by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID340725 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-1 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID285259 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-29 and ESBL by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID534615 | Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID535707 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID577238 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB125 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID532587 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C3 isolate PG-12X-03 by Etest method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID324360 | Antibacterial activity against Acinetobacter johnsonii 7037 expressing SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID585394 | Antimicrobial activity against Escherichia coli DH5[alpha] in presence of at 4 ug/ml Tazobactam by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID559270 | Antimicrobial activity against Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria. |
| AID573795 | Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574739 | Antimicrobial activity against Fusobacterium mortiferum after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID519740 | Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID528487 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4688 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID530107 | Antimicrobial activity against Escherichia coli TOP10 by Etest method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID325446 | Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Polyamine effects on antibiotic susceptibility in bacteria. |
| AID555213 | Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID529003 | Antimicrobial activity against Haemophilus influenzae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID373765 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh13 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID495631 | Antimicrobial activity against Pseudomonas luteola LAM expressing blaLUT-1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID406440 | Peripheral volume of distribution in cystic fibrosis patient with lean body mass of 53 kg at 4 g, iv | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. |
| AID533400 | Antimicrobial activity against Clostridium paraputrificum assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| AID562819 | Antimicrobial activity against Escherichia coli J53 in presence of beta-lactamase inhibitor Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID574757 | Antimicrobial activity against Anaerococcus prevotii assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID567321 | Antimicrobial activity against Escherichia coli ML4901 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. |
| AID561442 | Antibacterial activity against Escherichia coli YD006 harboring beta-lactamase CMY-33 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID567308 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2206 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID587522 | Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 1 ug/ml NXL104 beta-lactamase inhibitor | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. |
| AID535160 | Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. |
| AID322318 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID573624 | Antimicrobial activity against TEM-10 beta-lactamase producing Escherichia coli GC 2022 infected in CD-1 mouse treated 30 mins postinfection in presence of 8:1 ratio of compound to beta-lactamase inhibitor BLI-489 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. |
| AID372608 | Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-12 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID583096 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87F mutant beta-lactamase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID524244 | Antimicrobial activity against Escherichia coli DH5alpha | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID544586 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8128 expressing bla SHV-105 gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID544502 | Antibacterial activity against Pseudomonas aeruginosa PR280 harboring beta-lactamase KPC-5 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID540964 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c2 plasmid expressing cephalosporinase CMY-2 by agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID577239 | Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB134 with PFGE subgroup A2 containing carbapenemase OXA-23 and OXA-51 by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. |
| AID373756 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab20 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID574022 | Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID520896 | Antibacterial activity against Achromobacter xylosoxidans MER in presence of 4 ug/ml Tazobactam by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID559584 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID561276 | Antibacterial activity against Escherichia coli assessed as resistant isolates by CLSI M100-S17 method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. |
| AID574505 | Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates after 48 hrs by agar dilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. |
| AID558803 | Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method in presence of beta-lactamase inhibitor tazobactem | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID70957 | The compound was evaluated for antimicrobial activity against Escherichia coli OC 4075 by inhibiting enzyme TEM-1 | 2000 | Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19 | The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. |
| AID558003 | Antimicrobial activity in Clostridium clostridioforme by CLSI agar dilution method in presence of Tazobactam | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antianaerobic activity of sulopenem compared to six other agents. |
| AID529650 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-16 by agar dilution method in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID530816 | Antibacterial activity against Escherichia coli J53 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID96428 | In vitro synergistic activity against Klebsiella pneumoniae (ACT-1 + 3 blas, IPM=S) | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. |
| AID573571 | Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method in presence of Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. |
| AID574451 | Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method in presence of beta-lactamase inhibitor Tazobactam | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID529500 | Antimicrobial activity against Enterobacter cloacae isolate 1 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest in presence of beta-lactamase inhibitor Tazobactam | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID340735 | Antimicrobial activity against Escherichia coli HB101 harboring pBC-IND-5 plasmid containing metallo-beta-lactamase IND5 assessed as drug level at which microbial resistance was observed by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1800109 | IC50 Assay from Article 10.1021/cb400200h: \\Binding of (5S)-penicilloic acid to penicillin binding protein 3.\\ | 2013 | ACS chemical biology, Oct-18, Volume: 8, Issue:10 | Binding of (5S)-penicilloic acid to penicillin binding protein 3. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 599 (19.62) | 18.7374 |
| 1990's | 573 (18.77) | 18.2507 |
| 2000's | 720 (23.58) | 29.6817 |
| 2010's | 898 (29.41) | 24.3611 |
| 2020's | 263 (8.61) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (102.54) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 448 (14.09%) | 5.53% |
| Trials | 3 (6.12%) | 5.53% |
| Reviews | 142 (4.47%) | 6.00% |
| Reviews | 3 (6.12%) | 6.00% |
| Case Studies | 450 (14.15%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 41 (1.29%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2,099 (66.01%) | 84.16% |
| Other | 43 (87.76%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of AAI101 Administered Intravenously Alone or in Combination With Piperacillin or Cefepime to Healthy Adult Subjects [NCT03685084] | Phase 1 | 56 participants (Actual) | Interventional | 2013-10-10 | Completed | ||
| Role of Prophylactic Antibiotics in Preventing Neonatal Sepsis in Neonates Born Through Meconium Stained Amniotic Fluid - A Randomized Controlled Trial [NCT01290003] | 250 participants (Actual) | Interventional | 2010-06-30 | Completed | |||
| Rational Use of Broad-spectrum Antibiotics as Empiric Antibiotic Therapy in Febrile Neutropenia in Recipients of Allogeneic Hematopoietic Cell Transplantation [NCT03078010] | Phase 2 | 460 participants (Anticipated) | Interventional | 2017-02-10 | Recruiting | ||
| Comparison of the Nephrotoxicity of Vancomycin in Combination With Piperacillin/Tazobactam or Other Beta-lactams in Critically Ill Patients: A Retrospective, Multicenter Study in China [NCT03776409] | 700 participants (Actual) | Observational | 2018-12-12 | Completed | |||
| Comparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver Donors: A Randomized Controlled Trial [NCT03765645] | 126 participants (Actual) | Interventional | 2018-10-04 | Completed | |||
| Optimal Care of Complicated Appendicitis [NCT03159754] | Phase 4 | 40 participants (Actual) | Interventional | 2017-06-29 | Completed | ||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| A Randomized, Observer-blinded, Active-controlled, Phase Illb Study to Compare IV / Oral Delafloxacin Fixed-dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections [NCT04042077] | Phase 3 | 268 participants (Actual) | Interventional | 2019-09-25 | Terminated(stopped due to COVID-19 seriously affected the study execution as required by the protocol) | ||
| A Randomized, Double-blind, Multicenter, Phase2 Trial to Evaluate the Safety and Efficacy of YH1177 or YH1177-D Otic Soultion in Patients With Otitis Media and Otorrhea [NCT02817347] | Phase 1/Phase 2 | 135 participants (Actual) | Interventional | 2016-06-30 | Terminated(stopped due to Sponsor's decision for the Drug Development.) | ||
| A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis. [NCT03687255] | Phase 3 | 1,043 participants (Actual) | Interventional | 2018-09-24 | Completed | ||
| An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard of Care Plus Vancomycin, Lin [NCT03485950] | Phase 2 | 100 participants (Actual) | Interventional | 2018-05-16 | Completed | ||
| Optimisation, Valorisation and Application of UPLC-MS/MS Based Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients - Part 3: Non-blank Sputum Samples for Method Optimisation and Validation [NCT02840136] | 40 participants (Actual) | Interventional | 2016-02-29 | Terminated(stopped due to Lack of staff) | |||
| Continuous Infusion Piperacillin-Tazobactam for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis [NCT01694069] | Phase 4 | 6 participants (Actual) | Interventional | 2012-09-30 | Terminated(stopped due to Recruitment was not sufficient to complete the study) | ||
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults [NCT01370616] | Phase 3 | 565 participants (Actual) | Interventional | 2011-09-02 | Completed | ||
| A Randomized Controlled Trial Assessing Noninferiority of Three Antimicrobial Regimens for the Treatment of Grade III Open Fractures [NCT03560232] | Phase 4 | 17 participants (Actual) | Interventional | 2018-07-09 | Terminated(stopped due to Unable to recruit patients in a timely fashion and unable to recruit sufficient patients) | ||
| Efficacy and Safety of the Administration of Betalactam Antibiotics in Continuous or Extended Infusion Compared to Intermittent Infusion in Patients With Sepsis in Two Pediatric Third-level Care Hospitals [NCT03019965] | 426 participants (Actual) | Interventional | 2017-02-01 | Completed | |||
| Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species. [NCT02176122] | Phase 4 | 391 participants (Actual) | Interventional | 2014-02-28 | Terminated(stopped due to Secondary to third interim analysis by the study DSMB.) | ||
| Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults [NCT02753946] | Phase 2/Phase 3 | 465 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030] | Phase 2/Phase 3 | 170 participants (Actual) | Interventional | 2020-01-01 | Completed | ||
| Computer-basierte Dosierungsregime Von Antiinfektiva Bei eingeschränkter Nierenfunktion Und Kontinuierlichen Nierenersatztherapieverfahren (Computer-based Dosage Calculation for Antibiotics in Patients With Impaired Renal Function or Renal Replacement The [NCT03036826] | 0 participants (Actual) | Observational | 2019-06-30 | Withdrawn(stopped due to due to organisational changes) | |||
| Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in the Treatment of Late-onset Sepsis in Preterm Neonates: a Multicentre, Randomised, Open-label, Non-inferiority Study. [NCT05981079] | Phase 4 | 332 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| Randomized Control Trial: Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis [NCT03289351] | Phase 4 | 162 participants (Actual) | Interventional | 2017-05-22 | Active, not recruiting | ||
| Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia [NCT03108690] | Phase 4 | 0 participants (Actual) | Interventional | 2017-10-01 | Withdrawn(stopped due to Logistics) | ||
| Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum β-lactamase (ESBL)-Producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study) [NCT03891433] | Phase 4 | 198 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| Efficacy and Safety of Antibiotics in the Treatment of Early Onset Neonatal Sepsis [NCT03932123] | 500 participants (Anticipated) | Observational | 2019-05-05 | Recruiting | |||
| Randomized Phase II Trial of Total Gut Decontamination Followed by Fecal Microbiota Transplant (FMT), FMT-Alone or Standard of Care for Reduction in Acute Graft-Versus-Host Disease of the Gastrointestinal Tract in Patients Given Broad-Spectrum Antibiotics [NCT03862079] | Phase 2 | 0 participants (Actual) | Interventional | 2020-06-01 | Withdrawn(stopped due to Per PI's request) | ||
| Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion [NCT01198925] | Phase 4 | 14 participants (Actual) | Interventional | 2010-09-23 | Completed | ||
| Single Centre, Prospective, Comparative, Open-label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscess [NCT00629135] | Phase 3 | 180 participants (Actual) | Interventional | 2005-11-15 | Completed | ||
| Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868] | Phase 4 | 135 participants (Anticipated) | Interventional | 2023-08-04 | Enrolling by invitation | ||
| Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE) [NCT04233996] | Phase 4 | 150 participants (Anticipated) | Interventional | 2019-06-05 | Recruiting | ||
| Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia [NCT05102162] | Phase 4 | 35 participants (Actual) | Interventional | 2021-12-17 | Terminated(stopped due to Low recruitment.) | ||
| Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients - Finding the Best Predictor for Piperacillin-tazobactam Clearance [NCT03738683] | 40 participants (Actual) | Observational | 2019-02-01 | Completed | |||
| Alterations of Glycocalyx in Critical Illness and During Major Surgery and Approaches for Glycocalyx Protection [NCT03136796] | 20 participants (Actual) | Observational | 2017-05-02 | Completed | |||
| Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients [NCT03120663] | 120 participants (Anticipated) | Observational | 2016-11-30 | Recruiting | |||
| First Dose Pharmacokinetics for Piperacillin and Meropenem in ICU Patients [NCT05134298] | 50 participants (Anticipated) | Observational | 2019-11-01 | Recruiting | |||
| Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia [NCT02463747] | Phase 4 | 110 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| A Multi-centre Study to Define Novel Individualised Dosing Regimens to Maximise Antibiotic Effectiveness for Treatment of Pneumonia in Intensive Care Units [NCT04986254] | 80 participants (Anticipated) | Observational | 2019-10-17 | Recruiting | |||
| A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy [NCT03269994] | Phase 3 | 962 participants (Actual) | Interventional | 2017-11-21 | Active, not recruiting | ||
| Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia [NCT04948463] | Phase 4 | 312 participants (Anticipated) | Interventional | 2021-11-15 | Recruiting | ||
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707] | Phase 3 | 10,000 participants (Anticipated) | Interventional | 2016-04-11 | Recruiting | ||
| A Randomized, Open-label, Single-dose, 3-period Crossover Study to Describe the Pharmacokinetic Parameters of BLI-489 and Piperacillin When Administered Simultaneously Compared to When Each is Administered Alone. [NCT00894439] | Phase 1 | 24 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Population Pharmacokinetics and Pharmacodynamics Study of Piperacillin/Tazobactam During Early Phase in Critically Ill Patients With Severe Sepsis [NCT02730624] | Phase 4 | 50 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Target Attainment of TDM-guided Continuous Infusion of Piperacillin/Tazobactam and Cefepim in Critically Ill Patients: a Prospective Observational Study [NCT04530045] | 99 participants (Actual) | Observational | 2018-05-02 | Completed | |||
| Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? [NCT02171338] | Phase 4 | 55 participants (Anticipated) | Interventional | 2013-10-31 | Active, not recruiting | ||
| Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis [NCT02619149] | Phase 3 | 100 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Antibiotic Pharmacokinetics in Critically Ill Patients [NCT02609646] | 1,500 participants (Actual) | Observational | 2016-01-31 | Completed | |||
| Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock [NCT02473263] | Phase 3 | 398 participants (Actual) | Interventional | 2016-05-09 | Completed | ||
| Prospective Study Evaluating Plasma Exposure of Optimized Antibiotic Therapy According to TDM in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC) [NCT04132115] | 104 participants (Anticipated) | Observational | 2019-10-01 | Recruiting | |||
| A Comparison of Standard Vs Renal Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock [NCT00816790] | Phase 4 | 20 participants (Anticipated) | Interventional | 2009-01-31 | Terminated(stopped due to Study stopped because of study personel movement to another institution.) | ||
| Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients [NCT04257838] | 200 participants (Anticipated) | Observational | 2020-02-15 | Not yet recruiting | |||
| Validation of Uncertainty Quantifying Machine Learning Models to Predict Beta-lactam Antimicrobial Concentrations in ICU Patients [NCT06026852] | 600 participants (Anticipated) | Interventional | 2023-12-20 | Not yet recruiting | |||
| A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Or [NCT00402727] | Phase 3 | 813 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Single-Dose Pharmacokinetics Study of Tapimycin Injection(Piperacillin 4 g + Tazobactam 0.5 g Powder for Injection) Administered Under Fasting Conditions to Healthy Adult Subjects [NCT00924742] | 12 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| Population Pharmacokinetics and Dosage Individualization of Biapenem,Meropenem,Piperacillin and Tazobactam,Tigecycline,Levofloxacin .Etc in Elderly Patients Who Was Hospitalized in Intensive Care Unit [NCT04799626] | 500 participants (Anticipated) | Observational [Patient Registry] | 2021-04-01 | Recruiting | |||
| Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers [NCT04394182] | 15 participants (Anticipated) | Interventional | 2020-04-21 | Suspended(stopped due to lack of recruitment) | |||
| Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock [NCT02820987] | Phase 3 | 129 participants (Anticipated) | Interventional | 2016-09-01 | Recruiting | ||
| Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae [NCT02795949] | Phase 3 | 344 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Pharmacokinetics of Piperacillin and Tazobactam in Anuric Septic Patients Treated by Continuous Veno Venous Hemodiafiltration [NCT00703144] | Phase 4 | 10 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial [NCT06184659] | Phase 4 | 5,800 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT): A Randomized, Controlled Trial [NCT01027832] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter, [NCT03262142] | Phase 4 | 51 participants (Actual) | Interventional | 2018-01-10 | Terminated(stopped due to Slow recruitment) | ||
| Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial [NCT03671967] | Phase 4 | 1,084 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| An Investigator Initiated, Phase IV Single-Center, Randomized, Open-Label, Prospective Study to Determine the Impact of Serial Procalcitonin on Improving Antimicrobial Stewardship and on the Efficacy, Safety, and Tolerability of Imipenem - Relebactam Plus [NCT04983901] | Phase 2 | 100 participants (Actual) | Interventional | 2021-09-14 | Active, not recruiting | ||
| Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit. [NCT00167960] | 1,500 participants | Observational | 2005-01-31 | Completed | |||
| Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units. [NCT00167999] | 200 participants | Observational | 2005-02-28 | Completed | |||
| Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion [NCT00435305] | 40 participants (Anticipated) | Observational | 2006-11-30 | Terminated(stopped due to difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to continue enrolling patients,) | |||
| Appropriate Antimicrobial Therapy in Critical Care: A Pilot Randomized Controlled Trial [NCT00438269] | Phase 2 | 80 participants | Interventional | 2003-02-28 | Completed | ||
| Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria [NCT00488189] | Phase 4 | 134 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Antimicrobial Pharmacokinetics in High Risk Infants (Urinary Proteomics in Antimicrobial/Antifungal-Treated Newborns - add-on Study) [NCT00491426] | 450 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326] | 3,520 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®) [NCT04033029] | 20 participants (Actual) | Observational | 2021-01-01 | Completed | |||
| Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates [NCT00873327] | Phase 1 | 32 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Antimicrobial Therapy for Ventilator-associated Pneumonia Among Patients Colonized With Extended-spectrum Beta-lactamase-producing Enterobacteriaceae : Efficacy of a Strategy Using Piperacillin-tazobactam as Empirical Treatment. [NCT04276480] | 30 participants (Anticipated) | Interventional | 2022-02-16 | Recruiting | |||
| Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria [NCT00478855] | Phase 4 | 500 participants | Interventional | 2006-09-30 | Completed | ||
| Observed Pharmacokinetic of Piperacillin/Tazobactam in ICU Patients Compared to Therapeutic Drug Monitoring of Amikacin [NCT03990467] | 60 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | |||
| eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce Clinically Relevant PostOperative Pancreatic Fistula: A Phase 2 Randomized Control Trial (X-POPF) [NCT05753735] | Phase 2 | 96 participants (Anticipated) | Interventional | 2023-12-20 | Recruiting | ||
| Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study. [NCT00195533] | 801 participants (Actual) | Observational | 2001-07-31 | Completed | |||
| Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients [NCT01517815] | 50 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients [NCT00044746] | Phase 4 | 314 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections [NCT00389987] | Phase 3 | 300 participants | Interventional | 2001-09-30 | Completed | ||
| Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery [NCT01805856] | 2,164 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma [NCT00044759] | Phase 3 | 0 participants | Interventional | Completed | |||
| Standard vs. Biofilm Susceptibility Testing in CF [NCT00153634] | 75 participants (Actual) | Interventional | 2004-03-31 | Completed | |||
| Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection [NCT00044928] | Phase 4 | 262 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections. [NCT00195286] | 180 participants (Actual) | Observational | 2004-06-30 | Completed | |||
| Optimized Treatment for Uncomplicated Acute Appendicitis; Active Observation With or Without Antibiotic Treatment [NCT03985514] | Phase 4 | 126 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children [NCT02991937] | Phase 4 | 39 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults. [NCT00229112] | Phase 3 | 400 participants | Interventional | 2001-04-30 | Completed | ||
| An Open-Label, Multicenter, Multinational, Centrally Randomized, Two-Arm Parallel-Group Study to Demonstrate the Non-Inferiority in Clinical Efficacy of Levofloxacin 750mg od in Comparison With Piperacillin/Tazobactam 4g/500mg Every 8 Hours in the Treatme [NCT00253955] | Phase 3 | 460 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Continuous-infusion Anti-pseudomonal β-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic Fibrosis [NCT01667094] | Phase 4 | 50 participants (Actual) | Interventional | 2012-09-30 | Active, not recruiting | ||
| Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support [NCT03922451] | 4 participants (Actual) | Observational | 2019-08-27 | Terminated(stopped due to COVID-19 - study and recruitment not feasible) | |||
| Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis [NCT01697059] | 73 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Piperacillin/Tazobactam for Prophylaxis in Patients of Neutropenia After Hematopoietic Stem Cell Transplantation - A Pilot Study [NCT01714557] | 150 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | |||
| A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation [NCT01714570] | 123 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Phase IV Study on Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection [NCT01760109] | Phase 4 | 2,000 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Assessing the Longitudinal Outcomes of Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA): a Randomized Controlled Trial [NCT05943223] | Phase 2 | 16 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis: A Cluster Randomized Cluster Crossover Non-Inferiority Study. [NCT04803422] | 2,631 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | |||
| Antibiotic Safety in Infants With Complicated Intra-Abdominal Infections (SCAMP Trial) [NCT01994993] | Phase 2/Phase 3 | 260 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Pilot RCT of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Beta-lactamase Producing Enterobacter Spp., Citrobacter Freundii, Morganella Morganii, Providencia Spp. or Serratia Marcescens. in Low- [NCT02437045] | Phase 4 | 100 participants (Anticipated) | Interventional | 2015-04-30 | Completed | ||
| TAID Study - A Prospective Interventional Trial on Antibiotics Continuous Infusion at Home [NCT04816968] | Phase 1 | 50 participants (Anticipated) | Interventional | 2021-09-30 | Not yet recruiting | ||
| Efficacy and Safety of Piperacillin-Tazobactam Continuous Infusion vs Intermittent Infusion for Complicated or Nosocomial Pseudomonas Aeruginosa Infection or Suspected Infection [NCT01577368] | Phase 3 | 76 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis [NCT02166476] | Phase 3 | 550 participants (Actual) | Interventional | 2014-11-20 | Completed | ||
| Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam [NCT00003805] | Phase 3 | 859 participants (Actual) | Interventional | 1997-11-30 | Completed | ||
| Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care [NCT03748095] | 90 participants (Anticipated) | Observational | 2019-03-12 | Recruiting | |||
| Amplification and Selection of Antimicrobial Resistance in the Intestine II [NCT03140826] | 60 participants (Actual) | Observational | 2018-01-30 | Completed | |||
| Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent [NCT06123169] | Phase 3 | 326 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Clinical and Microbiological Effects of Local and Systemic Antimicrobials as an Adjunctive Therapy in Periodontitis Stages 2 and 3 [NCT05608564] | 40 participants (Actual) | Interventional | 2022-01-17 | Active, not recruiting | |||
| Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit [NCT05565222] | Phase 3 | 600 participants (Anticipated) | Interventional | 2023-03-11 | Recruiting | ||
| Extended-infusion Piperacillin-Tazobactam Versus Intermittent-Infusion Dosing Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Infections. [NCT04895657] | Phase 4 | 56 participants (Actual) | Interventional | 2018-07-27 | Completed | ||
| Phase Ⅱ, Randomized, Double-Blind,Double-Dummy Study Evaluating Safety,Tolerability,Efficacy of Meropenem-FL058 in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis [NCT05060419] | Phase 2 | 150 participants (Anticipated) | Interventional | 2021-10-08 | Not yet recruiting | ||
| A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia [NCT01853982] | Phase 3 | 4 participants (Actual) | Interventional | 2013-06-14 | Terminated(stopped due to Terminated to focus on a larger study within the clinical development program.) | ||
| A Phase IIIb, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Asso [NCT03006679] | Phase 3 | 0 participants (Actual) | Interventional | 2018-08-31 | Withdrawn(stopped due to Sponsor Decision) | ||
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pne [NCT02493764] | Phase 3 | 537 participants (Actual) | Interventional | 2015-11-24 | Completed | ||
| Safety and Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Infants and Children [NCT02466438] | Phase 1 | 141 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| PipEracillin/Tazobactam vs mERoPENem for Treatment of AmpC-producing Bloodstream Infections: an Extension of the Original PETERPEN Trial [NCT05355350] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| A Phase 1, Open-label, Randomized, 2-period, Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Subjects [NCT03441529] | Phase 1 | 18 participants (Actual) | Interventional | 2018-02-09 | Completed | ||
| A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Standard of Care Plus Vancomycin or Linezolid as Empiric The [NCT02732327] | Phase 2 | 2 participants (Actual) | Interventional | 2016-05-17 | Terminated(stopped due to No longer aligned with the revised clinical development plan and commercial strategy) | ||
| A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers [NCT03376529] | Phase 1 | 27 participants (Actual) | Interventional | 2017-11-10 | Completed | ||
| Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations With High Risk for EOS [NCT06076200] | 50 participants (Anticipated) | Observational | 2023-09-30 | Recruiting | |||
| Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin/Tazobactam in Obese Patients [NCT01923363] | 29 participants (Actual) | Interventional | 2014-02-25 | Completed | |||
| Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS) [NCT02168816] | Phase 2 | 30 participants (Actual) | Interventional | 2014-03-19 | Terminated(stopped due to The study was stopped for feasibility (i.e., low recruitment)) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||